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The development of prophylactic vaccines providing protection against infectious diseases 
constitutes one of the greatest advances in human health. Traditional vaccine strategies based 
on attenuated or inactivated pathogens prevent infection, but are associated with an increased 
health risk in immune compromised individuals as well as with the danger of spontaneous 
reversion to pathogenicity. Driven by these concerns, researchers have moved towards the 
design of vaccines composed of recombinant proteins, peptides, and plasmid DNA (pDNA) 
and mRNA molecules encoding antigenic structures. However, the advantage of a superior 
safety profile comes with the cost of a weak immunogenicity. In order to address this 
limitation, we aimed to develop novel vaccine technologies, which are safe and elicit strong 
humoral and cellular immune responses. 
In vitro transcribed mRNA has the capacity to encode a broad spectrum of antigens and 
offers in addition the advantage of a transient, and hence safe, expression by antigen 
presenting cells. In spite of these advantages, immune responses elicited by present day 
mRNA-based vaccines are not convincing. In this PhD research, we focused on the RALA 
peptide as a potential mRNA carrier for vaccination. The RALA peptide is rich in arginine, 
contains a number of amphipathic RALA repeats and exhibits a dual functionality; in 
addition to its ability to form complexes with nucleic acids that self assemble into 
nanoparticles, it acquires a helical structure at acidic pH. Acidification in endosomes will 
therefore result in RALA complexes engulfed by cells to acquire a helical structure that 
destabilises the endosomal membrane, resulting in leakage of RALA peptide (and its cargo) 
into the cytosol of the cell.  
In a first approach, we characterized the physicochemical properties of the RALA 
peptide/mRNA nanoparticle and confirmed its pH-dependent lytic activity. Immunologically, 
we found that modifying the mRNA by inclusion of pseudo-uridine and 5-methylcytidine 
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nucleotides elicited more potent cytolytic T cell responses compared to RALA 
peptide/mRNA nanoparticles containing unmodified mRNA. The increased immune efficacy 
of RALA peptide/modified mRNA complexes was accompanied by a lesser induction 
of/sensitivity to type I interferon. This observation is in line with previous reports from our 
lab documenting the negative impact of evoked type I interferons on the efficacy of mRNA-
based vaccines.  
In a next step, we fused CD4
+
 and CD8
+
 T cell antigen epitopes with the RALA peptide. 
Analysis of the physicochemical properties of the RALA-epitope peptide/pDNA showed that 
this fusion did not affect particle formation or uptake by dendritic cells. Immunization of 
mice with RALA-MHC I epitope peptide/pDNA nanoparticles induced strong CD8
+
 T cell 
proliferative and cytolytic responses. Immunization with RALA-MHC II epitope 
peptide/pDNA nanoparticles similarly elicited strong CD4
+
 T cell proliferation and, upon a 
booster immunization with (ovalbumin) antigen, resulted in high antibody titers and isotype 
switching to IgG1. Finally, immunization with both types of nanoparticles elicited both 
cellular and humoral immune defences. These immune features, similar to the mixed cellular 
and humoral immune response elicited upon viral infection, along with the fully synthetic 
nature of the RALA-epitope peptide/pDNA nanoparticles classify the nanoparticles as 
synthetic virus-like particles.  
In conclusion, the combined physicochemical and immune features of RALA-epitope 
peptide-based nanoparticles identify these particles as a highly promising new format for 
vaccination against various infectious diseases such as tuberculosis, malaria and AIDS that 
require besides humoral immune defences also strong cytolytic defences for protection. 
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De ontwikkeling van profylactische vaccins die bescherming bieden tegen infectieziekten 
vormt ongetwijfeld een van de grootste stappen in de medische geschiedenis. De meer 
traditionele vaccinatiestrategieën steunen op de toepassing van verzwakte of geïnactiveerde 
pathogenen. Alhoewel uitermate succesvol, houden deze strategieën ook risico’s in bij 
personen met een verzwakte immune afweer of als gevolg van een reverteren van het 
verzwakte pathogeen naar virulentie. Om aan deze bezorgdheid tegemoet te komen, wordt 
intensief gezocht naar het ontwikkelen van vaccins samengesteld uit onderdelen van het 
pathogeen eerder dan het pathogeen zelf. Dit omvat ondermeer recombinante eiwitantigenen, 
peptide, en plasmide DNA (pDNA) en mRNA coderend voor een of meerdere antigenische 
structuren. Echter, het voordeel van een superieure veiligheid komt ten koste van een 
verminderde immunogeniciteit. Dit doctoraatonderzoek legt zich dan ook toe op de 
ontwikkeling en validering van nieuwe technologieën die toelaten deze beperking te 
omzeilen. 
In vitro overgeschreven mRNA laat toe een breed spectrum aan antigenen te coderen en deze 
op een transiënte, en dus veilige, wijze tot expressie te brengen in antigeen-presenterende 
cellen. Ondanks dit belangrijke potentieel blijft de toepassing van mRNA in vaccins alsnog 
beperkt wegens ondermeer de relatief zwakke immuun antwoorden opgewekt door dergelijke 
vaccins. Een mogelijke oplossing hiertoe vormt het arginine-rijk amfipatisch RALA peptide. 
Dit peptide bevat meerdere RALA herhalingen en is in staat mRNA (en pDNA) te binden 
met de vorming van nanopartikels als gevolg. Opname van deze nanopartikels door cellen en 
de daaropvolgende verzuring in het endosoom resulteert in het verwerven van een helix-
structuur door het RALA peptide. Hierdoor verwerft het RALA peptide een (endosoom) 
membraan-verstorende activiteit waardoor het RALA-peptide en zijn eventuele cargo kunnen 
diffunderen naar het cytosol van de cel.  
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Uitgaande van deze functionele karakteristiek, werd nagegaan in welke mate het complexeren 
van het RALA-peptide met mRNA coderend voor het modelantigeen ovalbumine, toelaat een 
uitgesproken CD8
+
 cytolytisch T-cel antwoord op te wekken. Aldus werden de 
fysicochemische eigenschappen van het RALA-peptide/mRNA nanopartikel geanalyseerd 
alsook zijn pH-afhankelijke lytische activiteit. Immunologisch bleek mRNA gemodificeerd 
door het gebruik van pseudo-uridine en 5-methylcytidine een meer uitgesproken CD8
+
 
cytolytisch T cel antwoord op te wekken in vergelijking met niet-gemodificeerd mRNA. 
Deze verhoogde efficiëntie van het gemodificeerd mRNA ging gepaard met een verminderde 
opwekking/gevoeligheid aan type I interferon. Dit is in overeenstemming met voorafgaande 
studies van het laboratorium die een negatieve inwerking van type I interferon op de 
efficiëntie van mRNA vaccins hebben aangetoond. 
In een volgende stap werd aan het RALA-peptide een T-lymfocyt antigeen epitoop 
gekoppeld. Analyse toonde aan dat dit fusiepeptide nog steeds in staat was te interageren met 
pDNA en hierdoor spontaan te assembleren in nanopartikels die efficiënt werden opgenomen 
door dendritische cellen. Immunisatie van muizen met RALA-MHC I epitoop-peptide/pDNA 
nanopartikels resulteerde in de opwekking van een sterk CD8
+
 T cel antwoord en antigeen-
specifieke cytolytische activiteit. Immunisatie met RALA-MHC II epitoop-peptide/pDNA 
nanopartikels resulteerde in de opwekking van een beduidend CD4
+
 T cel antwoord en, na 
een booster immunisatie met ovalbumine eiwit, in hoge antilichaam titers en antilichaam 
isotype switching naar IgG1. Combinatie van de beide types partikels tenslotte gaf aanleiding 
tot een gemengd humoraal en cellulair immuun antwoord, sterk gelijkend op het antwoord dat 
anders wordt opgewekt bij een virale infectie. Op basis van deze eigenschap en het volledig 
synthetische karakter van deze nanopartikels, catalogeren we deze RALA-epitoop-
peptide/pDNA nanopartikels als synthetische virusachtige nanopartikels.  
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Samenvattend tonen de resultaten van dit doctoraatonderzoek aan dat de gecombineerde 
immunologische en fysicochemische kenmerken van op RALA-gebaseerde nanopartikels 
deze uitermate aantrekkelijk maken voor toepassing als vaccin tegen infectueuze 
aandoeningen zoals tuberculose, malaria en AIDS die naast een humorale afweer eveneens 
een uitgesproken cytolytische afweer vergen ter bescherming.  
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CHAPTER 1 
_______________________________________________________ 
 The way towards safer vaccine development 
 
 
 
 
 
 
 
 
 
“I pictured myself as a virus or a cancer cell and tried to sense what it would be like” 
- Jonas Salk (Inventor of polio vaccine) 
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1. Introduction 
Vaccines are one of the greatest public health innovations in human history. In 2016, the 
World Health Organization (WHO) estimated that vaccines prevent 2‒3 million human 
deaths annually and that these numbers will rise to 4.5 million if worldwide vaccination 
coverage improves
1
. As a result of vaccination, smallpox was officially declared eliminated 
in 1979 and the livestock disease rinderpest was declared eliminated in 2011, while measles 
and polio are close to elimination
2, 3
. Despite such noteworthy successes, there are no 
vaccines for many diseases. Intensive research has led to the development of several 
strategies for delivering specific, immunogenic vaccine components to the immune system to 
elicit therapeutic or prophylactic immune responses. 
2. Stepping stones towards safer vaccines 
Traditionally, vaccines have consisted of live attenuated or inactivated pathogens. However, 
many pathogens are difficult to culture in vitro, so they are not suitable for the production of 
live attenuated vaccines. Moreover, even attenuated microorganisms may elicit detrimental 
immune responses, and the pathogen may contain material that initiates other types of 
unwanted effects. The first commercialised vaccines against rabies, poliomyelitis, tetanus and 
some other diseases were based on the attenuation of pathogens and toxins. However, the 
potential toxicity and the difficulty of producing attenuated vaccines from complex pathogens 
such as hepatitis C virus (HCV) and human immune deficiency virus (HIV) have prompted 
the search for novel vaccine technology
4
. The mounting knowledge of pathogen 
characteristics and rapidly progressing biotechnological advances have led to the 
development of newer and safer subunit vaccines based on proteins, peptides and nucleic 
acids 
5
. 
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2.1. Proteins 
The concept of “reverse vaccinology,” which relies on scanning the whole genome of the 
pathogen to identify antigenic protein candidates, represents important progress in the 
development of new vaccines
6
. This strategy has led to the development of a new 
meningococcal vaccine (Bexsero, Novartis)
7
. Several vaccines against different infections 
have also been investigated using this approach, such as against Streptococcus pneumoniae 
and Leishmania infantum
8, 9
. Recombinant DNA technology has allowed the production of 
recombinant antigenic proteins, mostly in bacteria or yeast. A well-known example is the 
production of hepatitis B surface antigen in Escherichia coli, which has led to the first 
recombinant protein-based vaccines reaching the market and being used with different 
adjuvants, such as alum (Engerix GSK)
10
 and AS04 (combination of alum and 
monophosphoryl lipid A) (Recombivax Merck)
11
.  
2.2. Peptides 
Taking the reductionist approach one step further, the most precise selection of vaccine 
components is manifested in peptide vaccines. Antigenic proteins have important limitations, 
such as complexity of production, difficulty of purification, and instability in solution or 
suspension
12
. More importantly, antigens resembling human proteins could increase the risk 
of autoimmunity. meningococcal serogroup B capsule and group A streptococcal capsule 
proteins are the typical examples
13, 14
. For these reasons, efforts are currently focused on the 
production of small peptides as antigens. Antigenic peptides can be identified by analysis of 
regions within larger proteins that induce specific cellular and humoral immune responses. 
These peptide vaccines can be synthesised with high purity on a large scale and at a lower 
cost
15
.  
The use of vaccines based on antigenic peptides is restricted to patients of a given tissue type 
(human leukocyte antigen (HLA) haplotype), and so they need to be tailored to accommodate 
17 
 
the natural variation in HLA genes
16
. Although this personalized medicine approach was 
initially thought to be a major obstacle, new technologies have made it feasible. Moreover, 
the existence of HLA super types makes it possible to limit the production of epitope-based 
vaccines that target MHC-I restricted cytotoxic T cells to nine super families with shared 
peptide-binding specificity and shared epitope presentation
17, 18
. The examples of HLA super 
types are HLA- A (A1, A2, A3, A24) and HLA-B (B7, B27, B44, B58, B62). A2, A3, B7,
 B27 and B44 super types are evenly distributed. On the other hand, A1, A24, B58 and 
B62 are present at a greater frequency variation among populations
19, 20
. 
Several peptide-based vaccine formulations have already reached the clinical development 
phase, e.g., some preventive HIV vaccines
21
 as well as some therapeutic anticancer vaccines 
22, 23
. There are still no prophylactic peptide-based vaccines licensed for humans mainly due 
to difficulties associated with stability, delivery and low immunogenicity. 
2.3. Nucleic acids 
Over the last decades, nucleic acid-based vaccines have gained increasing attention. Nucleic 
acid vaccines enable the antigen to be produced in situ by the cellular machinery of the host. 
As this strategy leads to local synthesis of the antigenic molecules, it mimics natural infection 
by intracellular pathogens. Moreover, nucleic acids can be tailored to express antigens that 
are chemically or structurally different from their native form
24
. When used as vaccines, 
nucleic acids can not only trigger immunogenic responses to the antigens they encode, but 
also to innate sensors of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). 
 
2.3.1. Viral vector 
Viral vector vaccine consists of live attenuated virus that is genetically engineered to carry 
DNA encoding disease specific antigens. The vectors activate strong innate immune 
responses mediated by Toll-like receptors and the inflammasome, resulting in an adjuvant 
18 
 
effect
25
. The specific properties of the vector are determined by the virus from which it 
derives. Vaccinia virus and adenovirus are the most widely used vectors because they can 
induce a robust immune response, specifically involving cytotoxic T lymphocytes, against the 
expressed foreign antigens
26, 27
. Viral vector production requires cellular systems and a high 
biosafety level.  A major obstacle to the clinical use of viral vectors often is the presence of 
pre-existing immunity against the vector. This is caused by previous exposure to the virus 
and the production of neutralizing antibodies that reduce vaccine efficacy.  
2.3.2. Plasmid DNA  
Plasmid DNA vaccination, based on the administration of selected antigen-encoding DNA in 
a plasmid vector, has been used to prevent diseases such as malaria and HIV but has also 
been used in cancer immunotherapy. Several studies demonstrated that the addition of non-
coding plasmid to a DNA plasmid encoding a vaccine antigen enhances the induced immune 
responses
28, 29
. Because the plasmid DNA is of bacterial origin, the backbone contains 
unmethylated CpG motifs that can trigger TLR9 signalling
30
. The addition of CpG motifs into 
the plasmid backbone has been shown to improve the immunogenicity of DNA vaccines
30-32
.  
CpG DNA that does not encode antigen eliminated tumours in mice and resulted in long-term 
protection by increasing the activity of cytotoxic T cells and natural killer cells
33
. These 
findings suggested that CpG motifs in the plasmid acted as an adjuvant for the pDNA 
vaccine. However, experiments in wild type and TLR9 -/- mice showed that similar levels of 
antibodies and CD8+ T cell responses were evoked in both mouse types after vaccination 
with pDNA vaccines
34, 35
. In contrast, others suggest that TLR9 signalling is crucial for the 
induction of CD8+ cytotoxic T cell responses during the priming phase of DNA vaccines
36, 
37
.  
Several DNA vaccines have been licensed for veterinary use, including an equine vaccine for 
West Nile Virus (withdrawn from the market)
38
, a fish vaccine against infectious 
19 
 
hematopoietic necrosis virus
39
, and a therapeutic canine vaccine for melanoma
40
. However, 
the clinical potency of DNA vaccines in humans has been overall disappointing, and no 
human vaccines have been licensed to date
41
. Without using sophisticated delivery methods, 
enough pDNA might not end up in the cytoplasm, or otherwise species differences could 
exist in the sensitivity of the DNA sensors to stimulation
42-44
. Either of these factors might 
impair the efficacy of DNA vaccines in humans. Multiple efforts have been made to further 
improve the immunogenicity of pDNA vaccines.  
A wide range of genes producing endogenous immune-stimulatory proteins has been used to 
enhance the immunogenicity of DNA-encoded antigens, including GM-CSF, IL-2, IL-12, IL-
15, CD40 ligand
45
 and flagellin
46
. Local cytokine production at the site of plasmid 
administration and the type of cytokine adjuvant can influence the quality of innate and T 
cells responses. GM-CSF is effective in animal models, but the effect was not striking in 
humans 
47
. The same is true for some of the interleukin genes
48
.   
Approaches to enhance protein expression from pDNA include selection of promoter and 
codon usage. Another particularly effective approach to increase DNA vaccine efficacy is the 
use of in vivo electroporation, in which pulsed electrical currents are applied to the skin at the 
immunization site. This has been shown to substantially increase DNA uptake by the cells, 
leading to an increase in protein production and immunogenicity
49
. Phase II clinical trials 
have demonstrated the efficacy and tolerability of in vivo electroporation in a prime-boost 
combinatory DNA vaccination, and further testing of this technique in humans is ongoing 
50, 
51
. DNA priming followed by a heterologous boost with various viral vectors has also been 
studied. The use of Adenovirus 5 (Ad5), Modified Vaccinia Ankara or Cytomegalovirus 
resulted in strong immune responses
47, 52, 53
. Ad5 expressing gag protein of simian 
immunodeficiency virus (SIV) was able to attenuate the viral infection in monkeys after 
challenge with HIV-SIV hybrid virus (SHIV). However, the same results were not observed 
20 
 
in phase II trials in humans
54
. In phase II clinical trials, all the participants receiving the 
vaccine developed Ad5 antibodies as well as T-cell responses to the vector. However, the 
repeated administration of Ad5 vector caused undefinable immune response that led to 
increased HIV-1 acquisition
55
. Moreover, the risk of genomic integration effects of DNA 
based vaccines are not adequately known.  
2.3.3. Self-amplifying RNA 
Based on the increasing knowledge and technical advances in the molecular virology of 
single-stranded RNA viruses, self-amplifying RNA (termed RNA replicons) was developed. 
The gene sequences encoding the structural proteins in RNA viruses are replaced by the 
vaccine antigen as well as by the RNA polymerase for RNA replicon replication and 
transcription
56
. When introduced into cells, RNA replicons replicate and express the 
heterologous genes, inducing the synthesis of large amounts of the desired antigen within the 
cells. The best studied RNA molecules of this class are derived from alphavirus
57
 (such as 
Sindbis, Semliki Forest) and from flavi viruses
58
 (Kunjin virus, Yellow fever virus). Though 
the possibility of infection is eliminated by removal of the genes encoding viral structural 
proteins, more research on uncontrollable levels of antigen expression and associated 
tolerance is needed. Additionally, the RNA replicon is more complex than non-amplifying 
mRNA vaccines, and their greater size and complexity make it difficult to design an efficient 
delivery system.  
2.3.4. In vitro transcribed mRNA 
Since the discovery of mRNA in 1961, the focus has been on understanding the structural and 
functional aspects of mRNA and its metabolism in eukaryotic cell. Accumulated knowledge 
paved the way for recent scientific and technological advances to overcome some of the 
obstacles associated with the use of mRNA in vaccination, such as its short half-life and 
unfavourable immunogenicity. In vitro transcribed (IVT) mRNA is synthesized in a cell-free 
21 
 
system from a DNA template encoding all the structural elements of a functional mRNA 
except for the 5’ cap. In vitro transcription is performed with T7 or SP6 RNA polymerase in 
the presence of nucleotides
59
. There are two options for the in vitro transcription reaction 
depending on the capping strategy chosen. The first method is post-transcriptional capping. 
This involves the transcription reaction followed by capping through vaccinia virus capping 
enzyme. Another method is to incorporate cap analogues during transcription.  This method 
is termed as co-transcriptional capping. The template DNA is then digested by DNases and 
the mRNA is purified from the reaction mixture.   
Vaccines based on IVT mRNA consist of only the genetic information of the antigen of 
interest flanked by short 5’ and 3’ noncoding sequences with a 5’ terminal cap and a 3’ 
terminal poly(A) tail. mRNA vaccines do not contain other sequences in the plasmid 
backbone, so immune responses are elicited only against the desired antigen. Transient 
expression of the vaccine antigen enables more controlled antigen exposure and minimizes 
the risk of tolerance induction. mRNA vaccines are safer than plasmid DNA and viral vector 
vaccines. Moreover, absence of anti-vector immunity allows mRNA vaccines to be 
administered repeatedly
60
. The mRNA vaccine production process is highly flexible and 
scalable. If there is a need to produce new vaccine, the process can be easily adapted to GMP 
conditions in the manufacturing unit. Thus, the mRNA vaccine production process avoids 
expensive steps caused by the requirement to fulfil regulatory demands for product-specific 
validations. At the end, millions of new vaccine doses can be produced within few days.  
Therefore mRNA production appears to be no more costly than pDNA at an industrial 
scale
61
.  
  Substantial efforts have been invested in modifying the structural elements of IVT mRNA to 
improve its intracellular stability and translational efficiency.  
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 5’ Cap: 
Natural eukaryotic mRNA has a 7-methylguanosine (m7G) cap linked to the mRNA during 
the transcription process by a 5’-5’- triphosphate bridge (ppp). The most commonly used 
approach is to add a synthetic cap analogue (m7GpppG) into the in vitro transcription 
reaction. However, a substantial proportion of m7GpppG cap analogues is incorporated in 
reverse orientation into mRNA and remains translationally inactive. This might lead to 
inefficient and variable protein expression after administration. Anti-reverse cap analogues 
such as ARCA(m2
7,3’-O 
GpppG) can insert only in the correct orientation and can be 
recognized by the translational machinery
62
. 
 
 Poly(A) tail: 
In synergy with the 5’ cap, the 3’ poly (A) tail regulates the stability and translational 
efficiency of mRNA. Recombinant poly(A) polymerase enables the extension of IVT mRNA 
by two methods. The first method is addition of adenine during the in vitro transcription 
reaction, and the second is coding adenine in plasmid DNA. One shortcoming of enzymatic 
polyadenylation is that each RNA preparation consists of a mixture of RNA species differing 
in the lengths of their poly(A) tails. By contrast, in vitro transcription of mRNA from a DNA 
template results in a defined poly(A) tail length, and is therefore preferred. The efficacy of 
polyribosome formation increases with increasing length of the poly(A) tail, resulting in 
enhanced protein expression. However, the 3’end of the poly(A) tail should not be masked by 
additional bases. Therefore, the length of the poly(A) tail should be maintained between 120 
and 150 nucleotides
63
. 
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 Incorporation of modified nucleosides 
IVT mRNA initiates immune stimulation by triggering pattern recognition receptors, the 
natural role of which is to recognize and respond to viral RNAs by inducing various 
downstream effects
64
. IVT mRNA in endosomal compartments is recognized by TLR3, 
TLR7 and TLR8. Cytoplasmic delivery leads to activation of retinoic acid-inducible gene I 
(RIG-I) and melanoma differentiation-associated protein 5 (MDA5). This stimulation of 
innate responses leads to strong induction of type-I interferon (IFN). Type I IFNs play a key 
role in the anti-microbial host defence by initiating innate immune responses against viral 
RNA. Importantly, it has been shown that type I IFN inhibits the expression of antigen-
encoding mRNA
65
.   
 
Figure1. Innate sensing of RNA sequences through different pattern recognition receptors: RNA-specific 
PRRs include endosomal TLR3, TLR7 and TLR8 and cytosolic RIG-I and MDA5. Activation leads downstream 
phosphorylation and activation of transcription factors IRF3, IRF7 and NFκB which bind to the promoter region 
24 
 
of type I Interferons and pro-inflammatory genes such as IL-6, IL-12, TNF. Activation of the NOD-like 
receptors lead to the maturation of pro-IL β and pro-IL 18. TLR, Toll-like receptor; NOD2, nucleic-binding 
oligomerization domain-like receptor 2; RIG-I, retinoic acid-inducible gene-I; MDA5, melanoma differentiation 
associated protein; MAVS, mitochondrial antiviral signalling protein; TBK1, TRAF family-associated NF-κB 
activator (TANK)-binding kinase-1; TRIF, TIR domain-containing adaptor inducing IFN-β; MyD88,Myeloid 
differentiation factor-88; IRF, Interferon regulatory factor; NLRP3, Nacht, LRR, PYD domain containing 
protein. DEAD-box protein (DDX)   
 
 
Investigations of RNA sensors in cells identified the structural elements in IVT mRNA that 
stimulate the immune system. These elements have been replaced by components that are not 
recognized by innate sensors 
66
. In addition to adenine, guanine, cytosine and uridine, 
mammalian mRNA also contains 5-methyl-cytidine and N6-methyl-adenosine
67
. The 
existence of pseudo-uridine was the first post-transcriptional modification discovered
68, 69
. 
Bacteria lack such modified nucleosides, but they are abundant in viruses, where they are 
thought to contribute to immune avoidance 
69, 70
. TLR7 and TLR8 activation can be avoided 
by incorporating naturally occurring modified nucleosides such as pseudouridine, 2-
thiouridine, 5-methyluridine, and/or 5-methylcytidine into IVT mRNA. Pseudouridine and 2-
thiouridine were shown to make IVT mRNA undetectable by RIG-I and PKR
68, 71
. By using 
high-performance liquid chromatography (HPLC) purification, dsRNA contaminants were 
eliminated
72
, so that TLR3 activation is avoided. Thereby, the modified mRNA no longer 
induced any immune-stimulatory effect. The modified mRNA is translated efficiently and 
protein expression is improved due to the absence of inhibitory effects. Nucleoside-modified 
mRNA encoding erythropoietin neither increased cytokine levels nor de novo synthesised 
anti-erythropoietin antibodies. A single intramuscular injection of modified mRNA encoding 
erythropoietin raised the haematocrit from 51.5% to 64.2% after 28 days. In vivo delivery of 
modified mRNA is emerging as a replacement for or supplement to proteins, to generate 
pluripotent stem cells, and to engineer the genome
73
. 
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Recently, it was demonstrated that it is possible to use modified mRNA to encode the light 
and heavy chains of VRC01 antibody, which broadly neutralized diverse HIV-1 viral strains 
74
. Modified mRNA formulated with lipid carriers elicited potent and durable neutralizing 
antibody responses against Zika virus, in mice and in non-human primates, after a single low-
dose immunization
75, 76
. However, modification of mRNA reduces its recognition by innate 
sensors, which hampers rather than enables T cell activation, because dendritic cell activation 
and cytokine release are reduced
77
. 
3. Need for vaccines activating cellular immunity  
Traditional live attenuated or inactivated vaccines generate strong cellular and humoral 
immunity
78
. Even in the absence of adjuvants, live/inactivated vaccines are capable of 
activating innate immunity to a certain extent and to contribute to disease specific protection. 
However, addition of adjuvants improves the efficacy of these classical vaccines. The role of 
adjuvant in may involve the slow release of antigen or the skewing of the immune response. 
Although the purified forms of antigens are safer, they are less immunogenic than traditional 
whole-cell vaccines. Although some highly effective antibody-inducing vaccines (shown in 
Table 1) against viral and bacterial diseases are available, protection against more complex 
pathogens requires engagement of T cells
79
. Vaccines are being designed to induce strong 
enough CD8+ and/or CD4+ T cells possessing the necessary effector functions to directly 
contribute to pathogen clearance via cell-mediated effector mechanisms, rather than only 
CD4+ T-cell help for B cells leading to protective antibody responses
80
. 
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Type of vaccine Trade name Description 
 
 
 
 
 
 
 
 
Live 
BCG Vaccine For the prevention of 
tuberculosis in persons not 
previously infected with M. 
tuberculosis who are at high 
risk for exposure. 
M-M-Vax Measles and Mumps Virus 
vaccine 
Vaxchora Oral Cholera Vaccine  
 
 
M-M-R II and ProQuad 
Measles, Mumps, and 
Rubella Virus Vaccine 
ROTARIX Oral Rotavirus Vaccine 
ACAM2000 Smallpox (Vaccinia) Vaccine 
Zostavax Zoster Vaccine  
FluMist Quadrivalent Intranasal, Types A and 
Types B influenza vaccine 
 
 
 
 
Inactivated 
KINRIX, Quadracel Diphtheria and Tetanus, 
Poliovirus vaccine 
Havrix, VAQTA Hepatitis A vaccine 
JE-Vax, Ixiaro Japanese Encephalitis Virus 
Vaccine  
IPOL Poliovirus Vaccine 
Inactivated (Monkey Kidney 
Cell) 
Poliovax Poliovirus Vaccine 
Inactivated (Human Diploid 
Cell) 
 
 
 
 
 
 
FLUAD 
 
Trivalent inactivated 
influenza vaccine 
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Table 1: Vaccines licensed for human use (Data obtained from ‘European Centre for Disease 
Prevention and Control’ (ECDC) and ‘U.S. Food and drug administration’ (FDA) 
 
4. Concluding remarks 
The use of proteins, peptides and nucleic acids has improved the safety of vaccines in 
comparison with live attenuated pathogens, but their poor immunogenicity hinders their 
development and success. Therefore, novel vaccine designs that provide robust immune 
responses are needed. Moreover, induction of cellular immunity is important for long lasting 
protection. So, it is essential to understand the biology of CD8+ and CD4+ T cells in order to 
more rationally design vaccines. In the following chapter, we focus on the current knowledge 
of antigen processing mechanisms in APCs with respect to CD4+ and CD8+ T cell induction. 
 
 
 
 
 
 
 
 
 
Type of vaccine Trade name Description 
 
 
Recombinant 
Recombivax HB, Engerix-B Hepatitis B vaccine 
Gardasil 
 
Human Papillomavirus 
Quadrivalent (Types 6,11, 
16, 18) vaccine 
Cervarix Human Papillomavirus 
Bivalent (Types 16, 18) 
vaccine 
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CHAPTER 2 
 
Antigen processing and presentation to  
CD8+ and CD4+ T cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“Thus far the civilization of mankind has passed through four successive stages of evolution, 
namely, those based on the use of fire, the development of agriculture, the development of 
urban life and use of basic science for technological advancement” 
- Charles Darwin  (Naturalist, Geologist and Biologist) 
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1. Introduction  
T cell recognition of antigen-presenting cells depends on their expression of a spectrum of 
peptides bound to major histocompatibility complex class I (MHC-I) and class II (MHC-II) 
molecules
1. Since the 1980’s, our understanding of cell biology of antigen processing has 
increased greatly due to the characterization at the molecular level of the processes involved 
in generating peptides from intact proteins and loading them on MHC molecules. Due to the 
segregated pathways of biosynthesis of MHC-I & MHC-II molecules, peptide antigens are 
presented differently dependent on their intracellular location. In this chapter, we will 
summarize the current understanding concerning the biological mechanisms involved in 
antigen processing and presentation to CD8
+
 & CD4
+
 T cells. This knowledge is crucial for 
designing vaccines which can induce potent antigen specific T cell responses. 
2. Processing of cytosolic antigens for class I MHC-associated presentation 
All nucleated cells expressing MHC class I molecules and act as antigen presenting cells for 
CD8
+
 T cells
2
. Class I MHC-associated antigenic peptides are produced by a process 
involving the proteolytic degradation of cytosolic proteins, the transport of the generated 
peptides into the endoplasmic reticulum and their binding to newly synthesized class I 
molecules.  
 2.1. Production of proteins in the cytosol 
Fundamentally, the immune system cares about only one attribute of a protein: whether the 
peptide came from self or non-self source. Foreign antigens in the cytosol may be the 
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products of viruses or other intracellular microbes that infect cells and synthesize their own 
proteins during their life cycle. Peptides that are presented in association with class I 
molecules may also be derived from microbes that are phagocytosed into phagosome. Certain 
pathogens create pores in phagosome through which it enter into cytosol. For instance, 
pathogenic strains of Listeria monocytogenes produce listeriolysin protein that enables the 
bacteria to escape from phagosome vesicles into the cytosol
3
. Once the phagocytosed 
microbes are in the cytosol, microbe-derived proteins are processed like other cytosolic 
antigens. In tumour cells, mutated self-genes or oncogenes often produce protein antigens 
that are recognized by MHC class I-restricted cytotoxic T lymphocytes (CTLs) 
4, 5 
. Protein 
antigens in the cytosol can also arise from cryptic translational reading frames
6
. Cryptic 
epitopes are drawn from alternative translational reading frames and atypical translation 
products but may also include defective ribosomal products (DRiPs) resulting from 
premature termination and/or improper folding 
7, 8
. Recently, several cryptic polyepitopes 
have been demonstrated to provide an effective antigenic stimulus for the induction of CD8 
T-cell responses against diseases such as Hepatitis C, HIV-1. 
9-11,12
.  
 2.2. Proteolytic degradation of cytosolic proteins 
The major mechanism for the generation of peptides from cytosolic protein antigens is 
proteolysis by the proteasome. The proteasome is a large multiprotein enzyme complex with 
a broad range of proteolytic activities and that is present in the cytoplasm of most cells. 
Proteasome performs a basic housekeeping function in cells by degrading different 
cytoplasmic proteins. These proteins are targeted for proteasomal degradation by covalent 
linkage of several copies of a small polypeptide called ubiquitin
13
. Following ubiquitination, 
the protein is unfolded, the ubiquitin is removed and processed through proteasomes. The 
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proteasome has a broad substrate specificity and accordingly can generate a broad variety of 
peptides from cytosolic proteins
14
. 
 
The proteasome consists of barrel-shaped 20S proteolytic core and appears as a cylinder 
composed of a stacked array of two inner and two outer rings, each ring being composed of 
seven subunits. Three of the seven subunits are the catalytic sites for proteolysis – namely β1, 
β2 and β5. The replacement of these β-subunits by their immune counterparts β1i, β2i and β5i 
encoded by LMP2, MECL1 and LMP7 genes respectively, results in the formation of 
immunoproteosomes
15
. These are constitutively expressed in lymphoid cells but their 
synthesis can be induced rapidly also in non-immune cells by interferon-gamma (INF-γ) or 
TNF due to viral or bacterial infection
16,17
. The newly assembled immunoproteasomes have 
altered cleavage kinetics compared to their 20S standard proteasome, for efficient elimination 
of infected cells. The process results in the specific generation of antigenic peptides with 
hydrophobic or sometimes basic C termini 
18,
 
19
. Upon viral infection, the presentation of a 
majority of MHC class I epitopes was markedly reduced in immunoproteasome-deficient 
animals compared to wild-type animals, whereas presentation of MHC class II peptides was 
unaffected 
20
.  This shows the importance of immunoproteasome in MHC I processing and 
presentation. 
During antigen processing, a variety of peptides are produced from antigenic proteins and 
only some of these peptides possess the characteristics that enable them to bind to MHC 
molecules. A majority of responding T cells are specific for only one or a few linear amino 
acid sequences derived from a specific protein. These sequences accordingly constitute so-
called immunodominant epitopes
21
. In humans infected with the human immunodeficiency 
virus, individual patients contain T cells that recognize a small number of viral epitopes. The 
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same phenomenon has been seen with many other viruses and intracellular bacteria. This 
implies that even complex microbes produce very few peptides capable of binding to any one 
allelic MHC molecule. Through the high-throughput analysis of viral protein the 
immunodominant epitopes can be identified. It can be done by screening the presence of 
amino acid sequences that are capable of binding to MHC molecules with high affinity. 
An application of such knowledge can be applied in effective vaccine design
22
. Given the 
potential translational implications, prediction of B cell and T cell epitopes has long been the 
focus of immuno-informatics. Among the most popular tools are PSSM-based predictors 
(e.g., SYFPEITHI, RANKPEP or BIMAS), SVM-based predictors {e.g., SVMHC, 
SVRMHC) and ANN-based methods (e.g., netMHC). To find the most accurate prediction 
tool, several benchmark studies have been performed. However,  their results differ greatly, 
primarily owing to the use of different evaluation parameters. Although the binding affinity is 
crucial for epitope prediction, many peptides with predicted high affinity scores are not 
immunogenic. Thus, additional steps in antigen processing and recognition need to be 
considered as well. To predict each step of the antigen-processing pathway, predictors based 
on different machine learning methods have been developed. For example: ‘netChop Cterm 
and  ProteaSMM’ to predict proteasomal cleavage, ‘PredTAP and SVMTAP’ to predict TAP 
transport
23
. Synthetic peptides containing these epitopes may be effective vaccines for 
eliciting T cell responses. 
 2.3.Transport of peptides from the cytosol to the endoplasmic reticulumn 
Because antigenic peptides for the class I pathway are generated in the cytosol whereas class 
I MHC molecules are synthesized in the endoplasmic reticulum (ER), a mechanism must 
exist for delivery of cytosolic peptides into the ER. The initial insights into this mechanism 
came from studies with cell lines that are defective in assembling and displaying class I MHC 
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complexes on their surfaces. The mutations responsible for the defect turned out to involve 
two genes located within the MHC-locus. They are homologous to the ABC transporter 
family of genes, which encode proteins that mediate adenosine triphosphate(ATP) dependent 
transport of low molecular weight compounds across cell membranes. The genes involved 
encode the subunits of a heterodimer transmembrane complex called  transporter associated 
with antigen processing (TAP)
24
.  
Interestingly, TAP1 and TAP2 genes are next to the genes encoding LMP-2 and LMP-7 in the 
MHC-locus. Also here the synthesis of the TAP proteins is stimulated by INF-ץ. The TAP 
complex is located mainly in the ER, where it mediates active, ATP-dependent transport of 
peptides from the cytosol into the ER lumen
25
. Although TAP exhibits a broad range of 
specificities, it optimally transports peptides ranging from 6 to 30 amino acids long and 
containing carboxyl termini that are basic (in humans) or hydrophobic (in humans and mice). 
As mentioned before, the proteasome generates peptides with these features. Therefore, the 
TAP-dimer delivers to the ER peptides of the right size and characteristics for binding to 
class I MHC molecules.  
Antigen processing and presentation via MHC class I is regulated by INFץ which increases 
not only the expression of class I MHC molecules but also the expression of TAP1 and TAP2 
proteins and of the immunoproteasome LMP2 and LMP7 subunits
26
. The induction of TAP 
by INFץ is more rapid than that of MHC class I molecules, which is consistent with the view 
that the constitutive level of TAP expression is insufficient to support inducible increases of 
MHC class I 
27
. Patients carrying TAP1 and/or TAP2 mutant genes show defective class I 
MHC-associated antigen presentation and an increased susceptibility to bacterial infections
28
. 
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On the luminal side of the ER membrane, the TAP protein is non-covalently attached to 
newly synthesized class I MHC molecules by a linker protein called tapasin
29
. Thus, the class 
I molecule is strategically located at the site where it can receive peptides. 
 
 2.4. Assembly of peptide-Class I MHC complexes in the ER 
When peptide enters the ER via TAP, the peptide binds to the cleft of the associated class I 
molecule. The peptide-class I MHC complex is then released from tapasin
30
 and is able to 
exit the ER and to be transported to the cell surface. In the absence of bound peptide, the 
newly formed MHC α chain-β2-microglobulin dimers are unstable, cannot efficiently be 
transported out of the ER, and are presumably degraded in the ER. Peptides transported 
into the ER preferentially bind to class I, but not class II, MHC molecules. Because peptide 
binding clefts of newly synthesized class II molecules are blocked by the associated with 
invariant chain protein (Ii ) which is explained in MHC II presentation pathway below. 
 2.5. Surface expression of peptide-class I MHC complexes 
Stable peptide-class I MHC complexes that were produced in the ER then move through the 
Golgi complex to be transported to the cell surface by exocytic vesicles
31
. Once expressed on 
the cell surface, the peptide-class I MHC complexes will be recognized by CD8+ T cells. In 
this interaction, the CD8 co-receptor plays an essential role by specific binding to class I 
MHC molecule.  
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Figure1. Pathways of antigen processing and presentation:  In class I MHC pathway, protein antigens in the 
cytosol are processed by proteasomes and peptides are transported into the endoplasmic reticulum, where they 
bind to class I MHC molecules. In class II MHC pathway, extracellular protein antigens are endocytosed in 
vesicles, where the antigens are processed and the peptides bind to class II MHC molecules. 
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3. Processing of endocytosed antigens for class II MHC-associated presentation 
Dendritic cells, B cells and macrophages constitutively express MHC class II molecules and 
are regarded as ‘professional antigen presenting cells’. Recently, additional haematopoietic 
cell types have been suggested to present antigens on MHC II molecules to CD4+ T cells, 
including mast cells, basophils, eosinophils, neutrophils, innate lymphoid cells and CD4+ T 
cells themselves. However, these non-professional APCs are unlikely to replace professional 
APCs, because there is little compelling data that these cell types are able to activate naïve 
CD4+ T cells
32
.  The classical route of MHC II presentation involves the proteolytic 
degradation of internalized proteins in endocytic vesicles and binding of peptides to class II 
molecules present in those vesicles. 
 3.1. Extracellular proteins uptake into vesicular compartments of APCs 
Different APCs can trap protein antigens in several ways with varying efficiencies and 
specificities. Such as micropinocytosis, endocytosis, phagocytosis. Dendritic cells and 
macrophages express a variety of surface receptors that recognize structures shared by many 
microbes. However, recognition does not always mean uptake of the ligand for a number of 
pattern recognition receptors. After their internalization, protein antigens become localized in 
intracellular membrane-bound vesicles called endosomes which has acidic pH and contain 
proteolytic enzymes. The endosomal pathway of intracellular protein undergo transition from 
late endosomes to lysosomes, which are more dense membrane bound enzyme containing 
vesicles
33
. Particles internalized by phagocytosis follow a similar path, terminating in 
phagolysosomes that are formed by the fusion of phagosomes and lysosomes. 
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 3.2. Processing of internalized proteins in endosomal and lysosomal vesicles 
The degradation of protein antigens in vesicles is an active process mediated by proteases that 
have an acidic pH optima. Protein unfolding is promoted due to progressive acidification of 
organelles, which makes the protein more sensitive to protease action. The most abundant 
proteases of endosomes are cathepsins, which are thiol and aspartyl proteases with broad 
substrate specificities. In highly degradative cells, such as macrophages, successive cleavages 
are performed by these enzymes. This results in short peptides and free amino acids that are 
translocated into the cytosol to replenish tRNAs for new protein synthesis. But in less 
proteolytically active APCs, large intermediates form the dominant source of peptides for 
MHC II binding
34
.   
 3.3. Biosynthesis and transport of class II MHC molecules to endosomes 
 In endoplasmic reticulum (ER), α and β chains of class II MHC molecules are co-
ordinately synthesized and associate with invariant chain protein (Ii). The  Ii is a trimer 
composed of three 30kD subunits, each of which binds to one newly synthesized class  II 
MHC αβ heterodimer in a way that interferes with peptide loading of the cleft formed by the 
α and β chains. As a result, class II MHC molecules cannot bind and present (partially 
unfolded) proteins are encountered in ER. The Ii also promotes folding and assembly of the 
nascent MHC class II molecules and directs newly formed class II molecules to endosomal 
vesicles. Several forms of Ii chain exist due to alternative splicing and the use of alternate 
start codons
35
. The exocytic vesicles transporting class II molecules out of the ER fuse with 
vesicles containing internalized and processed antigens. The net result of this sequence of 
events is that class II molecules enter the vesicles that contain proteases processed protein 
antigen. 
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 3.4. Association of processed peptides with class II MHC molecules in vesicles 
Cathepsins that generate peptides from internalized proteins also act on Ii
36
. The degradation 
leaves only a 24-amino acid remnant called class II associated invariant chain peptide 
(CLIP). X-ray crystallographic analysis has shown that CLIP sits in the peptide-binding cleft 
in the same way that antigenic peptides bind to class II MHC molecules
37
. In order to access 
the cleft by antigenic peptides, CLIP needs to be removed. This is accomplished by 
heterodimeric glycoprotein (DM). In humans DM is known as HLA-DM and in mice as H2-
DM. It has a structure similar to that of MHC class II molecules
38
. HLA-DM acts as peptide 
editor by facilitating the removal of CLIP and its exchange with peptides possessing a higher 
affinity for the specific MHC II molecules. Because the class II MHC peptide binding cleft is 
open, large peptides or even unfolded whole proteins may bind and are then “trimmed” by 
proteases to an appropriate size for T cell recognition. 
 3.5. Expression of peptide-MHC class II complexes on the APC surface 
Selective trafficking of peptide-loaded class II molecules from the vesicular compartment to 
the cell surface while other molecules involved in antigen presentation such as HLA-DM, 
stay in the vesicle itself.  Only properly loaded peptide MHC complexes will stay long 
enough to be displayed on the cell surface.  MHC molecules that fail to obtain high affinity 
peptides are either subjected to immediate degradation or feature a short term expression at 
the cell surface followed by endocytosis and degradation
39
. Once expressed on the APC 
surface, the peptide-class II complexes may be recognized by CD4
+
 T cells, with the CD4 co-
receptor playing an essential role by specific binding to MHC class II molecule. 
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4. Cross-presentation 
It is defined as the presentation of exogenous antigens on MHC class I molecules. The 
sources of the exogenous antigen may be apoptotic cells, exosomes, peptides complexed with 
heat-shock proteins, live cellular material, particles. Cross presentation is mainly carried out 
by specific dendritic cell subsets through their endocytic and phagocytic pathways
40
. Recent 
studies have shown that Batf3-dependent resident cDCs displayed specific features favouring 
cross-presentation. Although pDC have been reported to cross-present ex vivo after TLR 
stimulation, in vivo studies have shown that pDCs are dispensable for cross-presentation 
during viral infections
41
 
The relative contributions of presentation to CD8+ T cell activation depend largely on the 
type and tropism of the pathogen. Dynamic intravital imaging has shown that infected DCs 
account for CD8+ T cell priming during Vaccinia virus infection
42
 
43
. By contrast, uninfected 
DCs cross present through Toxoplasma gondii infected neighbouring cells
44
. Due to the direct 
contact between DCs and infected cells, preformed MHCI/peptide complexes can be 
transferred and presented by DCs. This process is termed as cross dressing which can also 
occur through secreted membrane vesicles such as exosomes
45
. This process is termed as 
cross dressing which can also occur through direct contact between DCs and infected cells
46
. 
The contribution of cross-presentation to antiviral and anti-tumour immune responses 
remains uncertain. In one of the mechanisms proposed, the antigen is transferred from the 
phagosome into the cytosol, where it is hydrolyzed by proteasomes into oligopeptides that are 
then transported by the transporter associated with antigen processing to MHC class I 
molecules in the endoplasmic reticulum or phagosomes
47
. Another mechanism also involves 
the presence of MHC class I molecules in endosomes, which might contribute to eliciting 
CD8
+
 T cell responses
48
.   
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It is still unclear, which DC subtypes can or cannot cross-present antigens under specific 
situations. The main problems to resolve this issue include a lack of genetically modified 
mice with selective defects in cross-presentation and the identification of cross-presenting 
DC subpopulations
49
. Even now, the molecular basis of cross-presentation remains uncertain, 
such strong knowledge is a prerequisite for the development of novel vaccination strategies. 
5. Antigen presenting cells: instigators of T cell immunity 
Multiple decisions are made by APCs when initiating an immune response. such as whether 
to actively respond to the antigenic challenge and what type of active immune response to 
induce or instead to tolerate the antigenic challenge. After TCR engagement with antigen, the 
activation of a T-cell response is context dependent and finely modulated by diverse co-
regulatory signals ultimately deciding the response fate. This process comprises a complex 
mechanism of co-stimulatory and co-inhibitory pathways resulting in the elimination of self-
reactive T cells and the amplification of antigen-specific immune responses. Co-stimulators 
for T lymphocytes such as CD80, CD86 and CD28 are expressed on professional APCs. Co-
inhibitory receptors such CTLA-4 and PD-1 have a critical role in the maintenance of 
immune homeostasis. Their expression on effector T cells ensures the proper contraction of 
effector T cell responses
50
. Co-signalling ligands and counter-receptors have now been 
identified on nearly all cell types, although their expression has been most well characterized 
on antigen presenting cells (APCs), as APCs are the primary drivers of T cell activation and 
differentiation in lymphoid organs
51
. However antigen-specific T cell differentiation also 
depends on the cytokine milieu of the microenvironment and concentration of antigens, type 
of APCs 
52
. 
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Among APCs, dendritic cells (DCs) are considered to be most important due to their 
enhanced ability to stimulate naive T cells
53
. DC activation is typically induced by triggering 
Pattern Recognition Receptors (PRRs), which recognize evolutionary conserved pathogen 
associated molecular patterns (PAMPs) expressed naturally by micro-organisms. PAMPs 
include lipids, lipoproteins, proteins and nucleic acids derived from a wide range of 
pathogens such as bacteria, viruses, parasites and fungi
54
. The best known PRRs are Toll-like 
receptors and nucleotide oligomerization domain- (NOD-) like receptors. Addition of PAMPs 
in synthetic or detoxified derivative forms increases the strength of the T cell response by 
several orders of magnitude.  
6. Generation of humoral immunity 
Humoral immune responses are initiated by the recognition of humoral or cell-bound antigens 
by B-lymphocytes. Antigen binds to membrane IgM and IgD receptors on naïve B cells and 
activates these cells. B cell activation consists of a series of responses that lead to 
proliferation and differentiation, resulting in the generation of effector cells that secrete 
antibodies and memory B cells. Some activated B cells produce antibodies other than IgM 
and IgD and this process is termed as heavy chain isotype class switching. Activated B cells 
may also produce antibodies that bind to antigens with higher affinities, a process called 
affinity maturation. 
7. Concluding remarks  
In this chapter, we have focused on the segregated pathways of biosynthesis and assembly of 
antigenic peptides with class I & class II MHC molecules. Thereby, cytosolic antigens enter 
the pathway of MHC class I processing and are presented to MHC class I restricted CD8+ 
cytotoxic T cells (CTLs), which kill the cells producing the intracellular antigens. In contrast, 
antigens that end up in endosomal or phagosomal vesicles will be presented to MHC class-II 
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restricted CD4+ T cells because the pathways by which extracellular proteins are internalized 
converge with the pathway of MHC class II expression. These CD4+ T cells function as 
helpers to stimulate various immune effector mechanisms, such as antibody-producing B 
lymphocytes and phagocytes, which serve to eliminate extracellular antigens. By selectively 
targeting antigen processing pathways and promoting activation and differentiation of the 
APC, the type and strength of CD4+ and/or CD8+ T-cell responses can be modulated. In 
chapter 3, we will introduce particulate vaccines which mimic the size and shape of 
pathogens, thereby serving as natural targets for uptake and processing by APCs. 
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CHAPTER 3 
________________________________________________________ 
Particulate vaccines: the right path to 
 antigen presenting cells  
 
 
 
 
 
 
“There’s plenty of room at the bottom” 
- An invitation to nanotechnology by Richard Feynman 
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1. Introduction 
Multiple mechanisms govern the effector, memory and regulatory functions of adaptive 
immune cells through their surface antigen receptors. B-cells recognize antigen that directly 
binds to their receptors (BCRs), whereas T-cell receptors (TCRs) sense peptide fragments 
bound to MHC molecules displayed on the surface of APCs. Depending on the activation 
status of dendritic cells, the outcome of antigen presentation will be induction of 
immunogenicity or tolerance
1, 2
. 
 
Recent technological advances have enabled the large-scale production of well-defined, 
purified antigens. Though such antigens possess a better safety profile, they are less 
immunogenic than traditional whole-cell vaccines. The immune response to antigen can be 
enhanced by compounds named adjuvants. The scope of immunological adjuvants is wide 
and heterogeneous. Based on their inherent nature, they can be classified as immuno-
stimulants or delivery systems 
3, 4
.  Immuno-stimulants interact with specific innate receptors 
(such as TLRs and NLRs), whereas delivery systems increase the immune response by 
different mechanisms, depending on their characteristics. Particles provide an adjuvant effect 
by enhancing antigen delivery, co-delivering antigen and immuno-stimulant, or activating 
innate immunity through their intrinsic immuno-stimulatory properties
5
.  
 
Although co-administration of antigen and immuno-stimulant can be effective, high doses are 
often needed to ensure that APCs encountering antigen are also stimulated by the immuno-
stimulant
6
. Thus, particulate delivery enabling co-localized delivery of immuno-stimulant and 
antigen hold great promise for shifting the resultant immune response from tolerance to 
immunogenicity and for increasing the efficacy of subunit vaccines. Various factors influence 
the strength of the immune responses induced by these carriers. These factors include size, 
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surface charge, homogeneity, chemical composition, and location of antigens in the particle. 
Antigens associated with particles of 20‒400 nm mimic viruses, whereas components from 
0.5 µm to > 10 µm mimic key features of bacteria, fungi or parasites. As the immune system 
has evolved to react to particulate pathogens, these carriers are readily taken up by antigen 
presenting cells (APCs). Therefore, particulate vaccines represent a promising approach to 
surmount the deficiencies of purified antigens
7, 8
.   
 
As persistence of antigen at the immunization site induces strong sequestration and 
subsequent dysfunction and deletion of vaccine-induced T cells, research is focusing more on 
the development of non-persistent and rapidly biodegradable vaccines
9
. Entry of particles into 
lymphatic vessels can be influenced by different features of particles, among which size is an 
important factor. Particles < 50 nm were more efficiently transported than those > 100 nm 
10
. 
Nanoparticles of 20‒200 nm in lymph node-resident DCs and macrophages indicate passive 
drainage of these particles in the lymph node. By contrast, larger particles of 200‒500 nm 
require active transport by dendritic cells to the draining lymph node
11-13
. This phenomenon 
of particle trafficking into draining lymph nodes after immunization is illustrated in Figure 1. 
 
Antigens in the format of protein, peptide or nucleic acid are susceptible to degradation 
during transport to lymph nodes. Association of antigens with carrier particles can protect 
them against degradation. Additionally, it mimics the particulate nature of pathogens that 
promotes their uptake by antigen presenting cells. Although the association of antigens with 
carrier particles can protect them against such degradation, strong interaction with the carrier 
can also alter the inherent properties of the antigen
14
. So the choice of the appropriate particle 
in the vaccine formulation requires consideration of several factors. In this chapter, we 
describe nano-meter range carriers and the features they offer.  
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Figure 1: In vivo particle trafficking to draining lymph node upon immunization. Smaller 
nanoparticles (20‒200 nm) passively drain into the lymph node and are taken up by DCs 
resident in the lymph node. On the other hand, larger nanoparticles (200‒500 nm) remain 
at the injection site. Larger nanoparticles require active transport by DCs into lymph 
nodes for antigen presentation and subsequent activation of T cells and B cells. Particles 
are also taken up by macrophages and other dermis resident antigen presenting cells 
(APCs). But, migratory DCs have been reported to play crucial role in the elicitation of T 
cell immunity. 
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2. Liposomes 
Liposomes are spherical vesicles composed of phospholipid bilayers surrounding an aqueous 
compartment. Hydrophilic portions of the lipid bilayer are directed towards the internal and 
external aqueous phases, whereas hydrophobic portions of the two lipid layers are directed 
towards each other, forming the internal core of the membrane. This arrangement provides 
great potential for therapeutic delivery, as liposomes can encapsulate and localize both water-
soluble and water-insoluble substances, either together or separately. The encapsulation of 
antigen within the liposomes depends on the nature of the lipid bilayer, the size of cargo and 
the interaction of antigen with the lipid membrane
15
. The major drawback of the 
encapsulation approach is that it has a lower capacity for incorporating antigens within the 
internal core of the lipid bilayer. To overcome this drawback, antigen can be conjugated on 
the liposome, whereupon it becomes an integral part of the liposomal membrane. The most 
common mode of covalent lipid-antigen conjugation (either pre- or post-vesicle formation) 
resulted in superior antibody induction
16, 17
, which is expected because B cell receptors can 
recognize intact antigen on the liposome surface. As the size and complexity of the antigen 
decreases, the benefit of surface conjugation for antibody induction increases. Surface 
conjugation of antigenic peptides induced superior humoral immune responses compared to 
encapsulation of antigenic proteins, including peptides derived from viral antigens (HIV-1 
gp120, HSV glycoprotein D) and tumor antigens (MUC1)
18-20
. 
Lipid anchoring of the antigen involves inclusion of pre-conjugated antigen‒lipid complexes 
in the lipid solution before formation of the liposomes
21
. Lipid-anchored tumor-specific E7 
peptide antigen attached to cationic liposomes elicited stronger CD8+ T cell responses than 
the non-lipidated, encapsulated peptide 
22
. This method of lipidation should be considered 
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carefully, as attachment of lipids to peptides or proteins can affect the presentation and 
processing of antigen in APCs. 
Liposomes have little or no immuno-stimulatory effect when used without incorporation of 
additional innate-sensing ligands
23
. However, studies on the intrinsic immuno-stimulatory 
nature of liposomes are being reported. Recently, liposomes were identified as particulate 
activators of the NLRP3 inflammasome (nod-like receptor family, pyrin domain containing 
3) 
24
.  To improve the immune responses, additional immuno-stimulators are used alongside 
liposome-based vaccine formulations. The widely used two-phase vehicles are liposomes and 
micro-fluidized squalene or squalene emulsions. They bind to B-lymphocytes and activate the 
complement system, thereby stimulating the proliferation of B cells, leading to the generation 
of B-cell memory
25
. Anionic liposomes were more potent than cationic and neutral liposomes 
for generation of Th1 responses
26
. But the charge was found to affect the ability of liposomes 
to induce hypersensitivity, with more negatively charged liposomes generating more adverse 
effects
27
.Therefore, much research is going on to develop cationic adjuvant formulations 
28
.  
Cationic liposomes have good gene transfection capacity and biocompatibility. A few 
therapeutic clinical trials are underway, but clinical use of liposomes has been hindered by 
their in vivo instability
29
. It has been reported that intravenously injected lipoplexes form 
large aggregates with blood components, and that these aggregates become entrapped in the 
lung capillaries
30
. Therefore, cationic liposomes usually require additional components to 
enhance their in vivo stability in the presence of blood components. For example, 
hydrophobic cholesterol, non-ionic surfactants and PEG have been used to increase the 
physical stability of cationic liposomes in vivo 
31, 32
. Despite these drawbacks, liposomes 
represent a very promising non-viral gene delivery system for gene therapy.  
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 The use of liposomes in vaccine formulation (for induction of enhanced antibody responses 
to diphtheria toxoid) was first demonstrated in 1971
33
. Crucell’s Inflexal V for seasonal 
influenza
34
 and Epaxal for hepatitis A 
35
are liposomal systems currently approved for human 
use. Inflexal and Epaxal are vaccines for commercial use using the virosome-based antigen 
delivery system. These virosomes are reconstituted virus liposomes, composed of dioleoyl 
phosphatidylethanolamine (DOPE) and DOPC. For the production of Inflexal V, the 
influenza viruses are inactivated with beta-propiolactone. The influenza surface antigens, 
hemagglutinin and neuraminidase, are then purified and mixed with the phospholipid lecithin 
to form virosomes
9
. Epaxal is a vaccine based on formalin-inactivated hepatitis A (strain RG-
SB) antigen incorporated into virosomes
10
. Despite intensive research over the last 46 years, 
translation of liposomes to the clinic has not kept pace with the positive results obtained in 
pre-clinical studies. The issues encountered revolve around the manufacturing process and 
the stability of the formulation. Since different antigens interact differently with liposomes, it 
is difficult to develop liposomes that perform like a broadly applicable vaccine delivery 
platform. Moreover, vaccines need to be formulated in a single vial for easy use in the field. 
But liposomes normally require two vials, one for the lyophilized liposomes and antigens and 
the other for the liquid needed for reconstitution. The need for sterility in rural areas limits 
the potential use of a two-vial system.  
3. Polymer nanoparticles 
Polymers are long chains of repeating units formed by covalent binding of monomers. 
Biodegradable polymers are widely employed in medical research because they can be easily 
modified to fulfill the required criteria. Among the many available polymers, only a few are 
biocompatible with in vivo delivery. 
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3.1. Particles based on synthetic polymers  
The most commonly used synthetic polymers for the production of micro and nanoparticles 
are polyesters and their co-polymers. The major reasons for using these polymers are the ease 
with which their cargo can be incorporated, their hydrolytic biodegradability, and their 
predictable and tunable release kinetics 
36, 37
.  As listed in Table 1, the importance of co-
delivery of antigen and immuno-stimulant has been demonstrated using several synthetic 
polymer-based nanoparticles, such as poly(lactic-co-glycolic acid), poly-ε-caprolactone, and 
poly(methacrylic acid) in various disease models. PLG and PLGA nanoparticles have been 
the most extensively investigated due to their excellent biocompatibility and biodegradability. 
The prolonged release of antigens delivered by PLGA nanoparticles was shown to enhance 
the immune response to the model OVA antigen. PLGA nanoparticles provided an OVA 
release profile that extended over 10 weeks and was much slower than the release profile 
obtained from a liposomal formulation. In line with the sustained release profile, an OVA–
PLGA particulate vaccine formulation induced a higher antibody titre compared to the 
liposome formulation 8 weeks after subcutaneous administration in mice 
11
. Synthetic and 
natural polymers-based particles used in vaccine development are shown in Table 1. 
 To increase particle uptake and enhance antigen presentation to T cells, DC-specific 
targeting moieties are coated on or coupled to the surface of the particles. Besides the specific 
features and encouraging immunological performance of synthetic polymer-based 
nanoparticles, they suffer from multiple limitations, including low levels of antigen 
entrapment, damage to or denaturation of antigen, need for organic solvents in processing, 
and complex scale-up procedures. So the search for new biomaterials that can overcome these 
limitations continues. 
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Table 1: Synthetic and natural polymers based particles used in vaccine development 
Particle Study Components used Outcomes Ref 
Synthetic polymers 
Poly(lacti
c-co-
glycolic 
acid) 
(PLGA) 
Antigen and 
immuno-
stimulator co-
delivery 
OVA antigen 
LPS adjuvant 
Twofold increase in antigen specific IgG 
titers and IFNγ secretion 
 
38
 
Antigen and 
immuno-
stimulator in 
same carrier 
Ovalbumin protein and 
poly(I:c) adjuvant 
Nanoparticle induced balanced 
Th1/Th2-type antibody response, 
compared to vaccination with IFA, 
which predominantly stimulated Th2-
type response 
39
 
Comparison 
between co-
delivery and 
separate 
delivery 
TRP2 antigen and  
7-acyl lipid A adjuvant 
Co-delivery of antigen and adjuvant 
increased IFNγ secreting CD8+ T cells 
by 12-fold. 
40
 
 
Antigen and 
immuno-
stimulator  in 
separate 
particles  
 
H5N1-influenza-derived 
HA antigen and MPL, 
R837 adjuvants 
 
PLGA(HA) + PLGA(MPL+R837) 
induced balanced IgG1/IgG2a antibody 
responses. The synergic effect of 
PLGA(MPL + R837) particle was five 
times more than PLGA(MPL)  and 
PLGA (R837) particles 
41
 
 
Targeting 
molecules, 
immuno-
stimulator and 
antigen in 
same carrier  
 
Invariant NKT cell 
agonist α-
galactosylceramide (α-
Galcer) and TLR ligands 
(R848 and poly I:C) as 
adjuvant and ovalbumin 
protein 
OVA + α-GalCer nanoparticles are 
superior over OVA + TLR ligand 
nanoparticle in generating antigen-
specific cytotoxic T cells without the 
need for CD4+ T cells help 
 
42
 
 
Antigen and 
immuno-
stimulator 
carrier 
 
Multi-epitope peptide of 
Leishmania Cysteine 
Protease A (CPA160-
189) co-encapsulated 
with 
monophosphosphoryl 
lipid A (MPLA) in 
PLGA Nanoparticles 
Potent signatures of DC maturation 
obtained with anti-CPA cellular and 
humoral immune responses 
characterized by T cells producing large 
amounts of IL2, IFNγ and IgG1/IgG2a 
antibodies 
43
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Particle 
 
Study Components used Outcomes 
 
Ref 
 
 
poly-ε-
caprolact
one 
nanopart
icles 
(PCL) 
Antigen carrier 
 
 
Tetanus toxoid protein 
antigen 
 
 T helper Th1/Th2 polarized immune 
response 
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Antigen and 
immuno-
stimulator 
carrier 
 
Hepatitis B surface 
(HBs) protein antigen 
. 
Balanced IgG1/IgG2a antibody response 
 
45
 
 
Poly(meth
acrylic 
acid) 
(PMA) 
 
 
Antigen 
carrier 
OVA peptide 
 
PEGylation of PMA nanoparticles 
strongly improved lymph node 
targeting, which increased the priming 
of antigen-specific T cells. 
 
 
46
 
 
 
Natural polymers 
Alginate  Antigen and 
immuno-
stimulatory 
carrier 
 
Intrinsic 
immuno-
stimulatory 
nature 
Autoclaved Leishmania 
major (ALM) and CpG 
ODNs 
Th1 polarized response initiated 
significantly higher IgG titers than 
soluble antigen  
 
 
Alginate  by itself acts as adjuvant by 
activating the NF-κB pathway  
47
 
 
 
 
48
 
 
Dextran/ 
Dextran 
sulfate 
 
 
 
 
Antigen and 
immuno-
stimulatory 
carrier 
Antigen and 
immuno-
stimulatory 
carrier 
 
Tetanus toxoid and CpG 
oligonucleotides (ODNs) 
 
Ovalbumin and CpG 
ODNs 
Crosslinked dextran particles carrying 
tetanus toxin produced antitoxin titers 
that exceeded the protective levels 175 
times. 
Incorporation of protein antigen with 
CpG in dextran sulfate particles caused 
Th1/CTL polarization, but not without 
CpG 
49
 
 
 
50
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Particle 
 
 
Study Components used Outcomes 
 
Ref 
 
 
 
 
 
 
 
Chitosan 
 
Antigen 
Carrier 
 
inactivated Streptococcus 
equi cells 
Higher IgA levels, increased mucosal 
uptake and Th1/Th2 balanced responses 
in comparison with cationic liposomes  
51
 
 
Antigen and 
adjuvant 
carrier 
 
pDNA encoding 
pHSP65pep 
(Mycobacterium 
tuberculosis) 
 
Strong humoral and Th1-dependent 
cellular immunity. Increased protection 
against challenge observed after 4 
immunizations with 50 µg DNA 
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Antigen, 
adjuvant and 
DC targeting 
moieties 
carrier 
 
 
pDNA encoding 
Mycobacterium 
tuberculosis antigen 85B 
(Ag85B) co-encapsulated 
with another pDNA 
encoding an autophagy-
inducing factor (myc-
mTOR) 
 
 
Chitosan particle  with antigen and myc-
mTOR construct elicited significantly 
higher Ag85B-specific Th1antibody 
response than control groups (Ag85B 
plasmid alone or non-particulate format 
of plasmids) 
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Antigen, 
adjuvant and 
DC targetting 
moieties 
carrier 
pDNA encoding SARS-
CoV nucleocapsid 
containing particles 
functionalized with anti-
DEC-205 antibody 
A parallel comparison of targeted 
formulations showed that the 
intramuscular route is superior for 
induction of systemic IgG responses 
compared with the intranasal route 
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3.2. Particles based on natural polymers 
Natural polymers are composed of biological subunits, which are biocompatible and have 
low toxicity. These properties explain their use as vaccine carriers. However, while synthetic 
polymers such as PLGA are biocompatible, their degradation byproducts can alter the pH of 
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their milieu, which might be toxic or damage the vaccine antigen. Three major groups of 
natural polymers are used to form particulate carriers: polysaccharides, proteins and peptides. 
3.2.1. Polysaccharide-based particles 
Alginate, β-glucans, chitosan, dextran and mannan are the most widely used polysaccharide-
based particles used as vaccine carriers. A few of these polysaccharides are found in the cell 
walls of several pathogens, such as bacteria and yeast, where they act as PAMPs on the PRRs 
present in APCs. This provides the carrier with intrinsic immuno-stimulatory properties. 
Another specific advantage of polysaccharides is related to the unique particle synthesis 
methods. These methods rely on physicochemical processes such as ionic gelation, 
complexation and solvent displacement. These are generally simple and mild techniques that 
minimize the use of solvents and high-energy sources. 
Alginate is a linear, anionic polysaccharide found in the cell walls of brown algae. In addition 
to being a sufficiently effective carrier, it has been shown that in solution it triggers the NF-
kB pathway in macrophages, leading to the production of IL-1β, IL-6 and TNF-α48. As shown 
in Table 1, solid alginate particles induce a Th1 polarized immune response that can be 
enhanced by co-delivery of CpG ODNs.  Due to co-stimulation of multiple innate sensors by 
different immuno-stimulants, alginate particles containing CpG ODNs and Autoclaved 
Leishmania major (ALM) antigen induced high IgG2a/IgG1 antibody responses and 
generated stronger protection against leishmaniasis
47
. Sodium alginate is frequently used as a 
starting solution, which is then crosslinked by using ion-exchange and adding a divalent 
cationic solution containing Ca
2+
, Sr
2+
 or Ba
2+
. To form micro or nano particles, the 
formulation has to be homogenized or extruded.  
Mannan is a linear polymer consisting of D-mannose monomers connected by β-(1, 4) bonds. 
It can interact with C-type lectin receptors expressed in dendritic cells (DCs) and 
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macrophages. These receptors recognize different carbohydrates present in the cell wall of 
certain pathogens, which leads to their endocytosis or phagocytosis and subsequent activation 
of innate immunity. In addition to that, interactions with specific dendritic cell C-type lectins 
have been correlated with particle trafficking and simultaneous induction of cellular and 
humoral responses 
55
.  
Chitosan nanoparticles can also be prepared easily by electrostatic complexation with 
negatively charged molecules. They can also be synthesized by emulsion and extrusion 
techniques. Several studies have been performed on chitosan nanoparticles loaded with 
pDNA encoding antigens, such as the outer membrane protein of Chlamydia trachomatis, T-
cell epitopes of Esat-6, and Mycobacterium tuberculosis antigen. Chitosan is also combined 
with other polymers to enhance the immunogenicity of other polymers
56, 57
. Quaternization of 
chitosan by methyl groups produced the more water soluble and pH independent cationic N-
trimethyl chitosan (TMC). The maturation status of dendritic cells derived from human 
monocytes demonstrated the intrinsic adjuvant effect of TMC particles by the production of 
balanced IgG1/IgG2a titers
58
. It has been reported that soluble antigens usually elicit high 
levels of IgG1 antibodies but very low levels of IgG2a
59
. Both chitosan and TMC have been 
shown to be mucosal adjuvants and their influence on the Th1/Th2 balance depended on the 
antigen and the route of administration
60-62
.TMC nanoparticles had an intrinsic adjuvant 
effect on DCs, but PLGA nanoparticles did not
58
.  As shown in Table.1, natural polymers 
have been studied as much as synthetic polymers, and several additional features are being 
incorporated into them by altering the inherent chemical structure of natural biomaterials.  
3.2.3. Nanoparticles based on peptides and proteins  
Even amino acids, the building blocks of peptides, can be used as delivery system material. 
Poly(γ-glutamic acid) (γ-PGA) is composed of naturally occurring L-glutamic acid γ-linked 
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together through amide bonds. γ-PGA can be modified with other amino acids to form 
amphipathic, self-assembling nanoparticles. Nanoparticles encapsulated by HIV-1 gp120 protein 
triggered DC maturation and induced strong cellular immunity but weak humoral responses. These 
antigen-encapsulated nanoparticles produced ten times more functional cytotoxic T cells than soluble 
antigen.
63
 Due to the simplicity of creating nanostructures, molecular self-assembly acts as an 
attractive strategy
64
. 
 
Q11 peptide (Ac-QQKFQFQFEQQ-am) can form β-sheet fibrillary structures 50‒10 nm wide and 
100-1000 nm long. Immunization with these nanofibers fused to OVA-MHC II peptide elicited strong 
humoral immunity. IgG1 was the dominant antibody isotype, with smaller amounts of IgG2a, 
IgG2b, IgG3 and IgM65. The authors also tested another self-assembling peptide domain (KFE8: 
Ac-FKFEFKFE-Am) and proved that the adjuvant effect was not limited to a specific self-assembling 
peptide sequence. In contrast to alum, Q11 nanofibers did not induce swelling or local inflammation 
and did not recruit inflammatory cells to the site of injection. The authors hypothesized that fibril 
structures resemble bacterial flagellin and thus might activate the innate immune system through TLR 
interaction or inflammasome activation. They demonstrated that the antigen-specific immune 
response was dependent on T-cells and MyD88
66
. Recently, the same authors demonstrated that self-
adjuvanted nanofiber Q11 peptide induced a robust OVA-specific CD8+ T cell response in OT-I 
transgenic mice. Taken together, these results indicate that these self-adjuvanted vaccines can elicit 
not only CD4+ T cell responses but also CD8+ T cells 
67
. 
Protamine is a FDA approved, naturally occurring, small cationic protein obtained from the 
sperm of salmon. It can inherently condense negatively charged DNA in sperm due to its high 
arginine content (about 67%)
68
. Though it has been extensively exploited in gene delivery, 
the immunogenicity of the mRNA‒protamine complex was a breakthrough in the vaccination 
field. Particle size analysis indicated that mRNA‒protamine complexes form particles of 
about 250‒350 nm. As the complexes were very tight due to strong electrostatic interaction 
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between cationic protamine and mRNA, the intrinsic immuno-stimulatory effect comes at the 
cost of very weak antigen expression. Hence, a combination of naked mRNA and complexed 
mRNA can be used as a two-component system to achieve optimal antigen expression and 
immune stimulation. Previous studies have demonstrated the involvement of TLR7/TLR8 
and the generation of Th1 responses against antigen encoded in protamine-complexed mRNA 
69-71
. 
RNA associated with cationic peptide is present in many viruses, in which the nucleocapsid 
protects the genomic RNA from degradation. Therefore, moving on to peptide-based delivery 
systems might be useful in vaccine development. With the aim of reconstructing virus-like 
structures, systems based on self-assembling peptides have been investigated for vaccination 
purposes 
66, 72, 73
. The major drawbacks of virus-like particles (VLPs) in which the surface 
viral proteins themselves are immunogenic are the possible pre-existence of antibodies 
against the vaccine carrier and the potential unwanted immune responses. In contrast to 
VLPs, the self-assembly domain of a non-viral peptide vector itself would not be 
immunogenic, and the evoked immune responses will be directed against the incorporated 
antigenic epitopes
74, 75
. Boato et al. constructed a synthetic virus-like particle (SVLP) 
consisting of a peptide chain and a lipid tail (lipo-peptide) as a building block. SVLP are 
formed by the self-assembly of trimeric lipo-peptides and the hydrophobic interaction 
between lipophilic tails. The peptide end was fused to a sequence derived from the V3 region 
of gp120 from HIV-1, and the product was injected in New Zealand white rabbits. SVLP 
induced high titres of  antigen-specific antibody without the need for additional immune-
stimulants
72
. 
 
 
66 
 
4. Concluding remarks 
Though nanoparticle vaccines show lot of promises, several challenges need to be addressed 
through novel strategies (detailed in Box 1). Because nanoparticle-based vaccines reach 
APCs, they show promise in the elicitation of T cells. However, the induced CD8+ T cell 
responses are not strong enough to combat deadly diseases such as HIV and cancer. One of 
the main reasons is that these particles do not reach the cytosol of APCs and hence cannot 
efficiently undergo MHC I antigen processing. A few pathogens utilize certain amino acid 
sequences present on their cell membrane to effectively infect the cytosol of the host’s cells. 
TAT peptide of HIV was the first such peptide to be identified, and it was named cell 
penetrating peptide (CPP). Realizing their immense potential, several novel CPPs are being 
discovered and invented. In the next chapter, we describe the evolution of the CPP field and 
its wide biological applications. 
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Box 1 : Circumventing the challenges 
 
Loss of antigenicity and immunogenicity during particle synthesis 
 Milder treatment with chemicals 
 Antigen loading into particles  by self-assembly 
 
Ineffective lymphatic transport of particles 
 Direct intra-nodal injection of particle vaccines 
 Particles design of few hundred nanometers for passive drainage 
 PEGylating nanoparticles for enhanced lymphatic drainage 
 
 
Promotion of APC activation and maturation to avoid immune tolerance 
 Co-delivery of antigens and innate immune activators within particles 
 Use of intrinsically immuno-stimulatory materials as particle building 
blocks 
 
Degradation of antigens trapped in lysosomes 
 pH-responsive materials for endosomal escape 
 Cell-penetrating peptides for cytosolic antigen delivery 
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Abstract: 
 
Efficient delivery of antigenic cargo to APCs is a laborious challenge. Cell penetrating 
peptides are capable of crossing  cell membranes without causing a severe disruption of the 
phospholipid bilayer and to carry along diverse cargoes such as small drugs and various 
peptides but also antigen epitopes or nucleic acids encoding antigen epitopes. Hence, cell 
penetrating peptides possess a unique capability to induce potent T cell responses against 
infectious and non-infectious diseases. Yet, the potential of cell penetrating peptides for 
application in vaccine formulations has been largely overseen. In this review we provide a 
general framework for understanding cell penetrating peptides, their mechanism(s) of action 
and implications for the usage of cell penetrating peptides in vaccine development. Finally, 
we discuss novel types of cell penetrating peptides, the characteristics of which may render 
them particularly well suited for application in vaccines targeting the CD8 cytolytic T cell 
branch of the immune defense. 
Keywords: CPP, vaccines, CD8+ T cell responses, endosomal escape, pH responsive 
peptides 
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1. Introduction 
Although the definition of CPPs has changed over the years, they are now defined as short 
peptides, less than 70 amino acids long, that are able to cross cell membranes. CPPs have also 
been called membrane active peptides or protein transduction domains. Due to their intrinsic 
ability to enter cells and mediate uptake of a wide range of macromolecular cargos, including 
drugs, proteins, peptides, plasmid DNA and siRNAs, CPPs have rapidly emerged as attractive 
cellular delivery vectors. Accordingly, CPPs are actively researched for therapeutics 
development. This has resulted in a number of CPP based experimental therapeutics that have 
reached the stage of clinical trials, including XG-102 for hearing loss
1
, KAI-9803 for 
myocardial infraction
2
, AZX-100 for keloid scarring
3
, and RT-001 for wrinkling skin. Aside 
from these therapeutic approaches, CPPs are of particular interest for vaccine development as 
they are capable of delivering antigens into specific compartments of antigen presenting cells 
(APCs) such as dendritic cells and macrophages. Naturally, peptides and nucleic acids are not 
taken up efficiently by APCs. Nevertheless, delivering such antigenic information directly 
into the cytoplasm of APCs is necessary in order to achieve access to the MHC I antigen 
processing pathway that results in the presentation of derived antigen epitopes to CD8+ T 
lymphocytes exerting cytolytic immune defences. CPPs may therefore provide an effective 
means to induce antigen specific cytolytic T cell responses. 
The first CPP identified was part of transactivator of transcription (Tat) proteins of Human 
Immunodeficiency Virus type I (HIV-I)
4
. Tat is a regulatory protein of HIV-1 produced very 
early after infection and essential for virus gene expression, replication and infectivity 
5, 6
. 
During acute infection by HIV, Tat is released in the extracellular milieu and enters into 
neighbour cells, such as neurons, muscle cells
7-9
, where, according to the concentration and 
cell type, it can increase virus infectivity. 
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Figure 1: (A) Biological function of TAT peptide: In addition to transcriptional activity, Tat protein (structure 
source : ExPASy bioinformatics resource portal) also shows unique transcellular transport pathway. Through 
high-affinity binding of Tat to phospholipid, it crosses the membrane and reach the extracellular medium. It 
forms pores in the neighbouring target cells and reach its cytosol (B) Utilization of cell penetrating feature for 
delivery applications: TAT covalently conjugated with proteins (detonated as CPP-protein complexes) can 
enter animal and plant cells. In addition to that, TAT can also be non-covalently conjugated with proteins. In the 
same line, DNA, small interfering RNA, nanoparticles, drugs are also efficiently delivered into cells. 
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 Thus, an arginine-rich motif in the Tat protein was found to be necessary for the spontaneous 
translocation of Tat into cells. These and following studies resulted not only in the 
description of a novel biological function but also lead to a better understanding about the 
entry mechanisms of CPPs. The aim of this review is to provide a clear understanding about 
the main entry mechanism(s) of CPPs, their application for various vaccine formulations, and 
inherent limitations that have been met during these studies. Finally, we will discuss novel 
CPP designs that may help to overcome (some of) the limitations inherent to CPP based 
vaccine formulations. 
2. CPPs in vaccine formulations 
In order to avoid the safety concerns associated with live-attenuated and inactivated vaccines, 
research is focused more on the development of subunit synthetic vaccines. Such synthetic 
vaccines may contain antigenic information in the format of single proteins, peptides or 
nucleic acids. 
2.1. Protein antigens: 
CPP coupling with antigenic proteins has been achieved mainly via recombinant fusion 
constructs produced by bacterial expression vectors. Antennapedia homeodomain consists of 
60 amino acids and has been shown to efficiently cross plasma membranes. The induction of 
CD8+ T cells mediating anti-viral immunity has been demonstrated using a recombinant 
fusion protein of Influenza derived HLA-Cw3-restricted CTL epitope with Antennapedia 
homeodomain 
10
. Out of 60 aminoacids, 16 aminoacids present in the third helix of 
Antennapedia homeodomain has been shown to be sufficient for uptake of the whole 
protein
11
. This shorter peptide is termed as penetratin and added to the list of CPP.  
Recently, 42 amino acids fragment of ZEBRA protein derived from Epstein-Barr virus have 
been characterized with cell penetrating peptide and termed as Z12
12
. Ovalbumin fused with 
Z12 cell penetrating peptide promoted an integrated immune response with persistent CD8+ 
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effector T cells and Th1 polarized CD4+ T helper cells
13
.  In these studies, one of the main 
factors to be considered for the construction of the CPP-fusion proteins relates to the possible 
interference of the cargo protein with the CPP charge and hydrophobicity
14
. Though several 
linkers have been designed empirically, the derivation of a generic linker suited for all is 
highly unlikely, thus limiting the broader application of various CPPs and protein antigens. 
2.2. Peptide antigens: 
Being smaller than proteins, peptides offer the advantage over protein cargos to be less likely 
to interfere with the functionality of CPPs. Furthermore, due to recent advances in peptide 
synthesis technology, it has become possible to synthesize the CPP and the antigenic epitope 
sequences in a single reaction, thus circumventing the need for chemical crosslinking of both 
components
15
. Initially, antigenic peptides are directly fused with cell penetrating peptides 
and used for ex-vivo dendritic cell based immunotherapies
16,
 
17,
 
18,
 
19
. Ovalbumin(OVA) 
MHC class I epitope fused with penetratin and its capability to elicit CD8
+
 T cell was studied. 
As a turning point, intradermal immunization with ‘penetratin-OVA MHC I’ or ‘penetratin-
OVA MHC I pulsed DC’ appeared equally effective with mice generating potent CD8+ T cell 
responses
20,
 
21
. From then, the studies evolved from ex-vivo usage to in-vivo usage of cell 
penetrating peptides as carrier. 
Then, the feasibility of co-delivering innate immune stimulus along with antigen has been 
explored. Due to high arginine content in TAT peptide, it is cationic and able to complex with 
nucleic acids. Therefore, TAT was fused with MHC-I epitope of E7 protein from human 
papillomavirus. When it is complexed with GM-CSF encoding plasmid DNA, it formed 
nanoparticles less than 100nm in size. It primed enhanced CD8+ T cells and decreased 
tumour growth 
22
.  
In order to prime MHC class I and II responses restricted to several HLA alleles, multiple 
epitopes delivery is essential. A study on multi-epitope peptide incorporated three HER-2 
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MHC-I epitopes, 369,435 and 789 from hepatitis viral protein. Two consecutive arginine 
amino acids employed between the epitopes, thereby it can act as spacer for efficient antigen 
processing
23
. In another study, furin-sensitive aminoacid sequences were used between 
multiple T cell epitopes 
24
. Furin is the trans-Golgi network resident endopeptidase that 
recognizes RXRR or RXKR motifs
25
. Synthetic peptides containing multiple MHC I and 
MHC II epitopes are linked together through the furin-sensitive linker RVKR, and then 
joined to the Tat cell penetrating peptide (RKKRRQRRR) at the C-terminal end. The 
manufacturing difficulties existing with long peptide synthesis limit the potential application 
of tandem epitopes fusion strategy. There is a need for novel method through which multiple 
epitopes can combined with CPPs. 
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Table 1: CPP-based vaccine formulations 
Antigen CPP Adjuvant Route of 
administration 
Outcome of the 
study 
Ref 
Protein format  
Influenza derived 
HLA-Cw3-
restricted CTL 
epitope 
Antennapedia 
homeodomain 
SDS Subcutaneous 
immunization 
60% lysis of 
target cells by 
induced CTL 
responses 
10, 26
 
Ovalbumin Z12 Poly-ICLC,  
MPLA-SM, 
Resiquimod 
Subcutaneous 
(Z12-OVA)  
Intramuscular 
(adjuvant) 
injections 
47% to 90% of 
target cell lysis 
and induced 
therapeutic 
antitumor 
immunity 
13, 27
 
Peptide format  
OVA MHC-I 
epitope 
Penetratin - Intradermal 
immunizatio
n 
Mice showed 
protection 
against 
ovalbumin 
expressing 
tumour 
20
 
MUC1 MHC-
I epitope 
Penetratin - Intradermal 
immunizatio
n 
Strong IFN-γ 
secreting T 
cells and weak 
IgG1 
antibodies. 
Immunized 
C57BL/6 mice 
were protected 
against the 
growth of a 
MUC1
+
 tumor 
cell line 
21
 
OVA MHC-I 
epitope 
 
 
 
Penetratin CpG Epicutaneous 
immunizatio
n 
30% lysis of 
OVA specific 
cells and 
showed tumour 
protection 
28
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Antigen CPP Adjuvant Route of 
administration 
Outcome of the 
study 
Ref 
Survivin85-93 
MHC- I 
epitope 
TAT pDNA 
encoding  
IL-15 
Subcutaneou
s 
immunizatio
n 
Robust 
memory CTL-
mediated long-
term immunity 
and protection 
against tumour 
challenge 
29
 
HPV16 E749-57  TAT pDNA 
encoding 
mGM-CSF  
Subcutaneou
s 
immunizatio
n 
Particle format 
of ‘epitope 
fused TAT’ 
showed 
superior CTL 
responses and 
tumour 
protection 
22
 
OVA MHC I 
and MHC II 
epitopes 
TAT IFA and 
CpG 
oligodeoxy
nucleotide 
Subcutaneou
s 
immunizatio
n 
Both CTL and 
T-helper cell 
responses 
contributed to 
tumour 
protection 
24
 
 
2.3. DNA antigens: 
DNA vaccines promote immune response by providing antigen-encoding DNA to the 
recipient. A major hurdle in DNA vaccination is the need to transport the antigen encoding 
DNA across cellular and nuclear membranes in order to initiate transcription and translation 
into protein antigen. Here, CPP derived from the VP22 protein present in herpes simplex 
virus (HSV-1) received extensive attention. VP22 condenses nucleotides into nanoparticles 
with a diameter between 300nm and 1µm
30
 which are prone to be engulfed by dendritic cells 
and other antigen-presenting phagocytes. Immunization of mice with VP22-pDNA 
nanoparticles has been demonstrated to dramatically increase T cell immunity to pDNA 
encoded antigens from influenza
31
, bovine herpesvirus 1 (BHV1)
32
, porcine reproductive and 
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respiratory syndrome (PPRSV) virus
33
 and human papillomaviruses (HPVs)
34
. Strikingly, 
pDNA chemically linked to either TAT or penetratin CPP induced CD8+ T cell responses 
that were significantly weaker when compared to VP22 
35
. The enhanced DNA binding 
property of VP22 and its complexation into nanoparticles likely is at the basis of the higher 
efficiency of VP22 compared to other CPPs that do not complex DNA.  
3. Novel CPPs and their classification 
The variety of strategies followed reflects the inherent difficulty of delivering antigens 
intracellular. There are several on-going clinical trials of CPP in drug delivery; however, as 
yet, no CPP-based vaccines have reached the phase of clinical trial. One of the main reasons 
for this failure is the limited range of CPPs available along with the origin of these CPPs, 
namely from naturally occurring pathogens. Existing immunity against these pathogens is 
likely to interfere with the efficacy of vaccines based on naturally occurring CPPs. However, 
detailed studies about how CPPs interact with cell membranes and the elucidation of the 
underlying physical-chemical parameters have driven the design of novel, artificial CPPs 
with improved functional characteristics.  
CPPs may interact with cellular membranes through different mechanisms such as 
electrostatic interactions, hydrophobic effects or hydrogen bonding. Therefore, the specific 
physical-chemical property of the peptide determines the type of interaction through which 
the peptide may penetrate the cell. Based on their physical-chemical properties, CPPs can be 
classified into three main classes: cationic, hydrophobic and amphipathic.  
    3.1. Cationic CPPs 
The TAT peptide is highly cationic due to the presence of 6 arginine and 2 lysine 
residues(RKKRRQRRR).  For new CPP design, sequences of cationic charges made up of 
clusters of arginine or lysine amino acids have been tested for their membrane interaction and 
uptake properties
36, 37
 . These studies suggested that at least eight positive charges are needed 
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for efficient uptake of cationic CPPs
38
. Apparently, the positive charge of poly-arginine CPPs 
is needed in order to provide the anchor force to adhere with anionic components on the cell 
surface such as phospholipids, nucleolin and proteoglycans
39
. The binding between 
membrane phospholipid with arginine’s guanidinyl group is much stronger than ε-amino 
group in lysine. This study was demonstrated using solid-state NMR 
37. This finding is 
consistent with the general observation that arginine, rather than lysine, plays an important 
role in the cross-membrane transport of cationic CPPs and their cargoes such as drugs, 
fluorescent-proteins, oligonucleotides, quantum dots
40-48
.  
    3.2. Hydrophobic CPPs 
As the name already implies, hydrophobic CPPs interact with the cellular membrane through 
hydrophobic chemical groups present in the peptide motifs
49
. Moreover, this class of CPPs 
often displays the unique property of being insensitive to sequence scrambling. This property 
has been reported for a number of linear hydrophobic peptides such as BIP pentapeptides and 
C105Y synthetic peptide
50, 51
. This unique property differentiates these hydrophobic CPPs 
from cationic and amphipathic CPPs where scrambling of the amino acid sequence 
significantly affects the cell penetrating characteristic of the peptides
50
. Unfortunately, as yet 
only few hydrophobic CPPs have been discovered compared to cationic and amphipathic 
peptides. However, novel hydrophobic CPPs are being screened through rational design of 
library
52
.   
     3.3. Amphipathic CPPs 
Amphipathic peptides are characterized by the presence of both hydrophilic and hydrophobic 
amino acids. Though most amphipathic CPPs are cationic, evidence suggests that their 
penetrating characteristic is a consequence of their amphipathic nature. For instance, 
substitution of cationic lysine in model amphipathic peptide (MAP) with other polar residues 
maintained peptide uptake provided amphipathicity was conserved. This then resulted in the 
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derivation of cell penetrating neutral MAP1
53
and anionic MAP12
47
 peptides. Based on the 
structure, they are classified into primary and secondary amphipathic peptides. Primary 
amphipathic peptides contain hydrophobic and hydrophilic parts in opposite ends
54
. Several 
primary amphipathic CPPs are fusion peptides containing an extra domain allowing for a 
more efficient targeting of cellular and nuclear membranes. As an example, MPG and Pep-1 
CPPs contain a nuclear localization signal derived from SV40. The cell penetrating 
characteristic of MPG then is derived from HIV glycoprotein-41 whereas that of Pep-1 is 
made up of a tryptophan-rich cluster exhibiting a high affinity for cell membranes. In 
secondary amphipathic peptide, most common structure is the amphipathic alpha-helix. It 
contains polar residues placed on one face of the helix and hydrophobic side chains pointing 
to the opposite face, which facilitates the interaction with cellular membrane 
55
. Nevertheless, 
not all amphipathic peptides enable permeabilization. The main requirements for the uptake 
capacities of amphipathic CPPs, still to be determined. 
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Table 2: Classification of CPPs based on their physical chemical properties 
Peptides Sequence Ref 
Cationic 
HIV-1 TAT CFTTKALGISYGRKKRRQRRRPPQGSQTHQVSLSKQ 
7
 
Tat(48-60) GRKKRRQRRRPPQ 
4
 
Stearyl-Tat stearyl-GRKKRRQRRRPPQ 
56
 
Poly-arginine Rn (n= 6-15) 
46
 
HR9 HRRRRRRRRR 
57
 
IR9 IRRRRRRRRR 
41
 
Hydrophobic 
Bip VPTLK 
58
 
C105Y PFVYLI 
51
 
Primary amphipathic (cationic) 
Pep-1 KETWWETWWTEWSQPKKRKV 
59
 
MPG GLAFLGFLGAAGSTMGAWSQPKKKRKV 
60
 
Secondary amphipathic (cationic) 
Transportan GWTLNSAGYLLGKINLKALAALAKKIL 
61
 
MAP KLALKALKALKAALKLA 
62
 
CADY GLWRALWRLLRSLWRLLWRA 
63
 
EB-1 LIRLWSHLIHIWFQNRRLKWKKK 
64
 
Secondary amphipathic (anionic) 
GALA WEAALAEALAEALAEHLAEALAEALEALAA 
65
 
MAP12 LKTLTETLKELTKTLTEL 
47
 
 
  4. Entry mechanism determines the fate of CPP-cargo 
Understanding the uptake mechanism and intracellular trafficking of vaccine carriers is an 
essential step to produce maximum effect. Several mechanisms that enable CPP cellular entry 
exist, and may even coexist, depending on the physical-chemical properties, concentration, 
charge and length of the CPP. Furthermore, cellular uptake is also influenced by type, size 
and charge of the cargo molecules. In general, primary mechanisms for CPP intracellular 
uptake include direct penetration through the plasma membrane and endocytosis. 
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   4.1. Direct penetration pathways 
Direct penetration involves a strong binding of the CPP with the lipid bilayer of the cell 
membrane, followed by membrane destabilization
66
. The destabilization has been proposed to 
occur through the inverted micelle and/or the carpet model
67
. The inverted micelle model 
states that positively charged CPP residues (arginine and lysine) bind to the negatively 
charged membrane phospholipids. As a result, the CPP merges with the membrane and 
pocket-like micelles are formed that traverse towards the cytoplasm. As these micelles cross 
the membrane, they invert, releasing the CPP and its cargo into the cytoplasm
68
. In the carpet 
model, the positively charged CPP domains cover the cell membrane in a carpet-like manner. 
As a particular area of the membrane reaches a certain concentration of these peptides, the 
membrane becomes locally destabilized, leading to pore formation that enables passage into 
the cells
69
. While CPPs were originally thought to deliver cargo into cells via direct 
membrane penetration mechanisms, it has become increasingly clear that uptake of CPP-
cargo constructs may also occur via endocytotic pathways
70-72
. Especially nucleic acid 
complexed CPPs have been reported to enter intracellularly through endocytic pathways
40
. 
   4.2. Endocytosis-mediated pathways  
Endocytosis may occur via various pathways, which can be divided into clathrin-dependent 
and clathrin-independent endocytosis. In clathrin-dependent endocytosis, the cytoplasmic 
domains of plasma membrane proteins are recognized by adaptor proteins and packaged into 
clathrin-coated vesicles that are brought into the cell. Clathrin-independent endocytosis may 
involve macropinocytosis, caveolae or lipid raft-mediated endocytosis.  
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   5. Promoting endosomal escape of CPP 
As mentioned above, recent studies not only pointed to the uptake of CPP-cargo conjugates 
mainly by endocytic pathways, they also identified as main hurdle for intracellular delivery 
material being retained in the endosomes. To overcome this vesicular entrapment problem, 
there is a need to facilitate the transport of cargo across endosomal membrane
73
. While cell 
penetrating peptides have the unique property to translocate across cell membranes without 
disrupting the lipid bilayer, the addition of an endosome lytic property has proven to be 
challenging
74
. 
Endosomolytic agents such as sucrose and calcium that can destabilize endosomal 
membranes have been utilized in combination with CPP 
75
. Also chloroquine induces osmotic 
swelling and hereby promotes the disruption of endosomal compartments
43
. Though an 
improvement in cargo intracellular activity has been observed in in-vitro studies when using 
these additives, the inability to be used in an in-vivo setting limits the broader applicability of 
such endosomolytic agents. As an alternative, design strategies in CPP amino acid sequence 
have been performed to increase endosomal escape.  
   5.1. CPPs causing a proton sponge effect 
The addition of histidine amino acids is a promising strategy as this could induce endosomal 
disruption by a proton sponge effect
76
. Due to protonation of histidine in acidic pH, 
accumulation of protons together with their counter ions in the endosome stimulates entrance 
of water from the cytosol in order to balance the high osmotic pressure inside the endosome. 
The resulting swelling of the endosome then eventually leads to endosome bursting and 
release of the CPP complexes into the cytosol. 
This strategy has proven to be especially successful for promoting TAT-mediated DNA 
uptake. As such, the application of Tat CPP is limited by its inability to efficiently release 
DNA from endosomes. However, the incorporation of additional cysteine and histidine 
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residues resulted in a 7000-fold improvement in gene transfection efficiency. This strong 
increment in efficacy could be attributed to an increased endosomal escape of the cargo 
plasmid
77
.  In the same line, replacement by histidine of certain amino acids in penetratin 
resulted in novel penetratin analog EB1. This analog proved to be far more effective in 
transporting biologically active cargo (siRNA) across endosomal membranes compared to the 
parent peptide, penetratin
64
. 
   5.2. pH-sensitive fusogenic CPPs 
Certain peptides have conformations that change in response to acidification and hereby 
become disruptive for (endosomal) membranes
78
. Such peptides are termed as ‘pH-sensitive 
fusogenic peptides’. For example, Hemagglutinin-2 (HA2) 1-20 (amino acid sequence in table 
3) is seemingly unstructured at pH7 but adopts a short helix at pH5. As a result of the 
formation of a helix structure, a hydrophobic region becomes exposed that promotes 
endosomal membrane destabilization
79
. Combining the cell penetrating property of the Tat 
peptide with the fusogenic activity of peptide HA2 strongly promoted cellular internalization 
and endosomal escape by  Tat-HA2 fusion peptide
80
. Similarly, the capacity of penetratin to 
deliver drugs into the cytosol was strongly enhanced upon penetratin sequence elongation 
with HA2 fusogenic peptide 
81
.  
As mentioned in Table.3, the pH-sensitive fusogenic activity of HA2 peptide is a result of its 
inability to form a stable alpha-helix upon membrane binding at neutral pH due to 
electrostatic repulsion between the negatively charged Glutamic acids (E). At acidic pH 
however, a partial protonation of Glutamic acid favours a helical structure which will 
promote fusion and destabilization of lipid membranes. Based on this action mechanism, 
several attempts have been made to improve pH sensitivity and pH-dependent membrane 
disrupting interaction. These attempts resulted among others in the design of the GALA 
peptide
82
. The spacing of charged residues allows the peptide to acquire an amphipathic 
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alpha-helix conformation at lower pH. The reversible pH-driven helix-coil transition 
mechanism of GALA peptide was demonstrated using surface sensitive spectroscopy and 
allowed for excellent endosomal disruption and cytosolic cargo delivery
83,65
. Incorporation of 
arginine amino acids in the same fashion as glutamic acids in GALA resulted in the RALA cell 
penetrating peptide. In addition to exhibiting a pH-sensitive fusogenic property, the RALA 
CPP is capable of complexing DNA due to the presence of cationic arginine
84
.   
Table 3. Development of pH sensitive CPPs with different features 
Peptides Sequence 
HA2(1-23) N-GYWGDIMGEWGNEIFGAIAGFLG-C 
GALA N-WEAALAEALAEALAEHLAEALAEALEALAA-C 
RALA N-WEARLARALARALARHLARALARALRACEA-C 
 
    6.  Overcoming the limitations  
    6.1. Masking non-specificity 
One of the most notorious setbacks of CPPs is non-specific uptake. In the case of vaccine 
delivery, the problem of lack of specificity may be (partially) overcome by formulating the 
CPP as nanoparticle, thus allowing for a preferred uptake by APCs upon intradermal
20, 21
 or 
intranasal
85
 injection. However for drug delivery other approaches are needed to overcome 
this lack of specificity. Several studies have this issue using peptide modification strategies. 
Thus, in order to mask reactive sites, chemical modification of functional groups has been 
applied. To be successful, the masking agent should be labile and easily broken down for 
regeneration of the initial cell penetrating peptide by simple variation of physiological 
conditions. The feasibility of such an approach was illustrated with the amphipathic MAP 
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peptide using (S)-a-(2’-pentenyl) alanine containing olefin-bearing tethers. Hydrocarbon-
stapling was done in such a way that reactive olefinic residues would reside on the same face 
of the helix
86
. In another study, the epsilon-amino groups of lysine residues present in MAP 
were modified with citraconic anhydride (CA). The acid-labile amide linkages in the 
resulting MAP-CA conjugate effectively masked the cationic charge and therefore decreased 
non-specific binding at neutral pH while at acidic (endosomal) pH the membrane 
destabilizing function of the CPP was recovered
87
.  
   7. Conclusion and future prospects 
CPPs possess the unique potential of delivering cargo across cellular membranes. However, 
endosomal entrapment, non-specificity and stability issues limit CPP’s potential as a cargo 
delivery vehicle. Most of the existing vaccines suffer from these limitations as the 
formulation contains conventional CPPs derived from natural sources. Though there have 
been several clinical trials of CPP in drug delivery, no CPP-based vaccines are as yet in 
clinical trial.  
New insights into CPP-cell membrane interactions and entry pathways have resulted in the 
development of novel CPPs with increased functionality. Particularly pH-sensitive CPPs are 
highly promising for among others vaccine design. Because this new class of CPPs interacts 
strongly with endosomal membranes at lower pH, they greatly facilitate the release into the 
cytosol of the antigen cargo, hereby providing an effective means to induce cytolytic T 
lymphocyte responses protective against various diseases. In addition, by delivering the CPP 
in a nanoparticle format, their uptake by local antigen presenting phagocytes such as 
macrophages and dendritic cells will be promoted. This would bypass the overall lack of 
specificity of CPPs and allow to reduce the doses needed for in vivo application.  
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Live attenuated vaccines have been highly effective in controlling human infections such as 
smallpox, yellow fever, measles, mumps, rubella and chicken pox. These live vaccines 
stimulate robust humoral and cell-mediated immunity that can persist for decades after 
vaccination. Despite their effectiveness, there are disadvantages of using live attenuated 
vaccines, which include reversion to virulence, severe adverse effects, and contraindication in 
pregnant and immunocompromised individuals. In addition to that, many pathogens are 
difficult to culture in vitro, so they are not suitable for the production of live attenuated 
vaccines.   In search of safer and effective vaccines for many diseases, vaccine formulations 
are increasingly based on recombinant proteins, peptides, and pDNA and mRNA encoding 
antigens. However, these antigens are intrinsically poorly immunogenic and are therefore 
mixed with substances called adjuvants to boost immune responses. Only a few adjuvants 
have been approved for human use. Most of them elicit largely humoral immunity, often 
require repeated immunization to maintain protective levels of immunity, and typically 
stimulate poor CD8
+
 T cell responses. To address these limitations, we aimed to develop 
novel vaccine technologies that are safe and elicit strong cellular and humoral immune 
responses. 
In-vitro transcribed mRNA has the capacity to encode a broad spectrum of antigens and 
offers the additional advantage of a transient, and hence safe, expression by antigen 
presenting cells (APCs). Driven by this knowledge, the main objective in the first part of 
thesis was to explore the use of mRNA vaccines for inducing antigen specific CD8
+
 T-cell 
responses. 
Due to the inherent instability of mRNA molecules, additional stabilizing formulations are 
required to protect mRNA vaccines from degradation and to promote uptake by antigen 
presenting cells. We intended to use in-vitro transcribed mRNA encoding the model antigen 
ovalbumin (OVA). In order to mimic the virus, mRNA was formulated into nanoparticles 
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using ‘cell penetrating peptide (CPP)’ as carrier. Of the several CPPs, the main focus was on 
an arginine-rich amphipathic peptide (namely, RALA). Two properties differentiate RALA 
from several other CPPs. The first is its ability to self-assemble with nucleic acids and to 
form stable nanoparticles. The second is the remarkable pH-dependent α-helical structural 
change, which leads to endosomal membrane lysis and cargo release in the cytosol.  
We analyzed mRNA nanoparticles based on the use of arginine-rich amphipathic and non-
amphipathic peptides. We characterized the particles physico-chemically and conducted 
studies on their interaction with cultured primary dendritic cells, and on CD8
+
 T cell 
induction. In addition to a thorough assessment of the crucial features that determine the 
immunogenicity of RALA/mRNA nanoparticles at the peptide level, we determined the 
impact of the mRNA format on the strength of CD8
+
 T cell induction. For that, we 
investigated the ability of mRNA modified with pseudo-uridine and 5-methylcytidine and 
incorporated in RALA nanoparticles to induce innate immune activation and investigated the 
influence on CD8
+
 T-cell responses. 
 In the next part of the thesis, we explored an alternative strategy that relies on using short 
peptide fragments to engineer the induction of highly targeted immune responses. We used 
MHC I and MHC II epitopes of ovalbumin as antigenic peptide. Separately, these epitopes 
were fused with native RALA amino acid sequence and complexed with plasmid DNA. In 
contrast to our previous studies, the nucleic acid did not code for antigen. In that way, the 
cellular and humoral responses induced by the particle format of the antigenic peptide were 
investigated in a second line of research. 
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Arginine-rich peptide-based mRNA nanocomplexes  
efficiently instigate cytotoxic T cell immunity dependent on 
 the amphipathic organization of the peptide 
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Abstract 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To-date, the mRNA delivery field has been heavily dominated by lipid-based systems. 
Reports on the use of non-lipid carriers for mRNA delivery in contrast are rare in the 
context of mRNA vaccination. This paper describes the potential of a cell-penetrating 
peptide containing the amphipatic RALA motif to deliver antigen- encoding mRNA to the 
immune system. RALA condenses mRNA into nanocomplexes that display acidic pH-
dependent membrane disruptive properties. RALA mRNA nanocomplexes enable mRNA 
escape from endosomes and thereby allow expression of mRNA inside the dendritic cell 
cytosol. Strikingly, RALA mRNA nanocomplexes containing pseudo-uridine and 5-
methylcytidine modified mRNA elicit potent cytolytic T cell responses against the 
antigenic mRNA cargo and show superior efficacy in doing so when compared to RALA 
mRNA nanocomplexes containing unmodified mRNA. RALA’s unique sequence and 
structural organization are vital to act as mRNA vaccine vehicle, as arginine-rich peptide 
variants that lack the RALA motif showed reduced mRNA complexation, impaired 
cellular uptake and lost the ability to transfect dendritic cells in vitro and to evoke T cell 
immunity in vivo. 
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1. Introduction 
CD8+ cytolytic T cells have the unique potential to destroy virus infected cells and cancer 
cells. Cytolytic T cells are typically elicited against antigens present in the cytosol, which are 
processed by the proteasome and loaded onto nascent major histocompatibility class I 
(MHCI) complexes for presentation to CD8+ T cells. Vaccines based on recombinant protein 
antigens fail to access this cytosolic route of antigen processing and thereby yield poor 
cytolytic T cell responses. Conversely, nucleic acid based vaccines display a high potential to 
elicit cytolytic T cells provided they support the expression of adequate amounts of antigen in 
the cytosol of dendritic cells (DCs), the most potent antigen presenting cells. Within the field 
of nucleic acid based vaccination, mRNA has now outcompeted pDNA as the molecule of 
choice to deliver antigenic information due to its superior safety profile, its higher capacity to 
transfect non-dividing cells and its amenability to Good Manufacturing Practices (GMP) 
production 
2-6
. Over the past years, preclinical and clinical studies have highlighted the 
potential of antigen encoding mRNA to elicit T cell immunity upon intradermal
7
 and 
intranodal
8, 9
 immunization. Nonetheless, these studies have also unmasked the limitations of 
naked mRNA vaccines and have emphasized the necessity to develop formulation strategies 
that can improve the potency of current mRNA vaccines. Packing the vaccine mRNA into 
nanoparticulate carriers constitutes an interesting avenue to achieve this goal as nanocarriers 
can protect the mRNA from fast degradation as well as selectively target DCs. To date, the 
mRNA delivery field has been heavily dominated by lipid based systems 
10, 11
. Reports on the 
use of non-lipid carriers for mRNA delivery in contrast are scarce. Moreover, virtually all 
polymeric carriers have been developed to deliver plasmid DNA (pDNA) or small interfering 
RNA (siRNA) and perform very poor in the context of mRNA vaccination
12
. Protamine 
might constitute an exception to this rule, as protamine complexed mRNA has been 
demonstrated to evoke T cell responses upon intradermal administration. Nonetheless, 
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expression levels of protamine complexed mRNA are extremely low. Curevac has tackled the 
low expression levels of protamine complexed mRNA through development of a two 
component mRNA vaccine, in which a non-complexed, sequence optimized mRNA mediates 
antigen expression and protamine complexed mRNA mainly acts as adjuvant
13
. This failure 
of cationic polymers to deliver mRNA has been attributed to a too stringent binding of the 
mRNA to the cationic polymer along with an ineffective endosome-to-cytosol translocation. 
In a pioneering paper, Bettinger et al. demonstrated that the use of low molecular weight 
cationic polymers diminishes the strength of interaction between carrier and mRNA to such 
an extent that efficient mRNA expression can be achieved provided an endosome disrupting 
agent is added 
14
. Carriers suited for mRNA vaccination thereby should meet two major 
requirements. First, they need to bind mRNA with such strength that nanocomplexes are 
formed but ribosomal binding upon cytosolic delivery is not compromised. Second, they need 
to be endowed with endosome disrupting properties to translocate their mRNA cargo to the 
cytosol. Based on these premises, we speculated that cationic cell-penetrating peptides 
(CPPs) might constitute excellent vehicles for mRNA delivery as they combine lower charge 
densities with excellent membrane disruptive abilities. CPPs have been intensively exploited 
to deliver drugs, proteins, pDNA and siRNA to the cellular cytosol
15-17
 but have remained 
remarkably unexplored to deliver mRNA. Within the broad variety of CPPs, peptides 
containing the amphipathic RALA motif have emerged as particularly promising for systemic 
delivery of pDNA and siRNA because they selectively attack endosomal membranes and 
thereby display reduced toxicity 
18-20.
 
In this study, we have explored the potential of RALA to deliver antigen-encoding mRNA to 
the immune system. RALA condensed mRNA into nanocomplexes that displayed pH-
dependent membrane disruptive properties and efficiently translocated their mRNA cargo 
from endocytic vesicles to the cytosol. RALA mRNA nanocomplexes supported antigen 
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specific T cell proliferation in vivo. Strikingly, upon complexation to RALA, pseudo-uridine 
and 5-methylcytidine modified mRNA showed superior efficacy in instigating cytolytic T 
cell responses compared to non-modified mRNA. Arginine rich peptide variants that lacked 
the amphipathic motif completely lost the ability to transfect DCs in vitro and to evoke T cell 
immunity in vivo, stressing the importance of the RALA sequence. 
 
2. Results 
2.1. Characterization of RALA mRNA nanocomplexes 
The sequence and secondary structure of RALA are shown in Figure 1A. At acidic pH, 
RALA displays an amphipathic α-helical structure with all hydrophilic arginine residues 
facing one side and all hydrophobic leucine residues facing the other side. This amphipathic 
organization enables RALA to complex nucleic acids electrostatically and to intercalate into 
endosomal membranes
 [19]
. To address the capacity of RALA to condense mRNA into 
particles, we mixed increasing amounts of RALA with a fixed amount of mRNA and 
determined particle size by dynamic light scattering (DLS) and particle ζ-potential by 
electrophoretic mobility measurements. The amount of peptide to mRNA is indicated by the 
N/P ratio and represents the molar ratio of positively charged nitrogen atoms in the peptide to 
negatively charged phosphates in the mRNA backbone.  At N/P 1, a mean hydrodynamic 
diameter of 144 nm was measured while at higher N/P ratios, the hydrodynamic diameter 
decreased to 89 nm (N/P 5) and 91 nm (N/P 10) (Figure 1B). The ζ-potential shifted from a 
negative value of – 6.6 at N/P 1 to respectively +14.6 and +26.3 at N/P 5 and at N/P 10, in 
line with an increasing amount of RALA incorporated into the complexes at higher N/P ratios 
(Figure 1C). Nanoparticle formation was confirmed by transmission electron microscopy 
(TEM) (Figure 1D). The amount of mRNA incorporated into the RALA-mRNA 
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nanocomplexes increased with increasing N/P ratios, ranging from a mere 5 % at N/P 1, up to 
88 % at N/P 10 (Figure 1E).   
 
Figure 1. Characterization of RALA mRNA nanocomplexes. (A) RALA sequence and predicted secondary 
structure. Arginine residues (R) are shown in blue, Leucine and Alanine residues in red. (B) Hydrodynamic 
diameter and (C) ζ-potential of RALA mRNA nanocomplexes at N/P 1, N/P 5 and N/P 10. (D) TEM images of 
RALA mRNA nanocomplexes at N/P 10. (E) Encapsulation efficiency of mRNA into RALA mRNA 
nanocomplexes as a function of the N/P ratio. Measurements are shown as mean (n=3) ± SD. 
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2.2. pH dependent hemolytic activity of RALA mRNA nanocomplexes enable mRNA 
expression 
The most appealing property of RALA is its capacity to selectively disrupt membranes at 
acidic pH. This feature is illustrated in Figure 2A, showing RALA-induced hemolysis of 
chicken red blood cells (RBC) at neutral pH (pH 7.4) and at acidic pH (pH 5.6). To address 
whether this critical feature of RALA is retained upon mRNA binding, we performed an 
identical hemolysis assay, using mRNA complexed RALA. While little hemolysis was 
evident at N/P 1, RALA mRNA nanocomplexes did instigate significant hemolysis at N/P 5 
and especially at N/P 10 (Figure 2B). Furthermore, levels of hemolysis were strongly 
elevated by lowering the pH, thereby demonstrating that RALA indeed retains its pH 
dependent membrane disruptive properties even when complexed into mRNA 
nanocomplexes. To further verify to what extent this membrane disruptive feature of RALA 
mRNA complexes may enable mRNA expression inside DCs, we complexed mRNA 
encoding eGFP into RALA mRNA nanocomplexes. DC2.4 cells were incubated with free 
mRNA or with RALA mRNA nanocomplexes at respectively N/P 1, N/P 5 and N/P 10 for 4 
hours. The amount of mRNA delivered was kept constant in these experiments. Flow 
cytometric analysis revealed no eGFP expression upon incubation of DC2.4 cells with free 
mRNA or with RALA mRNA nanocomplexes at N/P 1 – at which we demonstrated most 
mRNA to be in a free, non-complexed status. Conversely, RALA mRNA nanocomplexes 
supported eGFP expression in approximately 35% of all cells at N/P 5 and at N/P 10 (Figure 
2C). Promoting endosomal disruption by addition of chloroquine – an endosomal disrupting 
agent did not significantly augment the transfection efficiency of the RALA mRNA 
nanocomplexes (Figure 2D). This indicates that RALA by itself is fully competent to 
translocate its mRNA cargo to the cytosol. 
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Figure 2. pH dependent hemolytic activity of RALA mRNA nanocomplexes enable mRNA expression. (A) 
Hemolytic activity on chicken RBCs at respectively pH 7.4 and pH 5.6. of RALA masses 0.29µg, 1.45µg and 
2.9 µg (B) their molar equivalent as mRNA nanocomplexes at N/P 1, N/P 5 and N/P 10. Measurements are 
shown as mean (n=6) ± SD; *** p<0.0001. unpaired t-test (C) Transfection efficiencies as determined by the 
percentage of DC2.4 dendritic cells expressing reporter eGFP mRNA after incubation with free mRNA or 
RALA-mRNA nanocomplexes at N/P 1, 5 and 10. Measurements are shown as mean (n =3)  ± SD; ** p < 
0.0001 (One-way ANOVA Newman-Keuls post test). (D) Transfection efficiencies as determined by the 
percentage of DC2.4 dendritic cells expressing reporter eGFP mRNA after incubation with free mRNA or 
RALA-mRNA nanocomplexes at N/P 10 in absence or presence of chloroquine. Data are shown as mean (n=3) 
± SD; ns = non-significant.(unpaired t-test) 
2.3. RALA mRNA nanocomplexes support antigen-specific CD8 T cell proliferation 
To determine the capacity of RALA mRNA nanocomplexes to prime CD8+ T cells, an OT-I 
proliferation assay was performed. C57BL6 mice were immunized with RALA complexed to 
mRNA encoding the model antigen ovalbumin (OVA) and T cell priming was assessed by 
flow cytometric quantification of the proliferation of CD8+ OT-I T cells. An overview of the 
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flow cytometry gating strategy is given in Figure S1. Figure 3A shows the flow cytometry 
plots and Figure 3B the percentages of OT-I T cells that have divided upon immunization 
with free mRNA or mRNA complexed with RALA at N/P 1, N/P 5 and N/P 10. No antigen-
specific T cell proliferation was observed upon immunization with free mRNA or RALA 
complexed mRNA at N/P 1, whereas immunization with N/P 5 and N/P 10 mRNA RALA 
nanocomplexes elicited significant OVA-specific T cell proliferation. 
 
Figure 3. RALA mRNA nanocomplexes support antigen-specific CD8 T cell proliferation.(A-B) Flow 
cytometric analysis of OT-I T cell proliferation to immunization with RALA mRNA nanocomplexes as a 
function of the N/P ratio applied. (A) Histograms showing the proliferation of CFSE labelled OVA-specific OT-
I T cells in response to intradermal immunization with RALA OVA mRNA nanocomplexes. (B) Percentages of 
divided OT-I T cells in response to intradermal injection of PBS, non-complexed OVA mRNA and mRNA 
OVA nanocomplexes. Measurements are shown as mean (n =3) ± SD; *** p < 0.001 (One-way ANOVA 
Newman-Keuls post test). 
2.4. Incorporation of pseudo-uridine and 5-methylcytidine nucleosides into RALA 
delivered mRNA enhances mRNA expression levels but reduces DC activation 
The incorporation of the modified nucleosides pseudo-uridine and 5-methylcytidine into 
mRNA has been reported to enhance mRNA expression levels by lowering the activation of 
protein kinase R (PKR)
21
. Uridine and cytidine nucleotides present in mRNA were 
completely replaced by pseudo-uridine and 5-methylcytidine. To address the impact of 
pseudo-uridine and 5-methylcytidine modified mRNA (hereafter named modified mRNA) on 
the expression levels of RALA delivered mRNA, we transfected bone marrow derived DCs 
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with respectively unmodified mRNA or modified mRNA (encoding eGFP) complexed to 
RALA at N/P 10. eGFP expression levels were quantified by flow cytometry. As can be 
appreciated from Figure 4B, DCs incubated with modified mRNA complexed to RALA 
showed significantly higher expression levels compared to DCs transfected with unmodified 
mRNA complexed to RALA. 
The use of modified mRNA has been demonstrated to reduce mRNA recognition by 
pathogen recognition receptors and hence to decrease innate immune activation. Activation of 
DCs constitutes a crucial prerequisite to initiate T cell responses.  We thus assessed the 
impact of RALA delivered mRNA on the activation status of DCs by flow cytometry (Fig4C) 
and by inflammatory cytokine secretion (Fig4D). Uptake of non-complexed mRNA is highly 
inefficient in vitro and did not promote DC activation, regardless of the mRNA format. Upon 
complexation to RALA (N/P 10), unmodified mRNA induced a strong upregulation of CD40, 
CD86 and MHCII. In line with its described lower capacity to trigger RNA sensors, modified 
mRNA complexed to RALA was less potent in activating DCs, but surface levels of CD40, 
MHCII and CD86 were still increased compared to PBS treated DCs. DCs incubated with 
unmodified mRNA complexed to RALA displayed a pronounced upregulation of IFN-β 
expression and - albeit to a lower extent - of IL-6 expression. Incorporation of modified 
mRNA into RALA mRNA nanocomplexes strongly reduced IFN-β production. Conversely, 
the use of modified mRNA did not decrease IL-6 expression. Similar results have been 
reported by Kariko et al.
22
, who demonstrated that incubation of DCs with modified mRNA 
reduced IFN-β production while leaving TNF-α production unaffected. 
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Figure 4. Incorporation of pseudo-uridine and 5-methylcytidine nucleosides into RALA delivered mRNA 
enhances mRNA expression levels but reduces DC activation. (A) Chemical structure of unmodified 
nucleotides (uridine and cytidine), modified nucleotides (Pseudouridine and 5’-methyl-cytidine) (B) Flow 
cytometry analysis of eGFP expression, 12 hours after transfection of BMDCs with 1µg of unmodified or 
modified eGFP encoding mRNA complexed with RALA N/P 10. Measurements are shown as mean (n =3)  ± 
SD; *** P<0.0001 (One-way ANOVA Newman-Keuls post test).  (C) Flow cytometry analysis of maturation 
markers CD86, CD40 and MHCII on CD11c+ BMDCs, 12 hours after transfection with 1µg of mRNA 
complexed with RALA N/P 10. Measurements are shown as mean (n =3) ± SD; ***, p<0.0001 (One-way 
ANOVA Newman-Keuls post test) (D) Transcript levels of IFN-β and IL-6  were determined by RT-qPCR, 6 
hours after transfection of BMDCs with 1µg mRNA and RALA N/P 10. Results represent mean n-fold 
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induction levels compared to unstimulated control cells. Measurements are shown as mean (n =3)  ± SD; ***, 
p<0.0001 (One-way ANOVA Newman-Keuls post test). 
2.5 Modified mRNA is superior to non-modified mRNA in instigating in vivo T cell 
immunity to RALA complexed mRNA  
To determine the optimal mRNA format in case of RALA-mediated mRNA vaccination, we 
compared the T cell response elicited by immunization with unmodified mRNA or modified 
mRNA complexed to RALA. In these experiments, N/P 10 was selected as this N/P ratio 
allowed the best complexation of mRNA and enabled efficient CD8+ T cell priming. Priming 
of vaccine specific T cell responses was analyzed by quantifying OT-I T cell proliferation. 
Representative flow cytometry plots are given in Figure 5A. Figure 5B shows the 
percentages and Figure 5C the total number of OT-I T cells having divided over 4 times. 
From these data it is clear that when complexed to RALA, modified OVA mRNA is far 
superior in eliciting OT-I T cell proliferation compared to unmodified mRNA.  
To determine whether the increased T cell proliferation following immunization also resulted 
in the differentiation of antigen-experienced T cells into cytolytic effectors, an in vivo killing 
assay was performed. In such assay, immunized mice are challenged with a 1/1 ratio of 
differentially CFSE labelled target cells and non-target cells. Two days after challenge, the 
ratio of both populations represents a direct measure of the antigen-specific cytolytic T cell 
activity. Vaccination with RALA-complexed modified OVA mRNA killed virtually all target 
cells, whereas no target cell killing was observed upon vaccination with RALA-complexed 
unmodified OVA mRNA (Figure 5D and Figure 5E). This higher immunogenicity of 
modified mRNA over unmodified mRNA is remarkable as modified mRNAs have been 
developed by the gene therapy field exactly to avoid immune responses against the encoded 
protein 
[21,22]
.  
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To address whether the improvement in T cell immunity conveyed by the use of modified 
mRNA represents a common feature of mRNA nanocomplexes upon intradermal vaccination, 
we performed a direct comparison with a conventional lipoplex (DOTAP/DOPE)-based 
mRNA vaccine, the current benchmark mRNA lipoplex formulation evaluated in clinical 
trials
11
. mRNA lipoplexes were used at N/P 1, which we recently demonstrated to be the 
optimal ratio for intradermal and subcutaneous mRNA lipoplex vaccination
10, 23, 24
. At this 
N/P ratio, mRNA lipoplexes typically possess a negative surface charge and contain an 
excess of non-complexed mRNA.  At N/P10, DOTAP/DOPE mRNA lipoplexes instead 
encapsulate most of the mRNA, are cationic in charge, but fail to elicit T cell responses in 
vivo. A similar low N/P ratio (1.7/2) was identified by the Sahin group 
11
 to be optimal for 
intravenous vaccination with DOTAP/DOPE mRNA lipoplexes. In sharp contrast to RALA 
mediated mRNA vaccination, lipoplex mediated vaccination however did not benefit from 
the use of modified mRNA (Figure 5E), thus demonstrating that the regulation of T cell 
immunity to mRNA vaccines is heavily influenced by the delivery system applied. 
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Figure 5. Modified mRNA is superior to non-modified mRNA in instigating in vivo T cell immunity to 
RALA complexed mRNA. (A-C) Flow cytometric analysis of OT-I T cell proliferation to immunizations with 
unmodified or modified OVA mRNA nanocomplexes (A) Histograms showing the proliferation of CFSE 
labelled OVA-specific OT-I T cells in response to intradermal immunization with non-complexed and RALA 
OVA mRNA nanocomplexes. (B) Percentages and (C) total number of divided OT-I T cells in response to 
intradermal injection of non-complexed OVA mRNA and mRNA OVA nanocomplexes. Means ± SD are shown 
of a total of 3 mice per group. *** p < 0.0001 (one-way ANOVA Newman-Keuls post test) (D-E) Flow 
cytometric analysis of antigen-specific killing of target cells in response to prime and boost vaccination with 
RALA complexed unmodified OVA mRNA or modified OVA mRNA or complexed in DOTAP/DOPE 
liposomes. (D) Histogram plots showing the presence of CFSE
hi
 target cells and CFSE
lo 
non-target cells in 
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spleen of immunized mice. (E) Graph showing the percentage of antigen-specific killing of target cells. Mean ± 
SD are shown of total of 4 mice per group; *** p < 0.0001(one-way ANOVA Newman-Keuls post test)   
2.6. Type I IFN regulate T cell immunity to RALA based immunization 
Earlier, we demonstrated that type I IFN negatively regulate T cell immunity to subcutaneous 
and intradermal vaccination with DOTAP/DOPE mRNA lipoplexes
10, 23, 24
. To address 
whether this feature also holds true for RALA mRNA nanocomplexes, we compared 
cytolytic T cell responses between wild type mice and mice lacking the common IFN-α/β 
receptor (Ifnar
-/-
) (mice model detailed in Box 1) after (prime-boost immunizations) with 
RALA mRNA nanocomplexes. Ifnar
-/-
 mice showed a far stronger induction of cytolytic T 
cell responses upon immunization with unmodified mRNA RALA nanocomplexes. 
Conversely, cytolytic effector responses were not augmented in   Ifnar
-/-
 mice upon 
immunization with modified mRNA RALA nanocomplexes, thus showing immune responses 
to modified mRNA RALA nanocomplexes are not affected by type I IFN (Figure 6A). A 
different observation was made for DOTAP/DOPE mRNA lipoplexes with Ifnar
-/-
 mice now 
showing a pronounced increase in cytolytic T cell activity upon immunization with modified 
mRNA containing lipoplexes (Figure 6B).  
To obtain a better insight into the differential outcome of immunization with modified 
mRNA complexed to respectively RALA (improvement) or DOTAP/DOPE (no effect), we 
monitored IFN-β induction in an IFN-β reporter mouse strain (detailed in Box1), in which 
expression of firefly luciferase is driven by the IFN-β promoter 25. In vivo bioluminescence 
imaging revealed a vast IFN-β response upon intradermal injection of non-complexed 
modified mRNA or modified mRNA containing lipoplexes (N/P 1). Consequently, modified 
mRNA does not succeed in dampening the negative effects of type I IFN on T cell immunity 
in the context of mRNA lipoplex vaccination, which explains the strong improvement of T 
cell immunity upon immunization of Ifnar
-/-
 mice with modified mRNA containing lipoplexes 
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(Figure 6B). Upon complexation to RALA, modified mRNA instead hardly provokes a IFN-
β response and thus avoided the negative impact of type I IFN (Figure 6E). Hence, no further 
increase in T cell immunity was observed in Ifnar
-/-
 mice upon immunization with modified 
mRNA RALA nanocomplexes (Figure 6A). 
 
Figure 6. Type I IFN regulate T cell immunity to RALA based immunization (A-B) Flow cytometric 
analysis of antigen-specific killing of target cells in response vaccination with RALA complexed unmodified 
OVA mRNA or modified OVA mRNA (N/P 10, 7 µg of mRNA) or complexed in DOTAP/DOPE liposomes 
(N/P 1, 7µg of mRNA). Measurements are from 5mice in each group; *** p<0.001(un-paired t-test) (C-E) Study 
of type I interferon induction using IFN-β+/Δβ-luc reporter mice (C) Graphical scheme of IFN-β reporter construct. 
The myc-tagged luciferase gene is brought under the control of the IFN-β promoter by the Cre-Lox system (D) 
IFN-β+/Δβ-luc reporter mice were injected i.d with 7ug of ovalbumin encoding mRNA DOTAP/DOPE lipoplexes 
of N/P 1 or RALA nanocomplexes of N/P 10 or PBS in a total volume of 20ul. IFN-β induction was measured 
via in vivo bioluminescence (E) Graphical representation of measured luminescence. Data are shown as mean 
±SEM of 3mice. ** p<0.005(un-paired t-test) 
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2.7 Non-amphipathic cationic peptide variants: characterization of peptide mRNA 
nanocomplexes 
Having established the capacity of RALA to efficiently deliver an antigenic mRNA cargo to 
the immune system, we aimed to delineate to what extent the immunogenic properties of 
RALA mRNA nanocomplexes depend on RALA’s sequence. To this end, we designed two 
additional arginine-rich peptides that contain identical numbers of arginine residues as RALA 
on a molar basis but lack RALA’s hydrophobic residues. In the first peptide (named RGSG 
hereafter), the RALA motif was replaced by a hydrophilic RGSG motif. In the second peptide 
(named RRRR hereafter), the hydrophobic alanine and leucine residues of RALA were 
omitted. Peptide sequences and predicted peptide secondary structures are depicted in Figure 
7A. Both peptides lack RALA’s amphipathic α-helical structure as they do not contain 
 
Box1: Transgenic mouse models to study interferon induction 
 
Despite a broad range of amino-acid homologies, all type I IFNs signal through a 
common heterodimeric receptor composed of low- (IFNAR1) and high-affinity 
(IFNAR2) receptor components
1
.  Knockout of this interferon alpha/beta receptor 
(IFNAR
-/-
) constitutes a suitable model to study the role of type I interferon induction 
during virus infection and vaccine administration. 
 
A versatile reporter mouse allows the detection of IFN- β induction in-vivo using firefly 
luciferase as a reporter. The myc-tagged luciferase gene is brought under the control of 
the IFN-β promoter by Cre-lox system. This system consists of Cre recombinase 
enzyme that recombines a pair of short target sequences called Lox. Deletions, 
insertions, translocations, and inversions at specific sites can be carried out using this 
site-specific recombinase technology. 
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hydrophobic residues. RGSG has a random-coil like structure, while RRRR forms a short α-
helical structure to minimize electrostatic repulsion between the adjacent cationic arginine 
residues.  
First, we assessed the impact of these sequence modifications on the capacity of the 
respective peptides to disrupt membranes by performing a hemolysis assay. Disturbance of 
the RALA motif abrogated hemolytic activity, with RGSG and RRRR clearly failing to lyse 
RBCs regardless of pH (Figure 7B).  Yet, due to their cationic arginine residues, RGSG and 
RRRR were still capable of condensing the mRNA into nanocomplexes. However, when 
compared to RALA, the dimensions of RGSG and RRRR mRNA nanocomplexes were 
strongly influenced by the N/P ratio applied (Figure 7C). Particle size for RGSG-modified 
mRNA nanocomplexes peaked to around 600 nm at N/P 5 and subsequently declined to 150 
nm at N/P 10. In case of RRRR-modified mRNA nanocomplexes, particle sizes ranged from 
140 nm at N/P 1 over 200 nm at N/P 5 up to 1050 nm at N/P 10. RGSG and RRRR -modified 
mRNA nanocomplexes also showed a different surface charge evolution with increasing N/P 
ratios. Whereas RALA mRNA nanocomplexes robustly shifted their ζ-potential from 
negative to positive values at higher N/P ratios, the shift in ζ-potential was far less 
pronounced for RGSG and RRRR mRNA nanocomplexes (Figure 7D). Instead, RGSG-
modified mRNA nanocomplexes adopted a near neutral charge at N/P 5 and at N/P 10, 
whereas RRRR-modified mRNA nanocomplexes remained negatively charged even at N/P 
10. 
Finally, in order to compare the capacities of RALA, RGSG and RRRR to encapsulate 
modified mRNA into nanocomplexes, we measured the amount of non-encapsulated mRNA 
(Figure 7E). Also here, RALA was far more efficient at encapsulating mRNA even at the 
low N/P 1 ratio. At N/P 5, RGSG encapsulated 72.5% of the added mRNA, whereas RRRR 
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still encapsulated a mere 10% at this N/P ratio. However, at N/P 10, all peptides succeeded in 
encapsulating over 75% of the added mRNA. Consequently, N/P 10 was selected for all 
subsequent experiments. 
 
Figure 7. Characterization of RGSG and RRRR based mRNA nanocomplexes. (A) Sequences and 
secondary structures of RALA, RGSG and RRRR peptides, based on the de novo PEP-FOLD peptide prediction 
server. Arginine residues (R) are shown in blue, Leucine and Alanine residues in red, serine and glycine in 
green. (B) Graph depicting the hemolytic activity of equivalent amounts of RALA, RGSG and RRRR at pH 7.4 
and at pH 5.6. (C) Hydrodynamic diameter (nm) of RALA, RGSG and RRRR peptide mRNA nanocomplexes at 
the indicated N/P ratios. (D) ζ-potential of RALA, RGSG and RRRR peptide mRNA nanocomplexes at the 
indicated N/P ratios. (E) Encapsulation efficiencies of mRNA into respectively RALA, RGSG and RRRR 
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mRNA nanocomplexes as a function of the indicated N/P ratios. The percentage mRNA encapsulated was 
calculated as 100% - % free mRNA. Measurements are shown as mean (n =3) ± SD.  
2.8 Lack of immunogenicity of RGSG and RRRR mRNA nanocomplexes 
To verify whether RSGS and RRRR would retain RALA’s capacity to prime CD8+ T cell 
responses against the mRNA encoded antigen, we complexed modified OVA-encoding 
mRNA with the respective peptides. All nanocomplexes were generated at a ratio of N/P 10 
as this ratio was most efficient in mRNA complexation for RGSG and RRRR as well as for 
RALA. The priming activity of the mRNA nanocomplexes was assayed on the basis of the in 
vivo proliferation of adoptively transferred CD8+ OT-I T cells as before. RGSG and RRRR 
OVA mRNA nanocomplexes failed to prime substantial CD8+ T cell responses (Figure 8A), 
thereby indicating RALA has unique features that mediate its effectiveness as a carrier for 
mRNA vaccination. To address whether the failure of RGSG and RRRR mRNA 
nanocomplexes to elicit CD8+ T cell reactivity might be traced back to an insufficient antigen 
expression in DCs, we co-incubated DC2.4 dendritic cells with modified eGFP mRNA 
complexed to either RALA, RGSG or RRRR. The results from flow cytometry (Figure 8B) 
confirm the efficacy of RALA-based transfection, and simultaneously unveil the failure of 
RGSG and RRRR mRNA nanocomplexes to enable eGFP expression in DC2.4 cells.  
The differential capacities of RALA, RGSG and RRRR to transfect cells and to prime CD8
+ 
T cell responses in vivo might reflect a differential uptake of the mRNA nanocomplexes 
and/or a differential capacity of the peptides to facilitate mRNA escape to the cytosol after 
endocytosis. In order to verify the uptake and intracellular fate of the mRNA cargo, mRNA 
was fluorescently labelled with Cy3b. Flow cytometric analysis showed significant 
differences in the percentages of DC2.4 DCs that had bound and/or internalized the 
respective peptide mRNA nanocomplexes (Figure S2a). Whereas 72% of DC2.4 cells 
stained Cy3b positive after incubation with RALA Cy3b mRNA, this percentage dropped to a 
125 
 
mere 7% for RGSG Cy3b mRNA and an intermediate 52% for RRRR Cy3b mRNA. Analysis 
of the mean fluorescence intensity revealed a similar trend with RALA enabling the strongest 
mRNA uptake, RGSG the lowest and RRRR an intermediate (Figure S2b). To quantify to 
what extent the RALA, RGSG and RRRR peptides facilitated endosomal escape of their 
mRNA cargo, Mander’s colocalization coefficient was calculated for colocalization of 
macropinosomes (ARF6), clathrin coated vesicles (Clathrin Light Chain) or caveolae 
(Caveolin) and mRNA nanocomplexes (Figure 8C-D). Only in the case of RALA-mediated 
mRNA delivery, we could detect mRNA inside DC2.4 cells that did not co-localize with any 
of these vesicular markers. Conversely, mRNA delivered by RRRR and RGSG always co-
localized with at least one of the vesicular markers applied. These data indicate that RALA 
mRNA nanocomplexes enables endosomal escape of the antigen mRNA, in contrast to 
RGSG and RRRR-delivered mRNA, which appears to remain trapped inside endocytic 
vesicles.  
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Figure 8. The lack of immunogenicity of RGSG and RRRR mRNA nanocomplexes. (A) Flow cytometric 
analysis of OT-I T cell proliferation in response to intradermal immunization with respectively RALA, RGSG 
and RRRR –modified OVA mRNA nanocomplexes. The graph shows the percentages of OT-I T cells having 
undergone over 4 divisions.  Measurements are shown as mean of 4mice ± SD; **** p < 0.0001; (one-way 
ANOVA Newman-Keuls post test). (B) Flow cytometric analysis of eGFP expression by DC2.4 dendritic cells 
incubated with non-complexed modified eGFP mRNA and modified eGFP mRNA complexed to respectively 
RALA, RGSG and RRRR at N/P 10. (n =3) ± SD; *** p < 0.0001; (one-way ANOVA Newman-Keuls post 
test). (C-D) RGSG or RRRR delivered mRNA remains trapped in endocytic vesicles. (C) DC2.4 cells were 
transfected with the indicated peptide using Cy3b-labeled modified GFP mRNA (red). Cells were then stained 
for the indicated endosomal markers (green). Nuclei were stained with DAPI (blue). Cropped images are 
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indicated by the white square. Line profiles are along the white arrow. Scale bar represents 10µm. (D) Bar graph 
summarizing the data from (C) that shows mean Mander’s colocalization coefficient per cell between mRNA 
and the indicated endosomal marker. Scale bars represent standard deviation. * p < 0.05 one-way ANOVA 
Kruskal-Wallis. 
3. Discussion 
CPPs have been widely explored in the context of siRNA and of pDNA delivery but have 
remained remarkably unexplored in the context of mRNA delivery. Here, we describe the use 
of the cationic, amphipathic CPP RALA to successfully deliver antigen encoding mRNA to 
the immune system. We showed that RALA-based mRNA delivery stimulated mRNA uptake 
by DCs and facilitated mRNA release from the endosomes to the cytosol, resulting in 
efficient antigen expression inside the DC. This capacity of RALA to instigate T cell 
immunity was strongly sequence dependent, as removal of the hydrophobic alanine and 
leucine residues or replacement by hydrophilic glycine and serine residues also abrogated the 
peptide’s immune-potentiating properties. Nanocomplexes of mRNA with arginine-rich 
peptide variants that lack the RALA motif showed reduced mRNA encapsulation efficiency 
and impaired DC uptake. Moreover, those mRNA nanocomplexes that were internalized 
remained entrapped in endosomal vesicles. As a consequence, these peptide variants failed to 
support the expression of the mRNA-encoded antigen that is required to prime T cell 
responses.  
In addition to a thorough assessment of the crucial features that determine the 
immunogenicity of RALA mRNA nanocomplexes at the peptide level, we also determined 
the impact of the mRNA format on the strength of the evoked T cell response at the mRNA 
level. In combination with RALA, 5-methylcytidine and pseudo-uridine modified mRNA 
proved to be superior to non-modified mRNA in eliciting cytolytic T cell responses. The 
beneficial outcome of modified mRNA on T cell immunity is striking, as these mRNA 
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modifications have been developed exactly to reduce innate immune activation in the context 
of gene replacement therapy. Our data strongly indicate that this phenomenon can be 
explained by the reduced type I IFN response generated yielded upon the use of modified 
mRNA. Earlier, we demonstrated that type I IFN have a negative impact on the efficacy of 
mRNA lipoplexes to instigate T cell response upon intradermal vaccination with 
DOTAP/DOPE mRNA lipoplexes
10, 23
. Much alike, T cell immunity to RALA mRNA nano 
complexes comprising non-modified suffered from the induction of type I IFN responses, as 
mice lacking IFNAR showed improved T cell responses to vaccination. Usage of modified 
mRNA in combination with RALA reduced the type I IFN response to such extent their block 
on T cell responses was relieved. The near-complete complexation of mRNA to RALA was 
of paramount importance in this respect, as the incomplete complexation of mRNA in case of 
DOTAP/DOPE mRNA lipoplexes failed to sufficiently reduce the type I IFN response to 
avoid its negative impact on the T cell immunity. 
4. Conclusion 
We have demonstrated the high potential of RALA in complexing antigen-encoding mRNA 
into highly immunogenic nanocomplexes. In terms of potency, RALA-mediated mRNA 
vaccination clearly outperformed a standard liposomal mRNA formulation composed of the 
cationic lipid DOTAP and the fusogenic lipid DOPE. Based on this combination of high 
immunogenicity and ease-of-production, we believe that RALA – and by extension other 
CPPs – constitute highly promising delivery vehicles for mRNA vaccines that merit further 
study.   
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5. Experimental Section  
Animals 
Female wild type C57BL/6 mice were purchased from Janvier (Le Genest Saint Isle, France). 
OT-I mice carrying a transgenic CD8
+
 T cell receptor specific for the MHC I-restricted 
ovalbumin (OVA) peptide SIINFEKL were donated by Dr. Bart Lambrecht from Ghent 
University (Ghent, Belgium). Ifnar1
-/-
mice were bred at the breeding facility of the Vlaams 
Instituut voor Biotechnolgoy (VIB, Ghent, Belgium). C57BL/6 luciferase reporter mice (IFN-
+/-luc) were bred at the Helmholtz Centre for Infection Research (HZI). All mice were 7-12 
weeks old at the start of the experiment and maintained under specific pathogen-free 
conditions. Animals were treated according to the European guidelines for animal 
experimentation. All experiments were approved by the local ethical committee for animal 
experiments of Ghent University (Ghent, Belgium) or of the Helmholtz Center for Infection 
Research (Braunschweig, Germany). 
Nanoparticle preparation 
RALA was produced by solid-state synthesis and supplied as an acetate salt lyophilized 
powder (Biomatik, USA). EGFP mRNA (unmod: L-6301; mod: L-6303) and Ovalbumin 
mRNA (unmod: L-6326; mod: L-6128) were purchased from TriLink BioTechnologies (San 
Diego, USA). RALA/mRNA complexes were prepared at N/P ratios 1, 5 and 10 by adding 
appropriate volumes of RALA peptide solution to a specific amount of mRNA. The N/P ratio 
represents the molar ratio of positively charged nitrogen atoms in the peptide to negatively 
charged phosphates in the mRNA backbone. For lipid-based complexation of mRNA cationic 
lipid 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) and 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE) were added to the mRNA at N/P ratio 1 (both Avanti Polar 
Lipids, Alabaster, AL, USA). 
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Nanoparticle characterization 
For size and zeta potential measurements, particles were analyzed using a Nano ZS Zetasizer 
(Malvern Instruments, UK). The shape and surface morphology were observed using Jeol 
JEM1400plus transmission electron microscope at 30 kV. 
Encapsulation assay 
Quant-iT™ RNA assay kit (Life Technologies, UK) was diluted 1:200 in TAE buffer and 
added to an equal volume of nanoparticle prepared solution. Sample fluorescence was 
analyzed using a Synergy 2 Multi-Mode Microplate Reader (BioTek Instruments Inc, UK).  
Hemolysis assay 
Chicken red blood cells (RBCs) (Veterinary department, UGent) were resuspended in pH 5.6 
and pH 7.4 buffer solutions separately. The cell suspensions were treated with the indicated 
formulations. 20% Triton was used as a positive control representing 100% hemolysis. After 
1 hour incubation (37°C), samples were centrifuged to pellet intact RBCs. Supernatants were 
collected and absorbance was measured at 450nm using iMark Microplate Reader (Biorad, 
USA) 
In vitro DC transfection 
DC2.4 cells (1.2 x 10
5
 cells/well) were incubated for 2 hours in Opti-MEM serum free media 
(Gibco, UK) prior to addition of 50 µl RALA-mRNA complexes (2.5µg mRNA). DC 
primary cultures were generated from bone marrow of WT C57BL/6 mice. At day 7, 
1x10
6
cells/well was incubated for 2 hours in Opti-MEM serum free media (Gibco, UK) prior 
to the addition of 1µg of mRNA complexed with appropriate amount of RALA according to 
NP ratios.  
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Flow cytometry 
All flow cytometric experiments were performed on a triple-laser (B-V-R) LSR-II (BD 
biosciences, USA) and analysed with FlowJo software (Treestar, OR). Cells were stained 
with α-CD16/CD32 (BD biosciences, USA) to block non-specific FcR binding. Live/Dead 
Fixable Aqua stain (Invitrogen) was used to eliminate dead cells from analysis. Expression of 
maturation markers was analysed by flow cytometry after staining with α-CD11c, α-CD40, α-
CD86, α-MHC II.(all from BD Biosciences, USA) 
Quantitative reverse transcriptase PCR 
RNA isolation was performed using the RNeasy Plus Mini Kit (Qiagen,Germany) according 
to manufacturer’s protocol. cDNA was synthesized using a Superscript II Reverse 
Transcription Reagent Kit (Invitrogen). Real-time quantitative PCR (qPCR) was performed 
on a Lightcycler 480 using a qPCR kit for SYBR Green (Instrument and kits were from 
Roche Diagnostics, Germany). Real-time qPCR amplification was performed in triplicate 
reactions. mRPL13a mRNA was used as reference housekeeping gene for normalization. All 
primers were purchased from Invitrogen. 
In vivo T cell proliferation assay 
OT-I T cells were labelled with 5 µM carboxyfluorescein diacetate succinimedyl ester 
(CFSE) (Invitrogen, Belgium) and 1 million CFSE labelled cells were i.v. injected two days 
prior to immunization. Mice were intradermally immunized with 7µg of unmodified or 
modified mRNA complexed with carrier in a total volume of 20 µl. Three days later, lymph 
nodes were isolated and OT-I T cell division was analysed by flow cytometry. Cells were 
stained with α-CD16/CD32 (BD Biosciences, USA), Live/Dead Fixable Aqua stain 
(Invitrogen), α-CD8 PerCP, α-CD3 pacific blue, α-CD19 APC-Cy7 (all BD Biosciences, 
USA) and MHC dextramer H-2 Kb/SIINFEKL-PE (Immudex, Denmark). 
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In vivo cytotoxicity assay 
WT and Ifnar
-/-
 mice were intradermally immunized with 7µg of unmodified or modified 
mRNA complexed with carrier in a total volume of 20 µl. Two weeks after prime and boost 
vaccination with a two week interval, splenocytes from naïve C57BL/6 mice were pulsed 
with MHC-I OVA peptide (target cells) (30 µg/ml) or left unpulsed (non-target cells) for 60 
minutes at 37°C, and subsequently labelled with respectively 5 µM or 0.5 µM CFSE 
(Invitrogen, Belgium) accordingly to the manufactur’s protocol. Labelled cells were injected 
into immunized mice at a 1/1 ratio. Spleen suspensions were analysed 48 hours later by flow 
cytometry. The percentage antigen-specific killing was determined using the following 
formula: 1 - ((%CFSEhi cells / %CFSElow cells)
immunized mice
 /(%CFSEhi cells / %CFSElow 
cells)
non-immunized mice
). 
mRNA labelling 
Multiply labeled tetravalent RNA imaging probes (MTRIPs) were constructed as described in  
reference
26. We designed four different 2’O-methyl RNA-DNA chimeric oligos containing 
17-18 nucleotide regions with a short 5-7 poly(T) linker. Oligos were antisense to 4 adjacent 
sequences spanning the mRNA 3’ UTR and contained three to four amino-modified 
thymidines each and containing a biotin modification (Biosearch). MTRIPs were assembled 
by conjugating Cy3B-NHS ester (GE Healthcare) to oligo amine groups using manufacturer 
protocols. Complete MTRIPs were assembled by incubation with Neutravidin (Pierce) for 1 
hour at RT followed by filtration using 30 kD MWCO centrifugal filters (Millipore). mRNA 
was buffer exchanged into 1x PBS and heated to 70°C for ten minutes and immediately 
placed on ice, combined with MTRIPs in a 1:1 mRNA:MTRIP ratio for each MTRIP, then 
incubated overnight at 37°C. The next day, the mixture was filtered using a 200 kD MWCO 
ultrafiltration unit (Advantec MFS Inc) and concentrated by 50 kD MWCO centrifugal filters 
(Millipore).  
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Co-localization studies 
DC 2.4 cells were plated on glass coverslips 24 hours prior to transfection with RALA, 
RGSG, or RRRR along with 250 ng of eGFP mRNA labeled with cy3b MTRIPs per well. 5 
hours post transfection, cells were fixed in 4% PFA and staining was performed for Caveolin 
(Santa Cruz Biotechnology - SCBT), Clathrin Light Chain (SCBT) and ARF6 (SCBT). 
Images were taken using a Flash 4.0 v2 sCMOS camera (Hamamatsu) with a 63x NA 1.4 
Plan-Apochromat objective on an Ultraview spinning disk confocal microscope (Perkin 
Elmer). Imaging and analysis was performed in Volocity (Perkin Elmer) as follows. 
Thresholds for mRNA and endocytic marker intensities were set such that all positive signal 
was included in colocalization analyses while background signal was discarded. Individual 
cells were then isolated and per-cell Mander's colocalization coefficients were calculated by 
the Volocity software. These per-cell measurements were then analyzed and plotted in Prism 
(Graphpad). Values were tested for statistical significance using Kruskal-Wallis one-way 
ANOVA with p<0.05. Multiple comparison's analyses was performed using Dunn's multiple 
comparison test with alpha set to 0.05.  
 
In-vivo bioluminescence imaging 
In vivo bioluminescence imaging is a sensitive and versatile tool which permits the 
visualization of engineered bioluminescence from living cells and tissues. It provides us a 
unique real-time perspective towards the understanding of biological processes. 6 hours after 
immunizations, type I IFN induction was measured as a signal using in vivo bioluminescence 
imaging. For in-vivo imaging, mice were injected intravenously with 150mg/kg of D-
luciferin (PerkinElmer, USA) in PBS and monitored using an IVIS lumina II imaging system. 
Photon flux was quantified using the Living Image 4.4 software (both from Caliper life 
sciences, USA) 
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7. Supplementary 
 
Figure S1. 
 
 
Figure S1. Gating strategy used for OVA- specific CD8+ T cell proliferation. Cells are 
gated based on FSC and SCC, before single cells are gated based on SSC-area and height. 
Living cells are selected and gated for CD3+CD19- T cells. Within CD8+ T cells, OVA-
specificity is gated by labelling with MHC-I SIINFEKL – PE dextramer. Proliferation of 
CFSE positive OVA-specific CD8+ T cells is shown by counting % OT-I cells above 4th 
division. 
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Figure S2 
Figure S2. Effects of peptide composition on uptake of the mRNA cargo. (A-B) Flow 
cytometric analysis of cargo mRNA uptake after incubation of DC2.4 dendritic cells with 
Cy3b-labeled mRNA complexed to respectively RALA, RGSG and RRRR at N/P 10. The 
percentage of Cy3b positive DC2.4 cells is shown in (A) whereas the mean fluorescence 
intensity (MFI) of Cy3b-positive DC2.4 is depicted in (B). Measurements are reported as 
means (n = 4) ± SD; *** p < 0.001, ** p < 0.01.  
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1. Abstract 
The development of synthetic vaccines is actively pursued due to among others to a superior 
safety profile and ease of manufacturing. However, the level of protective immunity induced 
by these vaccines often is not up to the level achieved by whole organism vaccines. Here, we 
propose a self-assembling nanoparticle containing an antigen-peptide shell and a nucleic acid 
core, thus essentially mimicking the immunogenic features of a virus. The antigen-peptide 
consists of a MHC I/II epitope fused to the carrier peptide RALA, possessing a pH-sensitive 
amphipathic structure that endows the peptide with an endosome disrupting activity. 
Combining the RALA peptide with non-coding DNA resulted into self-assembly into 
nanoparticles, promoting the uptake by dendritic cells and their maturation into antigen 
presenting cells. The combined features of this synthetic virus-like nanoparticle allowed for 
an highly efficient induction of CD8
+
 cytotoxic T cells upon inclusion of MHC I antigen 
epitope and/or priming for humoral antibody responses upon inclusion of MHC II antigen 
epitope.  
2. Introduction 
Vaccines eliciting protective immunity against pathogens have been extremely successful in 
reducing the incidence and medical burden of a variety of infectious diseases such as 
measles, polio, tetanus and small pox
1
. These successes have mostly been obtained using 
whole organism vaccines based on live attenuated or chemically inactivated viruses and 
derive their protective efficacy from a highly efficient induction of strong antibody responses 
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as well as CD8
+
 cytotoxic T cell (CTL) responses. However, safety concerns such as the risk 
of mutation to a more virulent form, causing disease in especially immune compromised 
people such as young children and elderly
2, 3
, as well as limitations in the production and 
storage have spurred a renewed interest in the development of synthetic vaccines using 
selected antigens rather than the whole organism. Due to the controllable production process 
of synthetic antigens, the safety profile of subunit vaccines is considerably better than that of 
whole organism vaccines 
4
. Yet, in order to increase and skew the immunogenicity of the 
vaccine protein antigen, subunit vaccines need to be formulated into nanostructures and/or to 
be accompanied by adjuvants 
5
. 
Synthetic antigens may occur in different formats such as in the format of recombinant 
protein, peptide or alternatively as DNA or RNA sequences containing the genetic 
information for the protein antigen. Of these different formats, peptides offer the advantage 
over proteins and nucleic acids that they can be easily and affordably synthesized. Moreover, 
peptides have been shown to be more readily processed and presented by dendritic cells when 
compared to whole proteins
6
. When administered at sufficiently high concentrations, peptide 
epitopes may directly bind to their specific MHC receptor, thus circumventing the need for a 
prior intracellular processing of the protein antigen
7
 . However, the absence of accompanying 
innate immune triggers renders such approaches poorly immunogenic. Fusion with self-
assembling viral capsid proteins or formulation of the peptide with lipid or polymer carriers 
generating nanoparticles, allows combining innate immune stimuli with an efficient uptake of 
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the vaccine nanoparticle by antigen presenting cells. Such approaches have been shown to be 
highly efficient in inducing CD4
+
 Th cell responses along with the induction of humoral 
immune defenses
8, 9
. Yet, because such nanoparticles are processed through the endosomal 
MHC class II-directed pathway and mostly fail to access the cytosolic route of antigen 
processing and loading of peptides onto nascent MHC class I molecules, the induction of 
CD8
+
 CTL responses is in general considerably weaker. 
 
Here, we propose a peptide-based nanoparticle vaccine formulation that by its specific 
features allows for a highly efficient induction of strong CD8
+
 CTL responses. This 
characteristic results on the one hand from a fusion of a MHC I peptide epitope with the 
cationic RALA peptide. At acidic pH, RALA has been shown to display an amphipathic 
structure that endows the complex with an endosome disrupting activity
10, 11
, thus allowing 
for the release of the peptide epitope into the cytosolic route of MHC I antigen processing 
and presentation. In order to create stable nanoparticles promoting uptake by antigen 
presenting dendritic cells, non-coding DNA was combined with the RALA-MHC I epitope 
peptide, thus enforcing its complexation into nanoparticles. The results obtained with these 
RALA-MHC I epitope nanoparticles demonstrated a potent induction of CD8
+
 CTL reactivity 
upon intradermal immunization of mice. Furthermore, addition to these RALA MHC I 
epitope particles of separate particles now carrying a peptide epitope for MHC class II, 
elicited besides potent CTL responses also Th2 cell reactivity sustaining a humoral antibody 
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response. The induction of both humoral and cellular immune responses, a feature otherwise 
characteristic of viral infection, renders the RALA-epitope/DNA nanocomplexes very similar 
to a synthetic virus, eliciting antiviral immune defenses in the absence of infection and 
pathology. 
3. Results 
3.1. Particle characterization 
Ovalbumin (OVA) is a T-cell dependent antigen commonly used as model protein for 
studying antigen specific immune responses in mice. OVA 257-264 peptide (table 1, amino 
acids shown in red) binds to the peptide-binding groove of the MHC I protein H-2K
b
, 
resulting in its recognition by CD8
+
 cytotoxic T cells 
12, 13
. In contrast, OVA 323-339 peptide 
(table 1, amino acids shown in brown) binds to the I-A
b
 MHC class II protein and hereby will 
interact with antigen specific CD4
+
 T helper cells
14, 15
.  We fused these MHC class I and  
MHC class II epitopes with the native RALA sequence (table 1, amino acids shown in blue), 
resulting in the RALA-MHC I epitope and RALA-MHC II epitope peptides respectively 
(table 1). The RALA repeats in these peptides confer α-helicity in a pH-dependent manner, 
resulting in membrane disruption and cytosolic release of the peptide in acidified endosomes 
11
. Naturally, arginine is found in DNA binding/condensing motifs, leading to a tight 
complexation and spontaneous formation of nanoparticles
16, 17
. 
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Table1: RALA and epitope fused RALA peptides used in this study 
Blue amino acids : Native RALA sequence 
Red amino acids : OVA 257-264 binds to the peptide-binding groove of  H-2K
b 
MHC I  
Brown amino acids : OVA 323-339 peptide binds to the I-A
b
 MHC class II protein 
Green amino acids : In order to facilitate proteolytic processing, amino acids preceding 
     the epitope in native ovalbumin protein were included 
 
In order to address the capacity of the RALA repeats to complex pDNA, we prepared 
formulations at N:P ratio 1 up to N:P ratio 10. The N:P ratio represents the molar ratio of 
positively charged nitrogen atoms in the peptide to negatively charged phosphates in the 
pDNA backbone.  Dynamic light scattering (DLS) measurements showed that an increase in 
NP ratio from 1 to 5 resulted in a decrease in particle size range from 250nm to 100nm 
(Figure 1.A). A further increase to N:P10 did not result in a further condensation of the 
nanoparticles. As shown in Figure 1.A, fusion of RALA with MHC I or MHC II epitope did 
not affect the particle formation ability of the RALA repeats. Nanoparticle formation was 
also validated by transmission electron microscopy (TEM). This showed the morphology of 
nanoparticles to be spherical and confirmed the absence of aggregation (Figure 1.B). Finally, 
we verified to what extend the different RALA peptides are engulfed by bone marrow-
Peptide 
names 
Amino acid sequences 
RALA  N-WEARLARALARALARHLARALARALRACEA-C 
RALA-
MHC I 
epitope  
N-WEARLARALARALARHLARALARALRACEASGLEQLESIINFEKL-C 
RALA-
MHC II 
epitope 
N-
WEARLARALARALARHLARALARALRACEAAESLKISQAVHAAHAEINEAGR-
C 
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derived dendritic cells (BMDCs) (Figure 1.C) and processed into epitope MHC complexes 
(Figure S1). Flow cytometry analysis showed a highly efficient uptake of RALA-pDNA 
nanocomplexes from N:P 5 on. Fusion of RALA with either MHC I or MHC II epitopes did 
not significantly affect the uptake efficiency of the nanoparticles. The intracellular location of 
the Cy5 fluorescence signal measured by flow cytometry was confirmed by confocal 
microscopy (Figure 1.D).  
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Figure 1: Characterisation of RALA epitope fusion peptide complexed with non-coding pDNA. (A) 
Particle size analysis of RALA/pDNA complexes and RALA-epitope/pDNA complexes at N:P ratios 1, 5 and 
10 through Dynamic light scattering (DLS) measurements. Mean ± SEM of 3 samples per group is shown.  (B) 
Transmission Electron Microscopy (TEM) image of RALA-epitope/pDNA complexes at N:P ratio 5, showing 
the occurrence of nanoparticles spherical in shape and devoid of aggregation. (C-D) In-vitro studies performed 
in dendritic cells primary culture. (C) According to NP ratio, Cy5-labelled pDNA complexed with RALA and 
RALA epitope fusion peptides. After 3 hours of incubation with dendritic cells, samples were measured in 
FACS. Percentage of Cy5 positive cells that have taken up RALA-epitope/pDNA complexes are shown. Mean ± 
SEM of 3 samples per group is shown. (D) Confocal microscopy image showing the intra-cellular localisation of 
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RALA-epitope/Cy5 labelled pDNA particles (red) and hoechst dyed nucleus (Blue) with in cholera toxin stained 
cell membrane (green)  
 
2.2. In vivo CD8
+
 T cell proliferation and cytolytic functionality 
In order to analyze to what extend the RALA-MHC I epitope peptide, complexed or not to 
non-coding pDNA, promotes CD8
+
 T cell proliferation, we used CD8
+
 T cells expressing the 
well-characterized OT-I TCR transgene, which confers recognition of the SIINFEKL  
epitope
18
. OVA-specific CD8
+
 T cells (OT-I cells) were isolated from C57BL/6-
Tg(TcraTcrb)1100Mjb/Crl, homozygous mice containing transgenic inserts for mouse Tcra-
V2 and Tcrb-V5 genes
19
. We labelled these OT-I cells with CFSE dye followed by their 
adoptive transfer into wild type mice (C57BL/6). Two days after adoptive transfer, mice were 
immunized with the respective peptides. The draining lymph nodes were dissected 48 hours 
post immunization and OT-I T cell proliferation analyzed by flow cytometry. The gating 
strategy used for quantifying OVA- specific CD8
+
 T cell proliferation is shown in Figure 
S.2. As shown in Figure 2.A-B, fusion of the MHC I epitope with RALA already resulted in 
a stronger CD8
+
 T cell proliferative response which in its turn was further increased if the 
RALA-MHC I epitope peptide was complexed with pDNA.  
In vivo killing assay was performed to estimate the conversion of proliferative response into  
antigen-specific cytolytic effectors.  In brief, two weeks following booster immunization, 
mice were challenged with a 1:1 ratio of OVA peptide-pulsed CFSE
hi
 splenocytes (target 
cells) and non-pulsed CFSE
low
 splenocytes (non-target cells). Two days later, spleens were 
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dissected and the ratio of target cells versus non-target cells was analyzed by flow cytometry 
in order to determine the extent of antigen-specific killing of the target cells. The results 
obtained show the presence of a strong cytolytic reactivity in mice immunized with RALA-
MHC I epitope/pDNA nanoparticles and which was clearly superior to the response induced 
by RALA-MHC I epitope peptide or the MHC I epitope peptide as such (Figure 2.C-D).  
 
Figure 2: In vivo CD8
+
 T cell proliferation and cytolytic function. Two days prior to immunization, CFSE-
labelled CD8
+
 OT-I cells were adoptively transferred to C5BL/6 mice. Intradermal immunization was performed 
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at the ear with RALA-MHC I epitope/pDNA nanoparticles, RALA-MHC I epitope peptide, and MHC I epitope 
peptide. After 48 hours, draining lymph nodes were isolated and CD8
+
 T cell proliferation was measured by 
flow cytometry. Proliferation peaks are shown in (A).  (B) Shows the percentages of proliferating OT-I T cells. 
Mean ± SEM of 5 mice per group is shown. ***, P< 0.0001 (One-way ANOVA Newman-Keuls post test).     
(C-D) In vivo killing assay was performed by adoptive transfer of CFSE-labeled peptide-loaded splenocytes to 
C5BL/6 mice that received a prime-boost immunization with RALA-MHC I epitope/pDNA nanoparticles, 
RALA-MHC I epitope peptide, and MHC I epitope peptide. Antigen-specific killing was measured 2 days later 
by flow cytometry. Mean±SEM of  5 mice per group is shown. ***, P< 0.0001 (One-way ANOVA Newman-
Keuls post test). 
 
2.3. In vivo CD4
+
 T cell proliferation and antibody responses 
In order to verify the capacity of RALA/pDNA-based nanoparticles to induce also CD4+ T 
cell responses, mice were immunized with RALA peptide fused with the MHC II epitope of 
OVA, namely RALA-MHC II epitope. The antigen-specific proliferative response elicited by 
the RALA-MHC II epitope peptide, complexed or not with non-coding pDNA, was 
quantified on the basis of the proliferation divisions of adoptively transferred, CFSE-labelled 
OT-II cells. These OT-II cells were isolated from C57BL/6-Tg(TcraTcrb)425Cbn/CrI), 
homozygous transgenic mice express the mouse α-chain and β-chain T cell receptor and is 
specific for OVA323-339 in the context of I-Ab
19
.  
We next verified to what extend the elicited CD4
+
 T cell response sustained a subsequent 
antibody response. Hereto, mice that first were immunized twice with RALA-MHC II 
epitope/pDNA nanoparticles were subsequently challenged with OVA protein. OVA-specific 
antibody titers were determined by ELISA in immune serum, collected two weeks after the 
protein boost immunization. As shown in Figure 3.C, priming with RALA-MHC II 
epitope/pDNA nanoparticles induced already a weak IgG1 antibody response. A subsequent 
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boost immunization with OVA protein strongly increased this IgG1 antibody response. This 
strong induction of an antibody isotype that is dependent on help from CD4
+
 Th2 cells, 
supports the notion that the CD4
+
 T cells elicited by the RALA-MHC II epitope/pDNA 
nanoparticles are functionally active, exerting helper activity for B cell antibody responses 
and isotype switching. 
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Figure 3: In vivo CD4
+
 T cell proliferation and function. Two days prior to immunization CFSE-labelled 
CD4+ OT-II cells were adoptively transferred to BL6 mice. Intradermal immunization was performed at the ear 
with RALA-MHC II epitope/pDNA nanoparticles. (A, B) After 48 hours, draining lymph nodes were isolated 
and OT-II T cell proliferation was measured by flow cytometry. Proliferation profiles are shown in (A). (B) 
Shows the percentages of proliferating T cells. Mean ± SEM of 5 mice per group is shown. ***, P< 0.0001 
(One-way ANOVA Newman-Keuls post test). (C) Immunized C5BL/6 mice received a booster immunization 
with OVA protein. After two weeks, blood samples were collected and serum isolated. Serum titers of anti-
ovalbumin antibodies were determined by ELISA. Mean±SEM of 5 mice per group is shown.** p<0.005 (un-
paired t-test) 
 
2.4. Co-induction of cellular and humoral immunity 
In order to induce both cellular and humoral immunity, RALA-MHC I epitope and RALA-
MHC II epitope peptides need to be co-administered. Co-administration can be achieved in 
two ways. A first method is to separately prepare RALA-MHC I epitope/pDNA and  RALA-
MHC II epitope/pDNA nanoparticles. This allows for the administration of uni-epitope 
particles with MHC I and II epitopes present in separate particles (Figure 4.A) and that can 
be mixed together at the time of immunization. In an alternative method, RALA-MHC I 
epitope peptide, RALA-MHC II epitope peptide and pDNA are mixed together. This will 
result in the formation of a multi-epitope particle with MHC I and II epitopes present in the 
same particle (Figure 4.B). In order to verify what type of particle is most potent in inducing 
CD8
+
 T cell dependent cellular cytotoxicity and CD4
+
 T cell dependent humoral antibody 
responses, we compared both formulations keeping the amount of epitopes constant.  
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Figure 4. (A) Uni-epitope particles with MHC I and II epitopes present in separate particles. (B) Multi-epitope 
particle with MHC I and II epitopes present in the same particle. 
 
As shown in Figure 5.A, immunization with a mix of MHC I epitope and MHC II epitope 
uni-epitope nanoparticles induced a significantly stronger cytolytic activity as compared to 
multi-epitope nanoparticles containing a mix of both MHC I and II epitopes. As expected, 
nanoparticles containing only MHC II epitope failed to induce cytolytic activity (Figure 5.A).  
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When looking at the antibody response shown in Figure 5.B, similar titers were observed 
upon immunization with either MHC I and MHC II epitopes mixed into a single multi-
epitope nanoparticle or co-administered in separate uni-epitope nanoparticles.  
Combining both data sets, an optimal cellular and humoral immune response clearly is 
induced by co-administration of a mix of uni-epitope RALA-MHC I epitope/pDNA and 
RALA-MHC II epitope/pDNA nanoparticles (Figure 5.A-B). 
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Figure 5: Co-induction of cellular and humoral immunity.  (A) Invivo cytolytic function measurement 
through killing assay. C57BL/6 mice received prime-boost intradermal immunizations with RALA-MHC I 
epitope/pDNA nanoparticles, RALA-MHC II epitope nanoparticles, uni-epitope particles with MHC I and II 
epitopes present in separate particles, multi-epitope particle with MHC I and II epitopes present in the same 
particle, free peptide format of RALA-MHC I epitope and RALA-MHC II epitope. In vivo killing assay was 
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performed by adoptive transfer of CFSE-labelled peptide loaded splenocytes and antigen-specific killing was 
measured 2 days later by flow cytometry. Mean±SEM of 5 mice per group is shown. *** p<0.0001 (One-way 
ANOVA Newman-Keuls post test).(B) Humoral antibody responses shown through serum ELISA. Intradermal 
immunizations were performed at the ear of C57BL/6 mice in prime-boost vaccination regimens with RALA-
MHC II epitope nanoparticles, uni-epitope particles with MHC I and II epitopes present in separate particles, 
multi-epitope particle with MHC I and II epitopes present in the same particle, free peptide format of RALA-
MHC II epitope. Additional protein boost immunizations were also performed for the groups shown here. After 
two weeks, blood samples were collected and serum isolated. Serum titers of anti-ovalbumin antibodies were 
determined by ELISA. Mean±SEM of 5 mice per group is shown. *** p<0.0001 (One-way ANOVA Newman-
Keuls post test).  
 
3. Discussion 
Cell penetrating peptide containing the amphipathic RALA motif complexes with pDNA and 
condenses to form stable nanoparticles. Here, we show that epitope fused peptide self-
assembles into particles and the size varies with respect to N:P ratio. Compared to the non-
particulate format of RALA-MHC I epitope peptide, the particle format strongly improved 
antigen-specific CD8
+
 T cell proliferation and cytolytic function after immunization. Upon 
fusing a MHC II epitope to RALA, again the particle format of the epitope induced strong 
CD4
+
 T cell proliferation as well as helper activity for antibody isotype switching. The 
occurrence of mainly IgG1 antibody titers points towards the elicitation of Th2 cell reactivity 
rather than Th1 cells.  
 
Strikingly, pDNA-driven self-assembly of the RALA-epitope peptide into nanoparticles 
strongly increased the magnitude of T cell proliferation and function. Uptake of a particle by 
APCs such as dendritic cells will result in a larger amount of antigenic cargo entered the cell 
and thus in a higher intracellular antigenic peptide load. However, also the pDNA driving the 
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self-assembly into nanoparticles may contribute to the enhanced immunogenicity of the 
RALA-epitope peptide/pDNA complexes. It is well known that DNA isolated from bacteria 
is rich in unmethylated 2’-deoxyribo (cytidine-phosphateguanosine) (CpG) dinucleotides, 
which activate the innate immune system through TLR9. In order to avoid such pro-
inflammatory innate immune activity, we used CpG-free pDNA, a new family of plasmids 
that are completely devoid of dinucleotides. Yet, RALA-epitope peptide/CpG-free pDNA 
nanoparticles induced dendritic cell maturation (Figure S4). This maturation was further 
enhanced when using pDNA rich in CpG (Figure S4). This suggests that the main function of 
the (CpG-free) pDNA is to self-assemble with RALA rather than to promote innate immune 
activation and that the particulate format itself of RALA-epitope peptide/pDNA exerts 
intrinsic immune-stimulatory activity.  
 
Considering that RALA has been shown before to promote in a pH dependent manner 
endosomal escape
11
, endosomal escape of RALA-epitope peptide/pDNA nanoparticles and 
processing of associated epitope through the cytosolic MHC I pathway likely underlies the 
potent induction of CD8
+
 T cell responses. The induction also of CD4
+
 T cell responses 
suggests that a fraction of the engulfed nanoparticles failed to enter into the cytosol, resulting 
in their processing through the endosomal MHC II pathway. When both MHC I and MHC II 
epitopes are present in the same particle, a lesser induction of cytolytic T cell activity was 
observed but not of antibody responses. In contrast herewith, immunization with MHC I and 
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MHC II epitopes administered in separate particles resulted in both strong cytolytic and 
humoral responses. Administering CD4 and CD8 T cell epitopes in separate particles 
therefore seems to be most indicated for inducing both cellular and humoral immunity. From 
a commercial perspective, manufacturing CD4 and CD8 T cell epitope particles separately 
and combining them accordingly to the desired type of immunity is an attractive perspective. 
From an immunological perspective, the RALA-epitope peptide/pDNA nanoparticles elicit 
immune responses typically observed during viral infection, thus classifying these particles as 
fully synthetic virus-like particles promoting strong anti-viral immune responses in the 
absence of pathogenesis. These combined features render the self-assembling RALA peptide-
based nanoparticles highly attractive to act  as vaccines against various infectious diseases 
such as tuberculosis, malaria and HIV that require humoral as well as cytolytic immune 
defenses for protection.  
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4. Experimental section 
Mice 
Female C57BL/6 mice and OT-I mice (7 weeks old) were purchased from Janvier (Le Genest 
Saint Isle, France). All mice were maintained under specific pathogen-free conditions and 
treated according to the European guidelines for animal experimentation. All experiments 
were approved by the local ethical committee of Ghent University (Ghent, Belgium). 
 
Preparation of peptide/pDNA nanoparticles 
RALA was produced by solid-state synthesis and supplied as an acetate salt lyophilized 
powder (Biomatik, USA). Plasmid DNA (pDNA) that are completely devoid of CpG 
dinucleotides purchased from Invivogen (San Diego, USA). Peptides and pDNA were tested 
for the presence of endotoxin using Endosafe testing system(Charles river, USA). 
Peptide/pDNA complexes were prepared at N/P ratios 1, 5 and 10 by adding appropriate 
amount of pDNA to specific amount of peptide which has 200ng of epitope.  
 
Particle size and zeta potential analysis 
For size and zeta potential measurements, particles were analyzed using Nano ZS Zetasizer 
and analyzed by DTS software (Malvern Instruments, UK). 
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Transmission electron microscopy (TEM) 
The shape and surface morphology were observed using Jeol JEM1400plus transmission 
electron microscope at 30 kV. 
 
In vitro transfections 
DC primary cultures were generated from bone marrow of WT C57BL/6 mice. At day 7, 
1x10
6
cells/well was incubated for 2 hours in Opti-MEM serum free media (Gibco, UK) prior 
to the addition of 1µg of epitope present in appropriate amount of RALA fused epitope 
complexed with pDNA according to respective NP ratios 
 
MHC peptide binding assay 
25-D1.16 monoclonal antibody specifically reacts with ovalbumin-derived peptide 
SIINFEKL bound to H-2Kb of MHC class I.  These antibodies are coupled with PE-
fluorophore. After overnight incubation of BMDC with particles, cells are stained with these 
antibodies. Epitope presentation will be analysed through flow cytometry.  
Flow cytometry 
All flow cytometric experiments were performed on a triple-laser (B-V-R) LSR-II (BD 
biosciences, USA) and analysed with FlowJo software (Treestar, OR). Cells were stained 
with α-CD16/CD32 (BD biosciences, USA) to block non-specific FcR binding. Live/Dead 
Fixable Aqua stain (Invitrogen) was used to eliminate dead cells from analysis.  
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Immunizations 
Intra-dermal immunization was performed in the ear of mice with 200ng epitope complexed 
with RALA in a total volume of 20µl nuclease-free water through insulin needles (BD-ultra 
fine). As a control, intradermal immunization was performed in the ear with 200ng epitope 
without adjuvant. 
 
In vivo T cell proliferation assay 
OT-I or OT-II T cells were labelled with 5 µM carboxyfluorescein diacetate succinimedyl 
ester (CFSE) (Invitrogen, Belgium) and 1 million CFSE labelled cells were i.v. injected two 
days prior to immunization. Three days later, lymph nodes were isolated and OT-I or OT-II T 
cell division was analyzed by flow cytometry. Cells were stained with α-CD16/CD32 (BD 
Biosciences, USA), Live/Dead Fixable Aqua stain (Invitrogen), α-CD8, α- CD3, α-CD19, α- 
CD4, α- TCR (all BD Biosciences, USA) and MHC dextramer H-2 Kb/SIINFEKL-PE 
(Immudex, Denmark). 
 
In vivo cytotoxicity assay 
2 weeks after prime and boost vaccination with a two week interval, splenocytes from naïve 
C57BL/6 mice were pulsed with MHC-I OVA peptide (target cells) (30 µg/ml) or left 
unpulsed (non-target cells) and subsequently labelled with respectively 5 µM or 0.5 µM 
CFSE. Labelled cells were injected into immunized mice at a 1/1 ratio. Spleen suspensions 
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were analysed 48 hours later by flow cytometry. The percentage antigen-specific killing was 
determined using the following formula: 1 - ((%CFSEhi cells / %CFSElow cells)immunized 
mice /(%CFSEhi cells / %CFSElow cells)non-immunized mice). 
ELISA  
Maxisorp plates (Nunc, Belgium) were coated overnight at 4°C with 5µg/ml ovalbumin 
protein and incubated with serial dilutions of serum. Ova-specific antibodies were determined 
by use of HRP-coupled anti-mouse IgG1 and IgG2a antibodies (Southern Biotech, USA) 
Statistical analysis 
Statistics were performed using GraphPad Prism 5 software (GraphPad software, La Jolla, 
CA, USA).  
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7. Supplementary material 
                                                             
Figure S1 : MHC peptide binding assay quantified the CD8 epitope/MHC I complex 
formed after efficient processing of intra-cellular particles. This assay also evidenced that 
free-format of epitope binds randomly on MHC expressed on cell surface.  
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Figure S2 : Gating strategy used for OT-I proliferation analysis  
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Figure S3 : Gating strategy used for OT-II proliferation analysis  
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Figure S4. Dendritic cell maturation due to RALA nano complexes with CpG-free and 
CpG-rich pDNA. Primary dendritic cell culture were incubated with RALA-epitpe/pDNA 
nanoparticles. After 12 hours, the maturation markers (CD40, CD86, MHC II) were measured 
using flow cytometry.  
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Chapter 7 
_______________________________________________________ 
 Synthetic virus-like vaccines for cancer immunotherapy 
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1. Introduction 
The principle goal of immunotherapy is thus a resurrection of the patient's inefficient or 
suppressed immune system so that it would once again become capable of launching a 
sustained cytolytic attacks against tumour cells, which would ideally result in a total and 
permanent eradication of the cancer
1
. 
Such activation of the patient's anticancer immunity, however, can be achieved by strikingly 
different ways. Immunotherapies either stimulate the activity of specific components of the 
immune system or counteract signals produced by cancer cells that suppress immune 
responses
2, 3
. Reciprocal to the blockade of co-inhibitory receptors, diverse strategies are used 
to directly stimulate the antitumor rejection, including vaccines, agonistic antibodies for co-
stimulatory receptors, immune-stimulatory cytokines, oncolytic viruses, and cell therapies. 
Cancer vaccines generate and augment the adaptive antitumour response largely by increased 
tumour antigen presentation. There are two types of tumour antigens that are considered 
targets for immunotherapy: tumour-specific antigens (TSAs) and tumour-associated antigens 
(TAAs)
4
. TSAs are highly tumour specific and expressed only in tumour cells, whereas 
TAAs are more widely expressed in both tumour and non-tumour cells. Use of TSAs can 
avoid off-target autoimmune adverse events, but anti-tumour responses are limited by the 
presence of the target antigen. TAAs are expressed in higher levels in tumours relative to 
non-tumour cells, but they generate a weaker immune response and higher off-target 
autoimmune events. APCs, like dendritic cells or macrophages, display these vaccine 
antigens to activate B and T cells, resulting in increased antitumour responses. Hence, in this 
study we aimed to test the functionality of the synthetic virus-like vaccine platform with 
melanocyte lineage-specific antigen gp100. 
2. Results and discussion 
According to the RALA-epitope fusion strategy, MHC class I H-2D
b
 human gp100 amino 
acid sequences were incorporated along with the native RALA sequence (Figure.1.A). As 
shown in Figure 1.B, fusion of RALA with gp100 epitope did not affect the particle 
formation ability of RALA repeats. Mice were immunized with 200ng gp100 containing 
RALA-gp100 epitope/pDNA particles at NP ratios 1, 5 and 10. After one week, blood 
samples were obtained from immunized mice and tetramer staining was performed using 
MHC class I H-2D
b
 human gp100 dextramer reagent. Dextramers contain MHC molecules 
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attached to a dextran backbone and are fluorescently labelled. The stained samples were 
measured using flow cytometry and the percentage of gp100-specific T cells quantified. 
Comparing to the peptide format of RALA-gp100 peptide, the particle format of RALA-
gp100 epitope induced slightly more gp100-specific CD8
+
 T cells. 
In order to verify to what extend the induced gp100-specific T cells also exerted antigen-
specific cytolytic effector function, we applied a in vivo killing assay. In brief, two weeks 
following booster immunization, mice were challenged with a 1:1 ratio of gp100 peptide-
pulsed CFSE
hi
 splenocytes (target cells) and non-pulsed CFSE
low
 splenocytes (non-target 
cells). Two days later, spleens were dissected and the ratio of target cells versus non-target 
cells was analysed by flow cytometry in order to determine the extent of antigen-specific 
killing of the target cells. The results obtained show the presence of cytolytic reactivity in 
mice immunized with RALA-gp100 epitope/pDNA nanoparticles and which was clearly 
superior to the response induced by RALA-gp100 epitope peptide as such (Figure 1.D).  
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Figure.1 (A) Amino acids sequence of RALA-gp100  fusion peptide used for this study (B) Particle size 
analysis of gp100 fused RALA peptide complexed with non-coding CpG free pDNA (C) C57BL/6 mice were 
immunized with RALA-gp100 peptide complexed with non-coding pDNA at NP ratios 1, 5 and 10, RALA-
gp100 peptide. After one week blood was isolated and the percentage of gp100 specific CD8+ T cells was 
determined by dextramer staining followed by flowcytometry. Mean±SD are shown of 4 mice per group.  (D) In 
vivo killing assay was performed by adoptive transfer of CFSE-labeled peptide-loaded splenocytes to mice 
received a prime and boost immunization with RALA-gp100 peptide complexed with non-coding pDNA at NP 
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ratios 1, 5 and 10, RALA-gp100 peptide . gp100-specific killing was measured 2 days later by flow cytometry. 
Mean±SEM of  5 mice per group is shown. ***, P< 0.0001 (One-way ANOVA Newman-Keuls post test).  
 
3. Conclusion 
Recent developments show that immunotherapy is likely to play an increasingly important 
role in cancer therapy. Particularly, vaccination may prove most useful in the context of 
lower tumour burden and as a means to attain longer-term immunity and memory. Our results 
show that this synthetic virus-like vaccine has successfully expanded cytotoxic T cell 
responses against a particular tumour antigen. This result underscores the flexibility feature 
offered by our vaccine platform, demonstrating that also other epitopes can be incorporated to 
induce potent T-cell functionality. 
 
4. Experimental section 
 
Preparation of peptide/pDNA nanoparticles 
RALA-gp100 peptide was produced by solid-state synthesis and supplied as an acetate salt 
lyophilized powder (Biomatik, USA). Plasmid DNA (pDNA) that are completely devoid of 
CpG dinucleotides purchased from Invivogen (San Diego, USA). Peptides and pDNA were 
tested for the presence of endotoxin using Endosafe testing system(Charles river, USA). 
Peptide/pDNA complexes were prepared at N/P ratio 5 by adding appropriate amount of 
pDNA to specific amount of peptide which has 200ng of MHC I epitope.  
 
Dynamic light scattering (DLS) measurements 
 For size, particles were analyzed using Nano ZS Zetasizer and analyzed by DTS software 
(Malvern Instruments, UK). 
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Flow cytometry 
All flow cytometric experiments were performed on a triple-laser (B-V-R) LSR-II (BD 
biosciences, USA) and analysed with FlowJo software (Treestar, OR). Cells were stained 
with α-CD16/CD32 (BD biosciences, USA) to block non-specific FcR binding. Live/Dead 
Fixable Aqua stain (Invitrogen) was used to eliminate dead cells from analysis.  
Immunizations 
C57BL/6 mice received prime-boost intradermal immunizations with 200ng gp100 
containing RALA-gp100 epitope/pDNA particles at NP ratios 1, 5 and 10 in a total volume of 
20µl nuclease-free water through insulin needles (BD-ultra fine). As a control, intradermal 
immunization was performed in the ear with 200ng gp100 epitope containing fusion peptide 
without adjuvant. 
Dextramer staining 
 Mice were immunized with 200ng epitope complexed RALA at respective NP ratios and 
controls. Five days after the boost immunization, blood samples were taken via tail-vein 
bleeding and red blood cells were removed using ACK lysis buffer. Cells were stained with 
α-CD8, α-CD19, α-MHC-II and MHC dextramer/gp100-PE (Immudex, Denmark) 
In vivo cytotoxicity assay 
2 weeks after prime and boost vaccination with a two week interval, splenocytes from naïve 
C57BL/6 mice were pulsed with gp100 peptide (target cells) (30 µg/ml) or left unpulsed 
(non-target cells) and subsequently labelled with respectively 5 µM or 0.5 µM CFSE. 
Labelled cells were injected into immunized mice at a 1/1 ratio. Spleen suspensions were 
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analysed 48 hours later by flow cytometry. The percentage antigen-specific killing was 
determined using the following formula: 1 - ((%CFSEhi cells / %CFSElow cells)immunized 
mice /(%CFSEhi cells / %CFSElow cells)non-immunized mice). 
Statistical analysis 
Statistics were performed using GraphPad Prism 5 software (GraphPad software, La Jolla, 
CA, USA).  
 
References: 
1. Alatrash, G., Jakher, H., Stafford, P.D. & Mittendorf, E.A. Cancer immunotherapies, their 
safety and toxicity. Expert opinion on drug safety 12, 631-645 (2013). 
2. Sui, X. et al. The anticancer immune response of anti-PD-1/PD-L1 and the genetic 
determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients. Oncotarget 6, 
19393-19404 (2015). 
3. Mashiko, S. et al. Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic 
strategy in ovarian cancer. Cancer biology & therapy 16, 253-260 (2015). 
4. Coulie, P.G., Van den Eynde, B.J., van der Bruggen, P. & Boon, T. Tumour antigens recognized 
by T lymphocytes: at the core of cancer immunotherapy. Nature reviews. Cancer 14, 135-146 
(2014). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
176 
 
 
 
 
 
 
 
 
 
 
      
 
 
 
 
PART IV: GENERAL DISCUSSION 
 
 
 
 
 
 
 
 
 
177 
 
Vaccine formulations based on recombinant proteins, peptides and pDNA or mRNA 
encoding antigens avoid the risks inherent in attenuated live vaccines, but they have the 
disadvantage of generating weak immune responses. To avoid this drawback, we aimed to 
develop novel vaccine technologies that are safe and elicit strong cellular and humoral 
immune responses. 
1. Development of antigen encoding mRNA-based vaccine 
In-vitro transcribed mRNA can be engineered to encode a broad spectrum of antigens and 
offers the additional advantage of transient, and hence safe, expression by antigen presenting 
cells (APCs). In the first part of study, we used in vitro transcribed mRNA encoding the 
model antigen ovalbumin (OVA). To mimic the virus, mRNA was formulated into 
nanoparticles using cell penetrating peptide (CPP) as carrier. Among several CPPs, we 
focused mainly on arginine-rich amphipathic peptide, namely RALA. Two properties 
differentiate RALA from several other CPPs. The first is the ability to self-assemble with 
nucleic acids and to form stable nanoparticles. The second is the remarkable pH-dependent α-
helical structure change, which leads to endosomal membrane lysis and cargo release in the 
cytosol.  
In our study, endosomal membrane destabilisation upon the uptake of RALA/mRNA 
particles resulted in leakage of RALA peptide and mRNA into the cytosol of dendritic cells 
(DCs). In vitro experiments on primary dendritic cell cultures demonstrated that the 
complexation of mRNA with RALA facilitated the expression of the encoded protein and 
activated DCs, but naked mRNA failed to do so. Furthermore, our in vivo studies showed the 
proliferation of CD8
+
 T cells and their functional cytolytic ability.  In contrast, we did not 
observe CD8
+
 T cell responses in mice immunized with mRNA complexed with arginine-rich 
non-amphipathic peptides (e.g., RGSG or PolyR peptides). These non-amphipathic peptides 
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do not participate in hydrophobic interactions, so they did not condense mRNA as efficiently 
as arginine-rich amphipathic peptide which subsequently showed differences in our physico-
chemical characterization studies of particles because the amount of peptide incorporated in 
the particle affected its biological functionality. 
1.1. mRNA expression and immune-stimulation 
Our experiments on cultured primary dendritic cells demonstrated that RALA/mRNA 
particles facilitated the expression of the encoded protein and DC activation. In previous 
studies performed by Curevac AG (Germany), the pioneer of mRNA vaccines, mRNA was 
condensed with the small cationic protein, protamine
1, 2. These protamine‒mRNA 
nanoparticles have been shown to be potent immunostimulants that activate APCs through a 
TLR7-dependent pathway
3
. 11 adjacent arginine residues are present in protamine; this 
feature promotes tight packing of mRNA molecules in nanoparticles
4, 5
. Due to strong 
electrostatic interaction between the positively charged arginine residues and the negatively 
charged mRNA, translation did not occur in protamine‒mRNA complexes. In RALA, 
arginine is placed after periodically spaced hydrophobic amino acids
6
. This promoted the 
translation and protein expression of mRNA complexed with RALA. 
1.2. Balance between antigen expression and innate immune activation for strong 
induction of potent CD8
+
 T-cells  
Protein expression improved when we modified the mRNA with pseudo-uridine and 5’-
methyl cytidine and complexed it with RALA. This observation corroborates previous studies 
showing that these modified nucleotides function in the same way as natural nucleotides 
during the process of post-transcriptional modifications
7
. Therefore, the improved translation 
of modified mRNA and enhanced protein expression was due to the absence of inhibitory 
effects. At the same time, such modified mRNAs do not trigger TLR7 and TLR8 and are not 
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recognized by RIG-I and PKR
8-12
. Modified mRNA formulated with lipid carriers elicited 
potent and durable neutralizing antibody responses in mice and non-human primates upon 
single low-dose vaccination
13, 14
 . However, use of modified mRNA in delivery systems that 
rely only on the immune-stimulatory nature of mRNA may be associated with a decrease in 
PRR triggering, DC activation and cytokine release, which hamper rather than enable T cell 
activation.  This is exemplified by a recent study in which the use of modified mRNA was 
shown to be counter-productive for CD8
+
 T cell proliferation and its cytolytic functionality
15
. 
In contrast, we observed improved proliferative CD8
+
 T cell responses and cytolytic 
functionality.  
In our study, transfection of cultured primary dendritic cells demonstrated that complexation 
of RALA with mRNA modified with pseudo-uridine and 5-methyl cytidine nucleotides 
improved the expression of the encoded protein and reduced dendritic cell activation 
compared to unmodified mRNA/RALA particles. Furthermore, in vivo studies showed that 
modified mRNA complexed with RALA induced the production of significantly less type I 
interferons compared to DOTAP/DOPE lipoplexes. Taken together, these results indicate that 
modified mRNA increases vaccine potency by decreasing innate activation. Type I 
interferons induce anti-viral response mechanisms that negatively affect the stability and 
translation of mRNA vaccines 
16-18
. We found that the use of modified mRNA in combination 
with RALA reduced type I interferon responses sufficiently to relieve the block on CD8
+
 T 
cell responses. The near complete complexation of mRNA with RALA was of paramount 
importance in this respect, as incomplete complexation of mRNA in DOTAP/DOPE mRNA 
lipoplexes failed to reduce the type I interferon response sufficiently to avoid its negative 
effect on T cell immunity. Therefore, mRNA vaccine potency can be improved by having the 
right balance between mRNA expression and intrinsic innate immune stimulatory features of 
the carrier.  
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2. Development of antigenic peptide-based vaccines 
In the next part of the research, we explored an alternative strategy that relies on the use of 
short peptide fragments to engineer the induction of highly targeted immune responses
19
. We 
used MHC I and MHC II epitopes of ovalbumin as antigenic peptides
20, 21
. We fused these 
epitopes with the carrier peptide RALA and studied its particulate format after complexing it 
with non-coding pDNA. 
Immunization of mice with RALA-MHC I epitope peptide/pDNA nanoparticles induced 
strong CD8
+
 T cell proliferative and cytolytic responses. Similarly, the particulate format of 
RALA-MHC II epitope peptide/pDNA nanoparticles elicited strong CD4
+
 T cell proliferation 
and humoral antibody responses. A booster immunization with ovalbumin protein resulted in 
high antibody titers and isotype switching to IgG1. These immune features, similar to the 
mixed cellular and humoral immune responses elicited by viral infection
22
, along with the 
fully synthetic nature of the RALA-epitope peptide/pDNA nanoparticles classify these 
nanoparticles as synthetic virus-like particles.  
2.1. How synthetic virus-like vaccines may make a difference in cancer immune therapy 
Sipuleucel-T is the only therapeutic cancer vaccine that is FDA approved
23
. It is a fusion 
protein (PAP-GM-CSF) consisting of prostatic acid phosphatase linked to granulocyte-
macrophage colony-stimulating factor, and needs to be incubated with the patient’s isolated 
APCs ex-vivo. However, the company producing this vaccine filed for bankruptcy, likely 
because of the difficulties and cost of continuously developing clinical-grade preparations. 
Being fully synthetic, RALA-epitope nanoparticle minimizes these complexity and cost 
issues by circumventing the ex-vivo processing step. In addition, new features can be 
included by replacing non-coding pDNA by e.g. cytokine encoding mRNA. Cytokines play a 
critical role in immune cell signalling, allowing immune cells to communicate and modulate 
181 
 
the intensity of the immune response against target antigens. Several clinical studies have 
shown the influence of cytokines on the efficacy of immune-therapy approaches
24, 25
. 
Through this combination approach, the immune therapy application of RALA-epitope 
particle could be enhanced. 
2.2. Role of nucleic acids in synthetic virus-like particles 
Nucleic acid-driven self-assembly of the RALA‒epitope peptide into nanoparticles strongly 
increased the magnitude of T cell proliferation and function. As each carrier RALA peptide is 
fused with antigen, the abundance and density of antigen are high in the RALA‒epitope 
peptide/pDNA nanoparticles. Uptake of particles by APCs such as dendritic cells results in a 
larger amount of antigenic cargo entering the cell and thus in a higher intracellular antigenic 
peptide load. Numerous studies have demonstrated that particulate forms of antigen drive 
stronger immune responses than free antigens when co-delivered with an immune-stimulant, 
thus reducing the required antigen dose 
26, 27. Using RALA‒epitope peptide/pDNA 
nanoparticles, we demonstrated strong cellular CD8
+
 T cell responses and humoral antibody 
responses induced by merely 200 ng of peptide antigen in the absence of conventional 
immune-stimulants.  
However, pDNA driving self-assembly into nanoparticles may also contribute to enhanced 
immunogenicity of RALA‒epitope peptide/pDNA nanoparticles. It is well known that DNA 
isolated from bacteria is rich in unmethylated 2’-deoxyribo (cytidine-phosphateguanosine) 
(CpG) dinucleotides, which activate the innate immune system through TLR9
28
. To avoid 
such pro-inflammatory innate immune activity, we used CpG-free pDNA, a new family of 
plasmids that are completely devoid of these dinucleotides
29, 30
. RALA‒epitope peptide 
pDNA nanoparticles devoid of CpG induced DC maturation, and this maturation was further 
enhanced when pDNA was rich in CpG. This suggests that the nucleic acid in this system 
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primarily functions as a scaffold for self-assembling with RALA rather than promoting innate 
immune activation.  
2.3. Evolvement of self-immune stimulatory antigen carriers 
While the recognition of CpG rich pDNA involves mainly TLR9, recognition of cytosolic 
DNA appears to involve several sensors, such as DAI (DNA-dependent activator of IFN-
regulatory factors)
31
, LRRFIP1
32
 and AIM2 (absent in melanoma 2)
33
. Recently, two 
independent teams confirmed the involvement of RIG-I in the response to dsDNA and 
demonstrated that, rather than the cytosolic DNA, an RNA intermediate was responsible for 
RIG-I activation
34, 35
. Thus, innate recognition of cytosolic nucleic acid is more complicated 
than first anticipated. Although DNA vaccines are quite effective in veterinary medicine, they 
tend to display low immunogenicity in humans, which has hindered their development. The 
reasons for this lower responsiveness of humans compared to other mammals are unclear. 
Possible explanations could involve lower expression levels of certain components of the 
DNA-sensing machinery, differing expression patterns of nucleic acid-sensing PRRs, or 
issues related to DNA delivery and processing in different cell types
36, 37
.    
An exciting direction for future research is to design materials that trigger innate immunity, 
which will then support the subsequent development of adaptive immunity. That would 
enhance the induction of vaccine-specific responses. Some materials with immune 
stimulatory properties that can also serve as antigen carrier have been identified. When an 
epitope sequence was conjugated to the self-assembling peptide Q11 (QQKFQFQFEQQ), the 
fusion peptides self-assembled into nanofibers and elicited a strong antibody response 
without the need for an additional immune-stimulant other than carrier peptide
38, 39
. In the 
same line, the immune-stimulatory nature of RALA depended on the self-assembled particle, 
but the self-assembling sequence was not immunogenic by itself. Previous studies reported 
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HIV LTR as well as NF-κB responsive genes stimulation by TAT protein, but not with TAT 
peptide
40
.  
It has been proposed that hydrophobicity dictates the immune stimulation of synthetic 
polymers and moieties of some microbial danger signals
41
 . As a promising starting point, a 
direct quantitative correlation between hydrophobicity and immune system activation has 
been demonstrated using gold nanoparticles with organic ligand shells of increasing 
hydrophobicity
42
. Petersen et al. recently demonstrated that the activation of innate immune 
responses by pathogen-mimicking nanoparticles was significantly influenced by polymer 
hydrophobicity
43
.  
Further exploration of such novel routes of adjuvant action may lead to new strategies for 
adjuvant development that move beyond the well-established classical adjuvants and 
established danger signal pathways. 
3. Future prospects 
3.1. Will it be a milestone in Tuberculosis vaccination? 
For most diseases for which no effective vaccine is available, we often do not know which 
type of immune response would give the best long-term protection. There is an emerging 
consensus that vaccines against complex pathogens such as HIV, Mycobacterium 
tuberculosis (Mtb) and Plasmodium require both antibodies and CD8
+
 T cells. It will be 
interesting to study the protective immunity induced by synthetic virus-like particles in 
animal models of AIDS, tuberculosis (TB) and malaria.  
Since Neolithic times (3900-1700 BC) TB has affected human beings. During 17
th
 and 18
th
 
centuries in Europe it caused the so-called “white plague” and accounted for 25% of all adult 
deaths during this period. According to the World Health Organization’s report, 10.4 million 
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people contracted TB, and 1.8 million died in 2015. TB has become a health threat again 
because its unique characteristics give it an enormous potential for developing resistance to 
antibiotics. While vaccine-resistant bacteria have never been reported, this provides evidence 
that vaccination can reduce the evolvement of antibiotic resistant strains by decreasing their 
use
44
 
45
.  
 The only licensed TB vaccine is Bacillus Calmette-Guerin (BCG). Vaccination with BCG is 
relatively efficient but has some shortcomings such as the risk of causing disease in 
immunocompromised people
46
. TB immunity likely has to be multifactorial and the best 
protection is likely to be elicited by the combination of strong humoral and cell-mediated 
immune responses
47
. Our synthetic virus-like vaccine platform allows the elicitation of both 
cellular and humoral immune responses and may therefore be suited to elicit protection 
against Mtb infection. Therefore, we have planned as a proof-of-principle experiment to 
incorporate MHC I and MHC II epitopes of the Mtb antigen, PPE44, in RALA particles. If 
this preclinical study succeeds, it may lead to the development of a new type of vaccine 
against Mtb.  
Human leukocyte antigens (HLA) are highly polymorphic. This polymorphism  limits the 
proportion of individuals who will respond to a particular peptide epitope present in a 
vaccine
48
. To overcome this problem, T cell epitopes that bind to multiple HLA alleles for 
maximal population coverage need be included in the vaccine design. A bioinformatics-based 
approach is the most feasible method in identifying from a given protein peptides that may fit 
multiple HLA alleles
49
. Previous studies have reported the usage of long peptides containing 
multiple epitopes 
50, 51
. However, technical limitations in synthesizing long and often 
hydrophobic peptides may limit the practical applicability of this strategy.  
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Nucleic acids encoding large set of epitopes can be an alternative to long multi-epitope 
peptides
52
. In our RALA vaccine platform, peptide antigen is delivered to the immune system 
in a particulate format using nucleic acid as scaffold.  In our study, we used non-coding 
pDNA as scaffold. As a follow-up study, it will be interesting to use coding pDNA, encoding 
multiple epitopes. In such a combined setting, the readily available RALA-associated (pan-) 
epitope will elicit a rapid T cell response which then through a bystander effect may further 
enhance the following T cell response elicited by the pDNA encoded epitopes. . It will be 
interesting to verify to what extend such synergism actually will occur and may further 
increase the strength of the elicited immune response.  
In a further step, it will be interesting to replace the coding pDNA by mRNA in the proposed 
synthetic virus-like vaccine. Whereas DNA needs a live bacterial expression system for its 
production, mRNA can be synthetically synthesized. Hence, it possesses a superior safety 
profile. In addition to that, mRNA production is highly flexible and scalable to industrial 
level and can be easily adapted to GMP manufacturing conditions. Thus, mRNA vaccine 
production process avoids expensive steps caused by the requirement to fulfil regulatory 
demands for product-specific validations. Therefore mRNA production appears to be no more 
costly than pDNA at industrial scale but clearly will be more expensive compared to the 
present day BCG vaccine. While a higher cost may be affordable for developed countries, 
obviously it will not for developing countries. Here, financial support from civil society 
organizations such as the World Health Organization, UNICEF and the GAVI Alliance and 
from private foundations such as the Bill and Melinda Gates foundation will be crucial. 
3.2. Further mechanistic study 
In our study, when both MHC I and MHC II epitopes are present in the same RALA particle, 
a lesser induction of cytolytic T cell activity was observed but not of antibody responses. In 
186 
 
contrast herewith, immunization with MHC I and MHC II epitopes administered in separate 
particles resulted in both strong cytolytic and humoral responses. This peculiar in-vivo 
performance of the RALA particles may indicate a lesser stability of the particles dependent 
on the peptide composition used. In our experimental observation, RALA-mRNA particles 
and RALA-epitope particles were stable for at least 48 hours. In a previous study, RALA 
nanoparticles were shown to be stable for over one month when stored at room temperature 
in an air tight container 
6
. This indicates that nanoparticles remain complexed and retain their 
electrostatic interaction without the need for complex storage conditions. Ruling out the 
stability issue, another possibility underlying the differential efficacy of mono- versus multi-
epitope RALA particles may be a differential endosomal escape ability of the particles. The 
secondary structure of RALA at various pH-values was studied using circular dichroism (CD) 
spectroscopy. At all pH-values assayed, the peptide maintained an α-helical conformation. 
Particularly at pH 7.16 the α-helical content was 31.13% and gradually increased to 39.37% 
at pH 4.3
6
. This implies that once the particles are inside the endosome, a decrease in pH 
would enable the alignment of the hydrophobic and hydrophilic residues in RALA, resulting 
in an increase in the α-helical content of the peptide’s secondary structure. This is anticipated 
to facilitate the destabilization of the endosomal membrane with subsequent release of cargo.  
We assessed this fusogenic activity using as an indicator functional membrane disruption 
assayed via an hemolysis assay
53
. Hemolytic assay was performed at physiological pH 7.4 
and pH 5.5 which are typically encountered in the cytosolic and endosomal environments. 
The hemolytic activity of RALA was significantly higher at pH 5.5 than pH 7.4 and as such 
we can conclude that RALA nanoparticles indeed have a functional level of membrane 
disruptive activity under acidic conditions. When long hydrophobic epitopes are fused, the 
overall hydrophobic index of RALA‒epitope peptide could however change. This might 
affect the pH-responsive nature of the peptide. Such interferences could cause a difference in 
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membrane disruptive actvity between the mono- and multi-epitope RALA particles, thus 
leading to slight differences in efficacy. Clearly, it will be essential to analysis in detail the 
physicochemical properties and pH responsive nature of the RALA-epitope peptide whenever 
a specific peptide is selected for fusion with RALA. Such analysis may be facilitated by using 
bioinformatics models predicting the structure-activity relationship
54
 as well as the existing 
amino acid-nucleotide interaction database that categorizes interactions from experimentally 
determined protein-nucleic acid structures
55
.  
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A 
 Ad5  Adenovirus 5 
 APC  Antigen presenting cell 
 ARCA  Anti-reverse cap analogues 
 ATP  Adenosine triphosphate 
 ALM  Autoclaved Leishmania major 
B 
 BCR  B-cell receptor 
 BHV  Bovine herpes virus 
C 
 CFSE  Carboxyfluorescein succinimidyl ester 
 CPG  cytidine-phosphateguanosine 
 CPP  Cell penetrating peptide 
 CTL  Cytotoxic T lymphocyte 
D 
 DRiPs  Defective ribosomal products 
 DLS  Dynamic light scattering 
 DM  Heterodimeric glycoprotein 
 DNA  Deoxyribonucleic acid 
 DOPE  1,2-dioleoyl-sn-glycero-3-phosphoethanolamine 
 DOTAP 1,2-dioleoyl-3-trimethylammonium-propane 
 
E 
 eGFP  Enhanced green fluorescence protein 
 ER  Endoplasmic reticulumn 
 
 
G 
 GM-CSF Granulocyte-macrophage colony-stimulating factor, 
H 
 HPLC  High-performance liquid chromatography 
 HPV  Human papillomavirus 
 HCV  Hepatitis C virus 
 HIV  Human immune deficiency virus 
 HLA  Human leukocyte antigen 
I 
 IRF  Interferon regulatory factor 
 IL  Interleukein 
 IFN  Interferon 
 IVT  In-vitro transcribed mRNA 
L 
 LPS  Lipopolysaccharide 
M 
 MAVS  Mitochondrial antiviral signalling protein 
 MDA5  Melanoma differentiation-associated protein 5 
 MHC  Major histocompatibility complex 
 MyD88 Myeloid differentiation factor-88 
 m75  7-methylguanosine 
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N 
 NLRP3 Nacht, LRR, PYD domain containing protein 
 NMR  Nuclear magnetic resonance 
 NOD  Nucleic-binding oligomerization domain 
O 
 ODN  Oligonucleotides 
 OT-I  Ovalbumin specific CD8+ T cells 
 OVA  Ovalbumin 
P 
 PAMP  Pathogen associated molecular pattern 
 PGA  Poly(γ-glutamic acid) 
 PCL  Poly-caprolactone 
 PKR  Protein kinase R 
 PLGA  Poly(lactic-co-glycolic acid) 
 PMA  Poly(methacrylic acid) 
 PRR  Pattern recognition receptor 
R 
 RIG-I  Retinoic acid-inducible gene I 
 RNA  Ribonucleic acid 
S 
 SHIV  Human immune deficiency virus-Simian immunodeficiency virus 
 SIV  Simian immunodeficiency virus 
 SVLP  Synthetic virus like particle 
T 
 TAT  Trans-Activator of Transcription 
 TCR  T-cell receptor 
 TAP  Transporter associated with antigen processing 
 TEM  Transmission electron microscopy 
 TRIF  TIR domain-containing adaptor inducing Interferonβ 
 TBK1  TRAF family-associated NF-κB activator(TANK)-binding kinase-1 
 TLR  Toll-like receptor 
 TMC  Trimethyl chitosan 
W WHO  World Health Organization 
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